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 Thesis Summary  
 
Tetraspanins are integral membrane proteins that play a key role in organising multi-molecular 
complexes. Tetraspanin CD81 is involved in cellular processes such as cell adhesion, cell 
proliferation, and mediating infection of medically important pathogens, including the hepatitis 
C virus. Despite these important roles, the comprehensive structural organisation, membrane 
distribution, and CD81 interaction with surrounding proteins and lipids are not known. To 
enable these studies, CD81 was solubilised and purified from Pichia pastoris membranes in 
poly (styrene-co-maleic-acid) lipid particles or SMALPs, to retain its surrounding membrane 
environment. Biophysical characterisation was conducted by circular dichroism spectroscopy 
and antigen-antibody ELISA. This indicated that SMALP-CD81 retains its secondary structure 
and is functionally stable, even at higher temperatures, in marked contrast with detergent-
purified CD81. Subsequently, gel filtration conditions have been optimised to isolate 
functionally active SMALP-CD81 fractions. The native CD81 membrane distribution in HEK 
293 and Huh-7 cell-lines was also studied using electron microscopy (EM). The EM images of 
cell sections indicated that CD81 is organised in isolated monomers as well as in clusters of 
potentially higher-order structures in both cell-lines. This data agrees with the general 
consensus that tetraspanins exist as tetraspanin-rich microdomains that modulate the function 
of interacting proteins. 
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AOX1   Alcohol oxidase 1 
AMP   Ampicillin 
APS   Ammonium persulphate   
BCA   Bicinchoninic acid  
BMGY   Buffered complex glycerol medium  
BMMY   Buffered complex methanol medium  
BSA   Bovine serum albumin 
CD  Circular dichroism   
CD81   Cluster of differentiation  
CHS  Cholesteryl hemisuccinate  
CMC   Critical micelle concentration  
Cryo-EM Cryogenic electron microscopy 
DLS   Dynamic light scattering  
DDM   n-dodecyl-β-D-maltopyranoside  
DM  Decyl β-D-maltopyranoside 
DMPC  1,2-dimyristoyl-sn-glycero-3-phosphocholine 
DMSO  Dimethyl sulfoxide  
DNA   Deoxyribonucleic acid  
E. coli   Escherichia coli  
ECL1   Small extracellular loop  
ECL2   Large extracellular loop 
EM  Electron microscopy  
FCB  Foetal calf serum 
HCV   Hepatitis C virus  
HEPES  2-[4-(2-hydroxyethyl) piperazin-1-yl] ethanesulfonic acid 
IMAC   Immobilized metal affinity chromatography 
LB   Luria-Bertani  
LCP  Lipidic cubic phase 
LSB   Laemmli sample buffer  
LEL   Large extracellular loop 
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mAb  Monoclonal antibody  
MP  Membrane protein 
Ni-NTA  Nickel nitrilotriacetic acid  
OG  Octyl β-D-glucopyranoside 
PAGE   Polyacrylamide gel electrophoresis  
PBS   Phosphate buffered saline 
PBST   Phosphate buffered saline Tween 20  
PDB  Protein Data Bank 
PEI  Polyethylenimine 
pH   Negative logarithm of the hydrogen ion concentration 
PM  Palmitoylation  
p-null   Palmitoylation-null  
P. pastoris  Pichia pastoris  
S. cerevisiae Saccharomyces cerevisiae 
SDS   Sodium dodecyl sulphate  
SEC   Size exclusion chromatography 
Sf9  Spodoptera frugiperda  
SMA   Poly (Styrene-co-maleic acid)  
SMALP Poly (styrene-c-maleic acid) lipid particles 
TEM  Transmission electron microscopy 
TEM   Tetraspanin enriched microdomain 
TEMED  N,N,N',N'-tetramethyl- ethane-1,2-diamine  
TM   Transmembrane domain  
4TMs  Four transmembrane domains 
Tris   Tris(hydroxymethyl)aminoethane 
Tween 20  Polyoxyethylene sorbitan monolaurate 
UV  Ultraviolet 
WT   Wild type 
w/v   Weight/volume 
YPD   Yeast peptone dextrose  




Units   
 
Å  Angstrom  
°C   Celsius  
g   Gram  
h   Hour  
kDa   Kilo Dalton  
L   Litre  
mAU  Milli absorbance unit 
mDeg  Milli degree 
mg   Milligram  
min   Minute  
ml   Millilitre  
mM   Millimole  
M   Mole  
nm   Nanometer  
psi   Pounds per square inch  
rpm   Revolutions per minute  
sec   Second  
V   Volts  
μL   Microlitre  
μg   Microgram  
























Alanine Ala A Leucine Leu L 
Arginine  Arg R Lysine Lys K 
Asparagine  Asn N Methionine Met M 
Aspartic acid Asp D Phenylalanine Phe F 
Cysteine Cys C Proline Pro P 
Glutamic acid Glu E Serine  Ser S 
Glutamine Gln Q Threonine Thr T 
Glycine Gly G Tryptophan Trp W 
Histidine His H Tyrosine Tyr Y 
Isoleucine Ile I Valine Val V 
 
Table 1: Standard amino acid abbreviations. List of standard amino acid abbreviations used 
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The work presented in this thesis concerns the study of the tetraspanin membrane protein, 
CD81, which is found in the plasma membrane of majority of human cells, such as in blood, 
liver and kidney cells. CD81 is involved in a wide range of biological functions, but many 
questions remained unanswered about its structure and function. This thesis presents data on 
CD81 solubilisation, purification and plasma membrane organisation in an attempt to increase 
current understanding of the structural and functional features of CD81. 
 
 
1.1 The plasma membrane 
The plasma membrane, also known as cell membrane or cytoplasmic membrane, is a 
biological membrane that separates the intracellular components from the external 
environment. The chief function of the plasma membrane is to protect cells from its 
surroundings. It is composed of a phospholipid bilayer that is embedded with proteins to form 
a semipermeable barrier that regulates the movement of certain ions and organic molecules 
in and out of cells (Bretscher, 1973). The plasma membrane also plays a crucial role in 
anchoring the cytoskeleton to provide shape to the cell but also has a very flexible structure 
in order to allow the flow of certain types of cells, such as blood cells, to change shape as they 
pass through narrow capillaries (Derganc et al., 2013).  
 
Plasma membranes are dotted with various types of membrane proteins that are responsible 
for many diverse cellular functions. Some membrane proteins act as receptors, where they 
facilitate the signal transduction of cellular reactions to environmental stimuli. Receptor 
proteins have transmembrane domains on both sides of the membrane to transmit information 
from one side of the membrane to the other. These extracellular domains also usually contain 
22 
 
ligand binding sites where external molecules bind to initiate signal transduction (Shi and 
Massague, 2003).  Another type of membrane proteins are called ion channels or pore-forming 
membrane proteins, where they allow the movement of small molecules such as ion or water 
molecules to pass through the cells (Paulsen et al., 2015). Membrane proteins can also 
function as enzymes to speed up/catalyse chemical reactions. While others acts as anchors 
to mediate cell attachment to the cytoskeleton and the extracellular matrix. These functions 




Figure 1.1: Illustration of diverse  plasma membrane proteins and their function. The 
membrane transporters are able to transport molecules to and from the plasma membrane. 
Receptor molecules are able to bind external molecules (ligands) to initiate downstream signal 
transduction. Enzymes are able to catalyse the chemical reaction to transform a molecule 
chemically. While anchor proteins can provide stability by linking to cytoskeleton, it also 
provide anchoring region to other protein to associate to the lipid bilayer of the membrane. 
Image created using Biorender. 
 
 
The selective permeability of the plasma membrane that regulates entry and exit of molecules 
can be either ‘passive’ that is the movement of molecules without the input of cellular energy, 
or ‘active’ where transport of molecules requires cells to use energy (Nikaido and Vaara, 
1985). Cells employ a number of transport mechanisms to move molecules across 
23 
 
membranes:  Firstly, passive osmosis and diffusion where transport of gases such as oxygen 
and carbon dioxide and other small ions can take place. Secondly, transmembrane protein 
channels that transport small organic molecules such as amino acids and sugars (Jentsch et 
al., 2002). Next is endocytosis where transport of larger molecules or even whole cells occurs 
by engulfing them, and finally exocytosis where cells remove or excretes out substances such 
as hormones or enzymes to the extracellular region (Preston et al., 1992).  
 
The main fabric of the membrane is composed of amphipathic phospholipid molecules that 
accounts for around 40% of the plasma membrane mass. Phospholipids form a thin polar 
membrane sheet made of two layers of lipid molecules, called lipid bilayer (Simons and Vaz, 
2004) . 
  
1.1.1 The lipid bilayer  
The plasma membrane is approximately 5 to 10 nm in thickness, containing mixtures of polar 
lipids and embedded proteins (van Meer et al., 2008). The classic Singer and Nicolson model 
describes the plasma membrane as a mosaic of phospholipids that is dotted with globular 
proteins, carbohydrates and cholesterol, which are able to move unrestricted in the plane of 
the membrane (Singer and Nicolson, 1972). This idea of the fluid mosaic model has been 
evolved over-time but still provides a basic description of the structure and function of the 
plasma membrane. Some have studies pointed out that proteins and lipids in the membrane 
encounter hindrance in movement, contrary to the fluid mosaic model, because of association 
with other lipoprotein complexes, the cytoskeleton and the extracellular matrix (Vereb et al., 
2003; Engelman, 2005).  Another important feature of the plasma membrane is the 
asymmetric location of proteins within the membrane, where intrinsic proteins are completely 
embedded in the membrane, whilst, extrinsic proteins are only partially embedded and 




Figure 1.2: Representative illustration of plasma membrane. The bilayer (black) is dotted 
with intrinsic and extrinsic proteins (blue), carbohydrates (orange) and cholesterol (yellow). 
Image created using Biorender. 
 
 
The principal components of the plasma membrane are proteins, lipids including 
phospholipids and cholesterol, and carbohydrate groups that are attached to some lipids and 
proteins, as listed in Table 1.1 (Andersen and Koeppe, 2007). The phospholipids are 
composed of glycerol, two fatty acid acyl chains and a phosphate-linked head group. The 
plasma membrane consists of two layers of phospholipids with their acyl chains pointing 
inwards, an organisation known as the phospholipid bilayer (Seelig and Seelig, 1974). 
Cholesterols are usually embedded in the membrane alongside phospholipids, they are 
composed of four fused carbon rings and play an important role in membrane fluidity (Mayor 
and Rao, 2004). Carbohydrate is also a major component of the plasma membrane, and is 
usually found on the extracellular side of the cell membrane. They are either bound to proteins 
to form glycoproteins or to lipids forming glycolipids, playing an important role in protein 
identification (Oldham et al., 2007). This thesis will focus on the phospholipid component of 






Major plasma membrane component and location 
Component Location 
Phospholipids Form the main fabric of the plasma 
membrane 
Integral protein Embedded in the lipid bilayer 
Peripheral protein Present on the outer or inner surface of 
the bilayer (does not penetrate the entire 
bilayer) 
Cholesterol Inserted between phospholipids to 
regulate membrane fluidity.  
Carbohydrates Attached to membrane proteins, mainly 
on the extracellular side 
 
Table 1.1: Major components and function of the plasma membrane. The main 
membrane components are lipids including phospholipids and cholesterol, integral and 






The main fabric of the plasma membrane is made up of amphipathic phospholipid molecules. 
A typical phospholipid molecule consists of a three-carbon containing glycerol backbone 
where two fatty acid acyl chains are attached to carbons 1 and 2, and a phosphate group 
attached to the third carbon, as illustrated in Figure 1.3. This arrangement gives the 
phospholipid molecules a hydrophobic head containing phosphate groups, which has a 
negative charge. The tail is consists of saturated and/or unsaturated fatty acid chains with no 
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charge (Lee, 2003). In aqueous solution, phospholipids self-assemble to form bilayers, with 
the polar head group exposed to water and the non-polar hydrocarbon tails shielded inside 
the bilayer. At nano scale, the bilayer appears to be infinitely long in two dimensions, and two 




Figure 1.3: Structure and chemical composition of a phospholipid. The phospholipid 
consists of two hydrophobic fatty acid tails that can be saturated or unsaturated, and a 
hydrophilic head region containing glycerol and phosphate groups. Image created using 
Biorender.com and modified from www.visionlearning.com 
 
 
An extensive range of polar head groups, hydrocarbon chain length, number of double bonds 
and many other characteristics are found in phospholipid molecules in plasma membranes 
and are characterised by the type of head group that is bound to the phosphate group 
(Matsumoto et al., 2006). There are four major types of phospholipids that are involved in 
membrane formation, they are; phosphatidylcholine, phosphatidylserine, 
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phosphatidylethanolamine, and phosphatidylinositol. Phosphatidylcholine (PC) is the most 
abundant lipid in plasma membranes and spontaneously organises into bilayers due to its 
cylindrical shape. It comprises 50% of all membrane lipids and makes up a high proportion of 
the lipids in outer leaflet of the plasma membrane (Pulfer and Murphy, 2003).  The two fatty 
acid chains are nonpolar and hydrophobic and are either saturated or unsaturated. The kink 
in unsaturated fatty acid chains provides flexibility and fluidity to the membrane (de Kroon, 
2007).  
 
Two general features of the phospholipid bilayers are crucial to membrane function. Firstly, 
the structure of phospholipids is responsible for the primary function of the biological 
membrane as providing a barrier between intracellular and extracellular environments 
(Chernomordik et al., 1995). The second feature is the fluidity of phospholipids in the bilayer 
that are naturally viscous fluids, not solids. The fatty acid acyl chains of most natural 
phospholipids have one or more double bonds that introduce bends or kinks, making it difficult 
for phospholipid molecules to tightly associate together. The long fatty acid chain therefore 
moves freely in the interior of the bilayer, making membranes flexible. Furthermore, many 
lipids and membrane proteins are able to diffuse laterally within the plasma membrane; this is 
an important characteristic that is critical for diverse membrane functions (Peitzsch and 
McLaughlin, 1993). However, recent studies have proposed that not all lipids can diffuse in 
the plasma membrane freely, instead, they associate through specific lipid rafts. The rafts are 
cholesterol and sphingolipid enriched isolated membrane domains that move laterally with the 
plasma membrane. Rafts may associate with specific membrane proteins and lipids, and are 
predicted to play important roles in cell signalling and in uptake of external molecules through 




While lipids are a crucial structural feature of the plasma membrane, membrane proteins are 
responsible for carrying out fundamental cellular functions.  
 
1.2 Membrane proteins 
Membrane proteins are ubiquitously present in the plasma membrane where they have crucial 
cellular functions, such as cell adhesion, cell communication and transport of various ions and 
biological molecules (Kinnunen, 1991). They comprise 30% of all cell proteome and are of 
major pharmacological interest. Around 60% of all commercially-available biopharmaceutical 
products are targeted to membrane proteins (Bill et al., 2011).  Most biological membranes 
constitute approximately 50% membrane proteins and 40% lipid according to the mass 
(Saxton et al. 1997). Since proteins are considerately bigger than lipids, this percentage 
indicates the presence of around one membrane protein per every 50 to 100 molecules of 
lipids. The remaining 10% membrane mass comes from carbohydrates that bind to some lipid 
and protein molecules (Engelman, 2005). 
  
The defining characteristic of a membrane protein is that it interacts either directly or indirectly 
to the plasma membrane. Some are bound only to the membrane surface, while others have 
regions that are completely buried the phospholipid bilayer and have domains on both 
extracellular and intracellular sides of the membrane (Opella, 1997). Membrane proteins are 
therefore distinguished into two groups, according to Singer and Nicolson, based on their 
interaction with the membrane. They are peripheral and integral membrane proteins (Singer 
and Nicolson, 1972). Peripheral proteins do not interact with the hydrophobic core of the 
phospholipid bilayer, whereas, integral membrane proteins have one or more hydrophobic 
regions that are embedded in the lipid bilayer that interacts with the fatty acid chains of the 
phospholipid bilayer. Most of an integral membrane protein spans the whole phospholipid 
bilayer through its transmembrane (or membrane spanning) domains and have domains that 
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extends to the aqueous medium on both sides of the lipid bilayer. The transmembrane domain 
is formed form α helices or multiple β strands that covalently bind to the fatty acid chains of 
the phospholipids, anchoring them to the membrane (Andersen and Koeppe, 2007).  
 
1.2.1 The tetraspanin superfamily 
Tetraspanins form a superfamily of evolutionarily conserved integral membrane proteins that 
are present in higher eukaryotes as well as in some unicellular organism, such as in amoeba. 
They are expressed by all metazoans, with 33 family members in mammals, 17 members in 
plants, 37 in Drosophila melanogaster and 20 in C. elegans, and 3 members in fungi. No 
tetraspanin homologs have been reported in yeast, bacteria or archaea so far (Hemler, 2008, 
Hemler, 2001). Tetraspanins are small receptor proteins of approximately ~26 kDa in size and 
protrude 3 – 5 nm on the extracellular side of the plasma membrane. The characteristic 
features of tetraspanins are the presence of four transmembrane helixes, a small extracellular 
loop and a large extracellular domain that serves as a family “finger print” consisting of a highly 
conserved cysteine-cysteine-glycine motif in mammals, as illustrated in Figure 1.4. 
Tetraspanins also contain one short loop at the  N-terminal and C-terminal ends. The 
intracellular tail contains cysteine residues that can be modified by lipidation, i.e. by addition 
of palmitate which has implications in tetraspanin interactions with other surface molecules 






Figure 1.4: Tetraspanin structure. A generic structure of a tetraspanin that includes four 
transmembrane domains (TMs) flanked by small extracellular loop (EC1) and large 
extracellular loop (EC2) containing a conserved CCG motif. The cytoplasmic cysteines are 
palmitoylation sites (shown in filled blue ovals), and the cysteines on EC2 form disulphide 
bonds. Image created using Biorender.  
 
 
Tetraspanins play vital roles in acting as scaffolding proteins in cell membranes by forming 
large webs with one another and other molecules, known as the tetraspanins web or 
tetraspanin enriched microdomains (TEMs). Through TEMs they associate with larger and 
diverse interacting partners, including integrins, adhesion molecules, members of the 
immunoglobulin family, signalling receptors and gangliosides (Berditchevski, 2001, Charrin et 
al., 2003). This diverse association enables tetraspanins to play many vital roles in 
physiological and pathophysiological processes, such as, modulating the  immune system, 
cell proliferation, vesicle trafficking, cell adhesion, cell migration, signal transduction, as well 
as in cancer biology and metastasis, infectious diseases and host-pathogen interactions 
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(Brimacombe et al., 2014, Levy and Shoham, 2005, Haeuw et al., 2011). Although major 
advances have been made in the understanding of the  physiological importance of 
tetraspanins and their roles in several pathologies, the molecular function exerted by them are 
still largely undiscovered. More scientific evidence is emerging that suggests tetraspanins 
forms oligomers, which are involved in regulating the trafficking and functioning of 
neighbouring protein and lipid molecules (Homsi and Lang, 2017, Schmidt et al., 2016). 
 
Out of 33 tetraspanins, tetraspanin CD81 is the most studied in the literature and is also the 
subject of investigation in this study.  
 
1.2.2 Tetraspanin CD81 
CD81 is an important member of the tetraspanin family and is known to have broad biological 
and medical importance. It is implicated in major cellular functions in humans such as cell 
proliferation, cell adhesion and cell signalling (Levy et al., 1998). However, CD81 has also 
been associated with mediating several clinical pathologies such as in cancer, malaria virus 
infection and binding to hepitis C virus E2 glycoprotein to mediate hepatitis C infection 
(Higginbottom et al., 2000, Carloni et al., 2004, Silvie et al., 2003). Despite, there important 
roles, the mechanism of action and interactions with other proteins and lipids are not known.   
CD81, also called TAPA-1 (target of anti-proliferative antibody-1) and Tspan 8 was first 
identified as a target of antibody screening for anti-proliferative membrane molecule (Stipp et 
al., 2003). CD81, along with two other tetraspanin proteins, ME491 and CD63, became the 
founding members of the tetraspanin superfamily in mammals (Hemler, 2003, Oren et al., 
1990). Tetraspanin CD81 is present on almost all nucleated cells and is predicted to arrange 




The human CD81 gene is located on the short arm of chromosome 11 and is 20,103 bases in 
length. It encodes a polypeptide chain of 236 amino acid residues with a predicted molecular 
weight of 25.809 kDa. The gene is ubiquitously present in mammalian cells including 
endothelial, epithelial, hepatocytes and B lymphocytes but  only absent in erythrocytes, 
platelets and neutrophils (Quast et al., 2011).  
 
The first full-length tetraspanin structure was revealed by Zimmerman et al. 2016, through 
high-resolution X-ray crystallography studies of recombinant CD81, obtaining a 2.9 Å 
resolution structure. The structure suggests that CD81 adopts a compact fold where EC2 sits 
close to the plasma membrane covering the four transmembrane alpha-helices (TMs). It 
further reveals an unexpected TM organisation: the TMs are arranged in a cone-like 
architecture forming a large cavity within the transmembrane region, rather than forming a 
more expected  tightly associated TM bundle (Seigneuret, 2006). The structure suggests that 
transmembrane domains 1 & 2 (TM1 & TM2), and TM3 & TM4 are present as two separate 
anti-parallel helical  pairs, which are attached to each other only on the cytoplasmic side, as 
shown in Figure 1.5. Cholesterol was shown to bind specifically inside this large hydrophobic 
pocket, where it regulates CD81 function. This was determined by the surface staining of a B-
lymphocyte receptor CD19 for CD81 binding. The interaction between these two proteins was 
increased 50% when cholesterol binding is compromised by mutating residues on the 
intramembrane cavity (Zimmerman et al., 2016). The functional link between CD81 and 
cholesterol has also been shown previously in some studies where cholesterol appeared to 
contribute to the organisation of tetraspanin-enriched microdomains on the plasma membrane 
and CD81 function during infection by malaria parasites (Silvie et al., 2006). According to 
molecular dynamic studies, it was suggested that CD81 exhibit both open and closed 
structural conformations, which are regulated by a single cholesterol molecule. In the presence 
of cholesterol, the extracellular region of the CD81 covers the transmembrane helices to form 
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a closed conformation, while the open conformation is favourable in the absence of cholesterol 
binding, also shown in Figure 1.5 (Zimmerman et al. 2016).    
Figure 1.5: Diagrammatic representation of open and closed CD81 structures as 
determined by Zimmerman et al. 2016. The CD81 high resolution crystal structure indicated 
a cone shaped arrangement of the transmembrane domain. Variable region in the first 
extracellular loop (EC2) is indicated in blue. Tetraspanin CD81 is not glycosylated but contain 
palmitoylation sites (usually on intracellular region) that is indicated by filled blue ovals. A) In 
the presence of a cholesterol molecule, CD81 form a closed conformation. B) EC2 domain 
unhinges or forms open conformation in the absence of cholesterol. Image adapted from 
Matthews et al. 2017. 
The crystal structure also suggests monomeric CD81 the native form rather than higher-order 
CD81 complexes (Zimmerman et al., 2016). This was also observed before by a super-
resolution microscopy study  suggesting that CD81 exist as  monomers that form complexes 
with its non-tetraspanin partners and not to other tetraspanins in the membrane 
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(Zuidscherwoude et al., 2015). In contrast to these two studies, a well-established notion in 
the tetraspanin literature is the presence the tetraspanin web or tetraspanin enriched 
microdomains (TEM), where multiple CD81 proteins along with other tetraspanins interact with 
each other as a functional unit to mediate diverse physiological and pathophysiological 
processes (Bailey et al., 2011, Hemler, 2005). TEMs for example, are predicted to regulate 
avidity of adhesion receptors, compartmentalise enzymatic activities and specifically mediate 
the progression of hepatocellular carcinoma  (Yanez-Mo et al., 2009, Mazzocca et al., 2014).  
 
The importance of CD81 binding with membrane lipid molecules has been suggested in many 
studies in the context of stabilising the tetraspanin web and mediating interactions with 
tetraspanin-binding partners. The presence of cholesterol disfavours partner protein binding, 
whereas, CD81 favours binding with its associated proteins in the absence of cholesterol. This 
is possibly due to conformational switching of CD81 between open and closed conformations 
due to cholesterol binding (Zimmerman et al., 2016); Palor et al. 2019). Although it has been 
identified that CD81 interacts with its lipid environment to modulate cellular functions, the 
actual binding mechanism and the information about interacting phospholipids is still largely 
unknown. This thesis aim to fill this knowledge gap by studying CD81 structural organisation 
in the presence of surrounding phospholipid environment.  
 
1.2.3 Role of CD81 in human cells 
Similar to other tetraspanin proteins, CD81 also associates with each other and their partner 
proteins in subcellular membrane microdomains acting as signalling platform. The subcellular 
membrane localisation of CD81 along with other tetraspanins and membrane proteins form 
tetraspanin-enriched microdomains (TEMs), where these partnership differs in various cell 
types (Bradbury et al., 1992). For example coimmunoprecipitation assay indicated that in B-
cells, CD81 interacts directly with CD19 and indirectly with CD21 to form TEMs (Fournier et 
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al., 2010), whereas in T cells it associates with CD4 and CD8 (Imai et al., 1995). The difference 
is also in their strength of association, where some partnerships are maintained even after cell 
lysis with harsh detergents.  
 
The function of TEMs is to facilitate transmission of extracellular stimuli to intracellular 
signalling pathway. For example, TEMs enable recruitment of cytoskeleton actin filaments to 
crosslink with plasma membranes by activating ERM protein family (ezrin, radixin and 
moesin). Furthermore, CD81 and EW1-2 interaction was shown to recruit alpha-actin to T cell 
immune synapses (Stipp et al., 2001). Therefore, CD81 present in TEMs function in 
transmitting signals received by the cell membrane to the downstream signalling molecules 
and to adaptor protein, thereby contributing in signal transmission in immune cells (Charrin et 
al., 2003). 
 
1.2.4 CD81 in immune cells 
The major role CD81 play in B cells is to traffic CD19 to the cell surface. This partnership was 
first demonstrated using coimmunoprecipitation studies that lead to subsequent generation of 
three independent lines of CD81 deficient mice (Bradbury et al. 1992). This showed reduced 
CD19 cell surface expression in CD81 deficient mice suggesting, for the first time, that CD81 
is required for normal trafficking of CD19 in B cells. Where CD81/CD19/CD21 molecular 
complex (where CD19 is the signalling molecule, CD21 binds to foreign antigen and CD81 
play role in trafficking CD19) bridges the adaptive and innate immune systems by interacting 
with B cell  receptor to enhance the receptor downstream signalling events. Mutation in CD18 
and CD19 have resulted in antibody deficit (Matsumoto et al. 1993, Mattila et al. 2013). 
Furthermore, the diagnosis of antibody deficiency in a patient with mutation in CD81 further 
emphasized the dependency of CD19 on CD81 for its cell surface expression, where surface 
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expression of CD19 is highly reduced but not completely obliterated CD81 negative mice 
(Matsumoto et al. 1993; (van Zelm et al., 2010)  
 
A super-resolution studies by Facundo Batista revealed that the amplification of B cell receptor 
signalling pathway is reliant on the presence of CD81 and CD19 in TEMs. Their studies 
indicated that CD81 or CD19 deficient mice have impaired downstream signalling 
mechanisms due to defects in cell membrane nano-cluster organisation that are required for 
optimal reaction. The results from these microscopy studies confirmed previous studies 
suggesting that CD81 is necessary for CD19,CD21 and B-cell receptor complexation in the 
formation of lipid rafts for downstream signalling (Mattila et al., 2013). 
 
CD81 was detected in T-cells by a functional assay that selected antibodies that block 
syncytium formation that are induced by human T cell leukaemia virus type 1 infection and 
formed by fusion of viral infected cells with neighbouring cells resulting in the formation of 
multinucleated enlarged cells (Burton and Bartee, 2019).  Syncytium formation by human 
immunodeficiency virus is also inhibited by several anti-CD81 antibodies (Gordon-Alonso et 
al., 2006). These examples highlights the importance of CD81 function in immune cells.  
 
CD81 was shown to associate with various partner proteins expressed on T cells surface, 
including CD4 and CD8. Where recent studies have shown the presence of CD4 dimers that 
are associated with CD81 in TEMs rather than in lipid rafts (Fournier et al., 2010). CD81 is 
also associated with an additional Ig superfamily member EW1-2 in mouse thymocytes (Clark 
et al., 2001). CD81 is also known to regulate multiple cellular functions by associating with the 
cytoplasmic protein 14-3-3ԑ that is an isotype of large family responsible for modulating 
important cellular functions by mediate signal transduction by binding to phosphoserine-
containing proteins (Clark et al., 2001; Luk et al., 1997). 
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CD81 is also a well-known receptor for hepatitis C virus (HCV) in humans. The HCV surface 
glycoprotein E2 was also detected to costimulate T cells and natural killer cells, where this 
association results in increase phosphorylation of Lck (lymphocyte-specific protein tyrosine 
kinase) (Soldaini et al., 2003). This results in CD81 engagement leading to cytoskeletal 
rearrangement in both T and natural killer cells and inhibition of interferon-ᵧ production 
reducing immune cells function (Tseng and Klimpel, 2002).  
 
Despite many important biological roles that CD81 play in humans, the focus of this thesis is 
on CD81 binding with its ligand E2, which is a surface glycoprotein expressed by hepatitis C 
virus to mediate its infection.   
 
1.2.5 Role of CD81 in HCV infection 
Hepatitis C virus is associated with more than half of newly diagnosed hepatocellular 
carcinoma in the developed world and a leading cause of the need for liver transplant (Israelow 
et al., 2014). HCV infection is transmitted by the enveloped virus classified as a Flavivirus due 
to the presence of a positive-strand RNA genome. The genome encodes for a large 
polyprotein precursor that produces ten viral proteins including the structural E1 and E2 
glycoproteins. These glycoproteins are expressed on the virus envelope to mediate virus 
attachment and entry to cells (Timpe et al., 2008).  Currently, there is no vaccine against HCV 
infection, although a number of drugs are in pipeline to target the HCV replicase enzyme. 
However, these trials have resulted in the appearance of drug resistant virus (Di Maio et al., 
2017). Another way to target virus infection is to target conserved pattern of virus entry to the 




It is established in the literature that CD81 is an entry factor for HCV to attach onto and infect 
hepatocytes. De novo infection of liver cells by HCV is mediated by two mechanisms, namely 
cell-free and cell-cell transmission.  Both mechanisms rely on the viral envelope glycoprotein 
E1 and E2 binding to several  liver cell surface proteins such as  CD81, claudin-1,  scavenger 
receptors, epidermal growth factors and various other host cell entry factors, as shown in 
Figure 1.6 (Timpe et al., 2008). Upon HCV-CD81 engagement via E2 viral glycoprotein, the 
MAPK and GTPases, Rac, Eho and Cdc42 signalling pathways are induced to mediate HCV 
entry into the cell. HCV particles enter cells through clathrin-dependent endocytosis (clathrin 
is a protein that plays a crucial role in the formation of coated vesicles for endocytosis) 
(Farquhar et al., 2011, Carloni et al., 2004) . The low pH in the endocytic vesicle prompts the 
fusion of virus and host membranes that releases viral genome (~9.6 kb) into the cytoplasm 
of the newly- infected cells, where the conserved untranslated regions (UTR) at the 5’ and 3’ 
ends mediate genome replication and translation of viral proteins. The ribosome-dependent 
translation of the HCV genome results in a polyprotein that is subsequently cleaved by host 
and viral proteases to obtain mature viral proteins. HCV replication and assembly occurs in 
the endoplasmic reticulum membrane, where virions are released through very low lipoprotein 
secretory pathway, where the released HCV can infect neighbouring liver cells via cell-free 
infection (Hsu et al., 2003). Moreover, the assembled viral particles can directly invade from 
the infected cells to adjacent cells to cause cell-cell infection transmission, which is predicted 
to maintain infection and viral dissemination (Brimacombe et al., 2014). 
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Figure 1.6: Model of CD81 co-receptor formation and interaction with HCV. The 
epidermal growth factor (EGFR) receptor signalling is crucial for HCV entry by recruiting and 
activating HRas. This then in-turn modulates lateral membrane diffusion of CD81 for formation 
of tetraspanin enriched microdomains (TEMs) by binding to claudin-1, integrin beta 1 and 
intracellularly to Rap2B. HCV exploits  HRas signalling for cellular entry by compartmentalising 
entry factors and protein trafficking, where HCV E2 protein binding to the EC1 region of CD81 
to gain entry in the cell through endocytosis (Zona et al., 2014).  
The tetraspanin CD81 was reported as one of the first host factors that mediates HCV entry 
and subsequent infection by interacting with HCV envelope E2 glycoprotein (Flint et al., 1999).  
Where HCV infectivity is inhibited by silencing CD81 expression, while knocking in CD81 
expression in CD81-negative hepatoma cell line HepG2 confers susceptibility to HCV 
infection. Additionally, CD81 expression levels have been shown to regulate the efficiency of 
the HCV entry, suggesting multiple roles of CD81 receptor in the HCV life-cycle (Koutsoudakis 
et al., 2007; Silvie et al., 2003). 
Several studies have pointed out the regions and residues of CD81 that are involved in E2 
binding. The EC2 region is known to interact directly with the HCV particles, where this 
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interaction is specific to only CD81 EC2 as no other tetraspanins are known to bind to the HCV 
glycoproteins. The CD81 small extracellular loop EC1, transmembrane residues, C-terminal 
intracellular region as well as the post translational modification (e.g. palmitoylation of cysteine 
residues) all play an indirect role to modulate HCV entry, as listed in the Table 1.2. These 
indirect roles include forming CD81 microdomains on the membrane, interaction with CD81 
partner proteins such as claudin-1 (another four-pass transmembrane protein that is similar to 
tetraspanins but lacks conserved cysteine residues and the CCG motif on EC2) and by 
cholesterol partitioning (Silvie et al., 2006, Davis et al., 2012). However these indirect roles 
exert only moderate effects on HCV entry, while the CD81 EC2 is the key determinant of viral 

















CD81 region and relevance to HCV infection 
CD81 Region Function (in HCV infection) 
Large extracellular loop (EC2) Directly binds to HCV E2 glycoprotein 
(Harris et al., 2008) 
 
Mediates viral attachment to liver cells (Pileri 
et al., 1998) 
 
Initiates downstream MAPK and GTPases 
Rac, Rho and Dcc42 signalling pathway 
(Quast et al., 2011) 
 
Complex with claudin-1 to facilitate HCV 
internalisation (Harris et al., 2008). 
 
Small extracellular loop (EC1)  Facilitates optimal expression of EC2 
(Bertaux and Dragic, 2006).  
Transmembrane helices Facilitates CD81 dimerisation (McKeating et 
al., 2004). 
 
Enables complexation with claudin-1 and 
other membrane bound proteins (Harris et 
al., 2008). 
C-terminal and small intracellular loop Palmitoylation of cytoplasmic cysteines to 
bind to partner proteins to form TEM 
(Charrin et al., 2002). 
 
Table 1.2: Table listing CD81 regions and their relevance in HCV infection. The large 
extracellular region (EC2) of the CD81 mediates multiple functions that are important for HCV 
attachment and entry to the liver cells. While other CD81 regions exhibit their function indirectly 





HCV exhibits profound genetic diversity due to error prone genome replication, consequently, 
viral particles quickly adapt to environmental change and develop resistance to antiviral 
therapies. This presents major challenges in generating vaccine design and antiviral treatment 
development (Zona et al., 2014).  In contract, argeting host cell components that are essential 
to HCV entry and life-cycle would generate novel drug targets and potentially an attractive 
solution to treat viral infection (Lupberger et al., 2011; Zeisel et al. 2013). The HCV attachment 
and entry factors linked with CD81 protein therefore present a prospective target for 
therapeutic benefit.   
 
1.3 Biophysical characterisation of membrane protein 
Study of integral membrane proteins (MP) is still one of the most challenging aspect of 
research in molecular and structural biology.  This is due to water-insolubility that keeps MP 
unstable once extracted from their membrane environment. As membrane proteins represent 
a substantial fraction of proteins encoded by the human genome (~30% of total genome), they 
mediate a variety of essential functions and have huge pharmacological relevance (Hardy et 
al., 2018).  Despite the evidence of their crucial cellular roles, our understanding of their  
underlying molecular mechanisms, interactions with surrounding membrane environment and 
structural organisation has remained poorly understood compared to soluble proteins (Bill et 
al., 2011). The structural understanding has therefore been largely under-represented in the 
protein database; so far 912 unique MP structures have been deposited that accounts for 
around 2% of all protein structures, according to the Membrane Proteins of Known Structure 
(https://blanco.biomol.uci.edu/mpstruc/). The primary issue is the complexity of the plasma 
membrane structure comprised of physiochemically-distinct layers and lipid composition that 
is difficult to replicate. MP have adapted to this environment where they function at the 
interphase of complex amphipathic interactions with the membrane. It is therefore important 
that any surfactant molecules replicate this complex membrane environment to maintain 
membrane protein stability and structural and functional relevance  (Lee et al., 2016).  
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A major bottleneck in membrane protein research is finding the environment that keeps the 
protein in its natural state after extraction while allowing a wide variety of downstream protein 
studies. The ideal environment would stabilise the protein, be amenable to purification 
techniques and not interfere with biochemical and functional studies. The most common 
strategy for extracting membrane proteins is solubilisation with detergents, such as n-dodecyl-
β-D-maltopyranoside (DDM) and decyl β-D-maltopyranoside (DM). This results in the 
formation of spherical micelles containing membrane protein, detergent molecules and 
possibly some lipids (le Maire et al., 2000; Prive, 2007). Although the detergent solubilisation 
approach has been used heavily in membrane protein research, it has some inherent 
drawbacks. Firstly, detergents are poor mimetics of plasma membranes as natural 
membranes are not made up of single lipid types but are a mixture of diverse lipids in complex 
arrangements. This results in unfavourable protein dynamics and stability in detergent 
micelles. Secondly, solubilisation of membrane proteins with detergent requires an extensive 
screening process to find a suitable detergent type. The final limitation is that detergent 
solubilisation strips away most lipid molecules within a membrane protein that are essential 
for structural and functional activities (Laganowsky et al., 2014). The crucial balance between 
the choice of successful solubilisation and retention of the target protein’s native interactions 
for  structural/functional integrity is rarely achieved with detergents (Prive, 2007).   
 
An alternative approach for membrane protein solubilisation is using amphipols as an 
amphipathic polymer. This approach was invented by Tribet et al 1992, and shown to keep 
membrane proteins soluble in aqueous environments. However, similar to detergents, 
amphipols have a major drawback of removing the surrounding lipid environment and thus 
reducing membrane protein stability and functional relevance (Tribet et al., 1996, Popot et al., 
2011). Another polymer- based approach utilised in membrane protein research is the use of 
membrane scaffolding proteins (MSPs). MSPs are derived from human serum albumin protein 
A1 containing alternating repeats of proline and glycine (Bayburt et al., 2002). These 
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alternating amino acid repeats spontaneously encircle nanometre sized lipid bilayers, 
containing the membrane protein of interest, by wrapping a belt around the nano particle. This 
keeps the membrane protein stable and soluble in aqueous environments. However, this 
method too has a major limitation: MSP nanoparticles do not represent native membrane 
protein lipid environment due to the prerequisite of membrane protein extraction and 
purification in detergent prior to reconstitution of the membrane protein along with lipids into 
MSP discs (Bayburt and Sligar, 2010, Denisov et al., 2004). 
 
More recently, a novel approach to membrane protein extraction was employed using poly 
(styrene-co-maleic-acid) or SMA polymer as the plasma membrane solubilising agent. The 
advantage of using SMA polymer instead of MSPs is that the SMA polymer directly extracts 
membrane proteins from the plasma membrane, without the need to use detergent at any 
stage. This assures the preservation of the annular and surrounding lipid bilayer environment 
around the membrane protein, and therefore maintains protein stability and native 























e.g. DDM, DM and OG 
 
Conventional method for 
membrane protein research 
 
Removal of surrounding 




e.g. A8-35, DAPol, NAPols, SAPols 
 
Forms nanodiscs and 




Removal of most lipids, 
therefore reduced protein 
stability. Solubilisation with 
detergent is a prerequisite. 
 
Membrane scaffolding proteins  
e.g. apolipoprotein  
 
Stabilisation of MPs in lipid 
bilayers and into nanodiscs 
 
Detergent solubilisation and 
purification is a prerequisite.   
 
SMA polymers 
e.g. SMA 2000 and SZ25010 
. 
Protein extraction directly 
from biological membrane 
and preservation of 
surrounding lipid bilayer. 
 
Polymer sensitive to divalent 
cations and low pH. 
 
Table 1.3: List of most popularly used surfactants to solubilise membrane proteins. 
Associated advantages and drawbacks of each membrane solubilising agent are also listed 







1.3.1 Membrane protein solubilisation using SMA co-polymers 
 An approach that has revolutionised the study of membrane proteins is the use of poly 
(styrene-co-maleic-acid) co-polymer (SMA) to solubilise membrane proteins. As amphipols, 
SMA belongs to the class of surfactants that enables the handling of membrane proteins in 
detergent-free aqueous solutions as though they were soluble proteins (Jamshad et al. 2015). 
The amphipathic SMA co-polymer spontaneously inserts into the biological membrane and 
forms small nanodics of bilayer that are surrounded by the polymer, termed as SMA lipid 
particles or SMALPs, as shown in Figure 1.7. In contrast to detergent solubilisation, the SMA 
polymer extracts the membrane protein in a portion of plasma membrane that surrounds it, 
therefore preserving the surrounding lipid environment (Knowles et al., 2009, Dafforn et al., 
2012). The small size of these nanodiscs (~10 nm diameter), containing protein of interest, 
can be purified with affinity chromatography whilst retaining their phospholipid profile.  The 
SMA method is also amenable to several biophysical and biochemical techniques such as 
western blots, circular dichroism spectroscopy and dynamic light scattering techniques (Gulati 





Figure 1.7: SMA co-polymer and SMA lipid particle (SMALP) structure. The SMA 2000 
polymer chemical structure comprises hydrophobic styrene and hydrophilic maleic acid 
subunits. The SMA polymer encircles small (~10 nm) lipid bilayer discs to solubilise membrane 
proteins of interest in SMA lipid particles, also known as SMALPs. Image modified from 
(Rothnie, 2016, Dorr et al., 2015). 
The preservation of the native annular lipid environment assists in mediating protein stability 
and allows the use of SMA polymer as a convenient tool to study endogenous lipid-protein 
interactions (Jamshad et al., 2015b, Lee et al., 2016). Historically, studies on membrane 
proteins required detergent solubilisation and purification that strips away membrane protein 
bound lipids. However, due to advancement in membrane protein research over the last 
decade, it has become clearer that studies of membrane proteins should take account the 
presence and preservation of the surrounding lipid environment. Recent studies have shown 
that membrane proteins associate closely with certain lipids in the plasma membrane that are 
essential for fundamental aspects of their structure and functional integrity (Saliba et al., 2015, 
Barrera et al., 2013). Therefore, SMA polymer solubilisation provides a suitable tool to study 
membrane proteins and their interactions with native lipid molecules.  
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SMA co-polymers consist of hydrophobic styrene and hydrophilic maleic acid monomeric 
subunits that are synthesised by co-polymerisation of both subunits, as shown in Figure 1.8. 
They are commercially available from Cray Valley, and Polyscope as an anhydride form that 
needs to be converted into an acid form through hydrolysis before use. The styrene-maleic 
anhydride (SMAnh) is mixed with water or an alkaline solution (sodium hydroxide) to convert 
anhydride subunits to the acid form where two carboxyl groups become partly deprotonated, 
yielding water soluble SMA polymer.  Only the hydride form of SMA co-polymers is used for 




Figure 1.8: Schematic showing SMA co-polymer synthesis and conversion of styrene 
maleic anhydride to the acid form.  1:1 styrene and maleic acid subunits are copolymerised 
to the anhydride form. This is then converted to the water-soluble acid form through alkaline 







 Many polymer variants are available that could be used to solubilise membrane proteins with 
different efficiencies.  The studies by Morrison et al. 2016 show that various SMA polymers 
can be used to extract membrane proteins comparably to detergents. However, the most 
widely used polymers for membrane protein research have a styrene-to-maleic acid ratio of 
2:1 (SMA 2000) or 3:1 (SMA 3000), where SMA 2000 is the best choice in terms of protein 
solubilisation and purification efficiency (Morrison et al., 2016). The pH of solubilisation 
experiments is usually in the range of 7.5 – 8.0, which is applicable for all SMA variants (Dorr 
et al., 2016b). The list of various SMA co-polymers used in membrane protein solubilisation 
are given in Table 1.4.  
 
SMA solubilisation also has, however, some limitations when used for membrane protein 
research: the small size of the polymer (10 nm diameter) is only suitable for isolating small 
proteins and does not capture large protein complexes (Dafforn et al., 2012). Also the SMA 
co-polymer is sensitive to the presence of divalent cations (such as magnesium, copper and 
zinc ions) above a concentration of approximately 4 mM, which results in SMA polymer 
precipitation from the solution (Gulamhussein et al., 2019).  Alternative SMA-derived polymers 
have been developed in order overcome divalent cation sensitivity. This includes styrene 
maleimide (SMI) and diisobutylene-maleic acid (DIBMA), which replaces maleic acid with 



















SMA 1000 50 5.5 
SMA 2000 33.3 7.5 
SMA 3000 25 9.5 
 
Polyscope 
XZ09006 40 7.5 
XZ09008 25 10 
SZ40005 42 5 
SZ25010 25 10 
SZ42010 42 10 
SZ33030 33 30 
SZ28065 28 65 
SZ28110 28 110 
 
Table 1.4: List of commercially available SMA co-polymer variants. The list shows 
various SMA co-polymers and the percentage of maleic acid content for each polymer along 
with their corresponding molecular mass. It is to be noted that variation/ polydispersity in 
SMA co-polymers has been observed (in styrene to maleic acid ratio) where final content of 
each subunit was taken statistically (Stroud et al., 2018).  
 
 
The formation of SMA lipid particles (SMALPs) or nanodiscs requires the solubilisation of cell 
membranes by the SMA co-polymer. The solubilisation mode of action can be described by a 
three-step model, as shown in Figure 1.9. Firstly, SMA polymer binds to the lipid bilayer 
surface. The membrane binding step can be promoted by the increasing the polymer amount 
and regulated through electrostatic interaction. The negatively-charged polymer repulses 
anionic lipids causing a decrease in binding efficiency, while the ionic lipid promotes polymer 
binding to the membrane surface. The second step is the insertion of the SMA co-polymer into 
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the hydrophobic core of the membrane. This step is affected by lipid packaging and bilayer 
thickness: presence of thick and tightly packed lipid layers hinders the penetration of polymer 
into hydrophobic core of the membrane. The final step is the actual solubilisation of the bilayer 
and simultaneous formation of SMA nanodiscs or SMALPs. This step is also affected by lipid 
thickness and packaging; the kinetic energy of breaking thicker lipid bilayer is higher, and the 
more tightly-packed lipid molecules are, the more difficult it is for  the hydrophobic polymer 
subunit to insert in between the hydrophobic parts of lipid bilayer (Scheidelaar et al., 2016).   
Figure 1.9: Illustration to show SMA polymer solubilisation. Three step model for 
biological membrane solubilisation using SMA co-polymers.  The first step is the binding of 
SMA to the outer surface of the membrane that is mediated by polymer concentration and 
negatively charged lipids. The second step is the insertion of the SMA co-polymer into 
hydrophobic core of membrane. Thefinal step is the solubilisation of the membranes into 
nanodiscs.  Image taken from (Dorr et al., 2016a). 
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In this study, two types of SMA co-polymers are employed to solubilise CD81 from biological 
membranes, namely SMA 2000 and SZ25010 polymers. These two polymers have previously 
been shown to effectively solubilise and purify membrane proteins of interest. SMA 2000 has 
an average molecular weight of 7.5 kDa, consisting of 33% maleic acid subunits, while 
SZ25010 polymer is 10 kDa and consists of 25% maleic acid content (Morrison et al., 2016).  
 
1.3.2 CD81 solubilisation with detergents and SMA co-polymer 
Previous work by Zimmerman et al, 2016 was carried out to perform structural analysis on the 
Sf9 overexpressed CD81 protein using conventional detergents such as DDM. The detergent 
solubilised and purified CD81 was taken forward for crystallisation using the lipidic cubic phase 
method to determine structure. This resulted in the structure determination of full length CD81 
protein for the first time, this was also the first tetraspanin protein to be determined structurally 
(out of 33 family members in humans). This was a significant advancement in the field of 
tetraspanin research as like several other membrane proteins, CD81 was also notoriously 
difficult to characterise structurally. This is mainly due to protein stability issues after extracting 
them from their surrounding plasma membrane environment. The published high-resolution 
structure of CD81 is shown in the Figure 1.10. The overall CD81 structure comprise a cone 
shaped transmembrane helices (TMs) where the large extracellular domain (EC2) covers an 
intramembrane cavity formed by the four TMs.  This is unexpected as the overall fold of the 
4TMs determined by the crystal structure appears unusual and does not bear a resemblance 
to any other integral MP of known structure. 
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Figure 1.10: The 3D structure of human CD81. The TMs were shown to be organised into 
two largely separated pairs of anti-parallel helices, where the two pairs only converge close to 
the cytoplasmic side of the membrane (Zimmerman et al., 2016). 
As the published CD81 structure is the only representative structure of the tetraspanin 
superfamily in the literature, we aimed to examine the unusual structural organisation of the 
CD81 protein. To conduct this study, P. pastoris was used to efficiently overexpress CD81 in 
large amounts. So far, all the studies that required tetraspanins extraction from the plasma 
membrane were carried out using conventional detergents (DDM, DM and OG) as the MP 
solubilising agent (Zimmerman et al., 2016, Rodrigues et al., 2011). Although this has resulted 
in successful protein extraction into detergent micelles, this method has an inherent drawback. 
The detergent solubilisation removes the interacting lipid environment from the protein which 
could result in reduced protein stability and changes in native structural organisation. It is 
possible that the unusual cone shaped TM organisation observed in the published structure 
could be an artefact of detergent extraction and spontaneous reorganisation of TM into 
detergent micelles. To overcome this limitation, SMA co-polymers (SMA 2000 and SZ25010) 
were utilised in this project to extract CD81 protein in its surrounding plasma membrane 
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environment without stripping away interacting lipid molecules, thus keeping protein 
structurally and functionally stable (Rothnie et al. 2016; Knowles et al. 2009). 
The full length CD81 crystal stucture studies from Zimmerman et al., 2016, revealed an 
abundance of alpha helical structure in CD81 protein. Around 68% of the protein had in alpha 
helical secondary structure along with the identification of secondary structure bends and 
turns, as shown in the sequence chain view in Figure 1.11.  Previous work by Jamshed et al. 
2008 using octyl-beta-glucoside (OG) solubilized hCD81 also suggested predominant aplha 
helical secondary structure of the CD81 protein. This study calculated high alpha-helical 
abundance of ~77% (Jamshed et al. 2008). 
Figure 1.11: The secondary structure sequence chain view calculated from the 3D 
structure of human tetraspanin CD81. According to this, around 68% of the purified CD81 
was in alpha helical secondary structure (spanning around 10 helices; 168 reisdues). Image 




1.4 CD81 overexpression in host cells 
A major limitation in membrane protein research and structural biology is the low abundance 
of membrane proteins of interest in their native membrane.  Therefore in order to harvest 
sufficient amounts of membrane protein, large quantities of their natural cell types are 
required. This is problematic as primary cells are notoriously difficult to cultivate in tissue 
culture conditions (Nyblom et al., 2007). To overcome the problem, overexpression of 
membrane proteins is routinely performed to increase protein yield per cell. This method has 
an added advantage of being able to generate recombinant membrane proteins containing 
structure-stabilising mutations (e.g. mutation on palmitoylation site to prevent protein 
aggregation) and purification tags, such as hexa-His or FLAG tag, to aid protein stability and 
ease purification. However, it is important to check that these mutations and affinity tag 
addition do not alter membrane protein structure, expression level and function significantly.  
 
To overexpress recombinant membrane proteins effectively, an efficient overexpression 
system is required. Escherichia coli (E. coli) is most commonly used to overexpress 
exogenous proteins (Miroux and Walker, 1996). Despite achieving high membrane protein 
expression in relatively quick succession, this system may not be suitable for human protein 
overexpression due to lack of post-translation machinery required in E. coli to correctly fold 
eukaryotic proteins (Makrides, 1996).   
 
To overexpress human membrane proteins, such as tetraspanin CD81, in high amounts a 
eukaryotic expression system could be utilised. Eukaryotic host cells include yeast, such as 
Pichia pastoris or Saccharomyces cerevisiae; insect cells such as Spodoptera frugiperda 
(Sf9); or mammalian cell lines, such as human embryonic kidney cells (HEK 293). These 




 1.4.1 Pichia pastoris  
P. pastoris, also known as Komagataella pastoris, belongs to a class of methylotrophic yeasts. 
It is widely used by the scientific research community as a eukaryotic expression system to 
produce proteins for basic research and medical applications (Jamshad et al., 2006). The 
increasing popularity of P. pastoris expression system is attributed to several factors: the first 
and foremost advantage is the shared  intracellular organisation with higher eukaryotes. This 
includes compartmentalisation of intracellular organelles, complex intracellular protein 
trafficking pathways and  the ability to perform many eukaryotic post-translational 
modifications e.g. glycosylation, disulphide bond formation and proteolytic processes 
(Washburn et al., 2001). The second benefit is the ease of handling compared to other higher 
eukaryotes. P. pastoris cells can be grown in simple and inexpensive media, with a generation 
time of about 1.5 hours. They are usually grown on a large scale using shake-flasks, 
bioreactors or fermenters, and can be stored short or long term on petri dishes at 4 o C or in 
stocks in 80 oC freezer (Bill, 2014, Routledge et al., 2016). The next benefit is that P. pastoris 
is one of the most well-established and commercially accessible yeast technologies (as 
expression kits), after S. cerevisiae, providing ease of transgene propagation, tight regulation 
of methanol-inducible transgene expression and efficient secretion of protein intracellularly or 
to the extracellular medium (Oberg and Hedfalk, 2013). Finally a major benefit of using P. 
pastoris is its genetic tractability. The host cells can easily manipulated by classic genetic 
engineering techniques to change their genetic make-up. With the advancement of molecular 
biology, specific modifications can be performed to P. pastoris cells to generate stable deletion 
mutants, fusion-proteins and insert or swap promoters to produce proteins with more 
humanised characteristics for biopharmaceutical research (Bawa et al., 2011, Ashe and Bill, 
2011, Emmerstorfer et al., 2014, Bonander and Bill, 2009).  
 
P. pastoris has two major benefits over S. cerevisiae for the production of recombinant 
proteins in the laboratory or industrial settings. P. pastoris cells can grow in methanol as its 
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only carbon source. This is also beneficial for reducing culture contamination by killing 
methanol-intolerant microorganisms (Routledge et al., 2016). Therefore, P. pastoris culture 
growth is cheaper to set up and maintain. Another major benefit is that P. pastoris cells can 
grow to a very high densities. A high cell biomass yield has the potential to result in higher 
protein yield, this makes P. pastoris ideal for large-scale protein production assays without the 
use of expensive equipment (Bill, 2014, Fernandez et al., 2016).  
 
There are two gene that encode the enzyme alcohol oxidase in P. pastoris cells, they are 
AOX1 and AOX2. AOX1 expression is responsible for methanol utilisation and most of the 
alcohol oxidase activity in the cell, which is controlled at the transcriptional level. AOX1 can 
comprise up to 30% of total soluble protein in P. pastoris when grown solely on methanol as 
carbon source, indicating the strength of the AOX1 promoter (Fernandez et al., 2016). The 
AOX1 gene is regulated by two mechanisms:  activation and repression. Cells grown in 
methanol activate the AOX1 promoter, while in the presence of other carbon sources, such as 
glycerol or glucose, gene activity is repressed.  The approach behind heterologous protein 
production is to express the gene of interest under the control of the AOX1 promoter. The 
recombinant P. pastoris cells are gown on glycerol in batch culture to increase cell biomass 
and repress foreign gene transcription.  This is followed by induction with methanol in the fed 
batch phase to promote foreign protein expression by activating the AOX1 promoter (Moser 
et al., 2017, Routledge et al., 2016).    
 
To aid CD81 studies in this project, the hCD81 coding sequence was tagged at the 3´ end 
with His6 tag coding sequence and cloned into the P. pastoris expression vector pPICZB 
downstream of an AOX1 promoter sequence. To avoid potential CD81 aggregation and to 
achieve homogeneous recombinant proteins, palmitoylation sites were eliminated by 
conserved point mutation. The palmitoylation deletion in CD81 sequence does not affect their 
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overall function and stability (Berditchevski and Odintsova, 1999). This work has previously 
been established to study tetraspanin CD81 (Jamshad et al., 2008). 
 
1.4.2 Insect cell expression system using Sf9 cells 
Insect cell expression is a powerful tool to overexpress recombinant mammalian membrane 
proteins in large amounts. This system utilises recombinant baculoviruses (insect viruses), 
carrying the gene of interest to infect insect cells to produce high yields of heterologous 
proteins (Chen et al., 2013). There are three main types of insect cell lines that are used for 
recombinant protein production, namely, Spodoptera frugiperda 9 (Sf9), Spodoptera 
frugiperda 21 (Sf21) and High-five (developed from Trichoplusia ni). The difference between 
these cell lines is determined in terms of baculovirus susceptibility, virus production and 
product yield (Lai et al., 2006). Previously, insect cell expression systems lacked sophisticated 
glycosylation machinery, which was rectified by the generation of a new strain called SfSWT-
5, which contain six key glyogenes (McKenzie and Abbott, 2018). 
 
As with all membrane protein expression systems, the insect cell expression has its 
advantages and disadvantages. The advantages of using this system are safety and size of 
exogenous gene insertion: baculoviruses are non-pathogenic to mammalian and plant cells 
and can accommodate larger or multiple genes. Next is the ease of scale up, where infected 
cells expressing the protein of interest grow well in suspension culture on a large scale using 
a shake flask or bioreactor (McKenzie and Abbott, 2018).  Also, high level of membrane protein 
expression is achieved as the system utilises a combination of an efficient gene promoter for 
early and late gene expression. An added benefit is the proper folding of mammalian proteins 
due to the presence of posttranslational modification machinery in insect cells.  A few 
disadvantages of insect cell protein expression is that this system is more labour intensive and 
time-consuming than simple bacterial and yeast methods (Pozza et al., 2009). Overall, despite 
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few disadvantages, the insect cell protein expression using baculovirus remains one of the 
most efficient eukaryotic system for heterologous protein expression.   
 
For CD81 overexpression in this project, the full-length human CD81 sequence was 
assembled using synthetic gene blocks (gblocks, Integrated DNA Technologies) and 
integrated into baculovirus transfer vector pVL1392. The sequence contains an amino-
terminal FLAG epitope tag followed by a 3C protease cleavage site to potentially cleave off 
the tag (after protein purification). Also, four intracellular cysteine residues at position 6, 9, 227 
and 228 were mutated to serine to prevent protein cross-linking after purification. The 
recombinant protein was expressed in Spodoptera frugiperda ovarian tissue (Sf9) cells. This 
system was previously developed in-house by Dr Michelle Clare to aid CD81 crystallographic 
studies.  
 
1.4.3 Mammalian expression systems 
Mammalian expression systems offer the most relevant cellular environment for exogenous 
human membrane protein expression (McKenzie and Abbott, 2018). This major benefit comes 
with some draw backs:  cell culture techniques are labour intensive and time-consuming 
requiring specialist and costly consumables, for example, a laminar flow-hood, 5% carbon 
dioxide gas exchange incubators and the demand for nutrient rich growth medium. Also, most 
mammalian cells grow as an adherent monolayer and do not favour the high density 
suspension culture growth achieved in E. coli and yeast (Forstner et al., 2007). Therefore, 
obtaining high cell biomass and protein yields are challenging in mammalian expression 
systems. Despite these drawbacks, mammalian cells provide the best environment for 
exogenous gene expression. This is because the signal for gene synthesis, processing and 
secretion of recombinant genes (from eukaryotic origin) are correctly and efficiently 
recognised by the mammalian host cells (Pozza et al., 2009). The recombinant gene 
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expression levels mainly depend on gene transcription efficiency. Exogenous gene expression 
in mammalian cells require a suitable cell-line to enable efficient gene transcription, translation 
and to also able to perform relevant post translational modification (Forstner et al., 2007) . 
 
Many mammalian cell lines have been used for protein expression with the most common 
being HEK 293 (human embryonic kidney cells). The HEK 293 cell-line was chosen for this 
study as these cells endogenously expresses CD81 and thus containing the appropriate 
machinery to effectively transcribe and translate transfected CD81. HEK 293 cells can be used 
to overexpress recombinant membrane proteins by either producing a transient or stable cell 
lines (Baldi et al., 2005) . Transient transfection involves generation of appropriate mammalian 
plasmids containing a strong promoter and multiple cloning sites to clone recombinant 
membrane protein gene (usually containing a sequence encodes a purification tag). Plasmid 
DNA is then transfected into host cells using transfection reagents, such as polyethylenimine 
(PEI), lipofectamine or calcium phosphate (Sonawane et al., 2003) (Maurisse et al., 2010). 
HEK 293 transfection is usually most efficient using PEI transfection. According to a study by 
Huh et al. 2017, PEI mediated green fluorescent protein (GFP) expression resulted in 50 – 
80% cells being transfected and the protein was also not cytotoxic (Huh et al., 2007). The HEK 
293 cell line is, therefore, widely used for membrane protein overproduction by transient 
transfection, as well as by stable transfection.  
 
In this study, HEK 293 cells will be utilised to perform transient transfection with recombinant 
CD81 protein to aid biophysical and structural studies. Moreover, Huh-7 cells (hepatocytes 
derived human carcinoma cell line) will also be utilised to study CD81 from a suitable model 
liver cells to further the understanding on endogenous CD81 expression, membrane 




1.5  Aims and Objectives 
This thesis describes an investigation on the tetraspanin CD81 biophysical, functional and 
structural analysis in its phospholipid environment. This was achieved by using SMA co-
polymers to solubilise and purify recombinant CD81 with its surrounding plasma membrane 
portion using Pichia pastoris and Sf9 cells. Biophysical characterisation was subsequently 
performed to determine structural and functional relevance of SMALP-CD81. 
 
CD81 plasma membrane distribution was also investigated using electron microscopy to 
understand native CD81 organisation on the liver cells (using Huh-7cell-line) and HEK 293 
cell membranes.  
  
Specific thesis objectives were:  
 
 To solubilise and purify CD81 with its surrounding phospholipids using SMA co-
polymers 
 
 To perform biophysical characterisation on the purified SMALP-CD81 to determine 
intact secondary structure and function. 
 
 To obtain high-resolution structure information using X-ray crystallography. 
 













The P. pastoris wild type strain X-33 (Invitrogen) was electroporated to transform with hCD81 
expression plasmid pPICZB containing recombinant and C-terminus his6 tagged CD81 
(Jamshed et al, 2008).  SMA 2000 co-polymer (2:1 Cray Valley) and SZ25010 co-polymer (3:1 
Polyscope). Detergent n-dodecyl-B-D-maltoside was purchased as pure powder from 
ThermoFisher Scientific and Cholesteryl Hemisuccinate from Sigma-Aldrich. The mammalian 
cell lines, HEK 293S and HEK 293T cells were provided by Dr John Simms. HepG2 cell line 
was purchased from (ATCC® Number: HB-8065™). Huh 7 cells were provided by Prof Alex 
Cameron (University of Warwick). All cell lines were grown in Dulbecco’s Modified Eagle 
Medium (DMEM) from Sigma Aldrich. The pEF6.A plasmid was used to transfect mammalian 
cells with exogenous CD81 protein. Four pEF6.A vectors were used: one empty vector with 
no CD81 gene; with wild type CD81 gene; with four intracellular cysteines mutated to serins; 
all six intracellular cysteines mutated to serines. The plasmids were a kind gift from Dr Mike 
Tomlinson for the University of Birmingham. HCV E2 protein (strep tagged) and Anti-Step 
antibody was provided by Prof Thomas Krey (from the Institute of Virology, MHH in Hannover).  
 
XL-10 Gold Ultracompetent E-coli stock was purchased from Stratagene (Agilent 
technologies) and stored at -80 °C. Zeocin and Ampicillin antibiotics was purchase from 
ThermoFisher Scientific as 1.25 ml reagent at 100 mg/ml. Zymolase 20 T for protoplast work 
was purchased from Amsbio, UK. Yeast extract, peptone and agar were purchased from 
Fisher Scientific. Ni+2 NTA resin for IMAC purification was purchased Qiagen and  Bio-Rad 




Remaining reagents were purchased from Sigma-Aldrich, unless stated otherwise.  
 
2.2 Pichia pastoris growth  
 
2.2.1 Growth plates, stock solutions and growth media 
 
Agar plates 
1% of yeast extract, 2% peptone, 2% dextrose, 2% agar, and 100 mg/ml Zeocin 
For 500 ml L solution, add 5 g yeast extract, 10 g peptone and 10 g agar were dissolved in 
450 ml of water. The solution was autoclaved on a liquid cycles and cooled to ~40 °C before 
adding 50 ml of 20% dextrose and 500 µl of a 100 mg/ml Zeocin stock.   
 
Stock solutions 
10× YNB (13.4% Yeast Nitrogen Base with Ammonium Sulphate without amino acids) 
134 g yeast nitrogen base (YNB) with ammonium sulphate and without amino acids was 
dissolved in 1 L water. The solution was heated to dissolve YNB completely in water. 
Alternatively, 34 g YNB without ammonium sulphate and amino acids and 100 g ammonium 
sulphate can be used. The solution was filter sterilised and stored at 4°C.  
 
0.02% Biotin 











5 ml methanol mixed with 95 ml water. The solution was filter sterilised and stored at 4°C. 
 
10% Glycerol 
100 ml glycerol mixed with 900 ml of water. The solution was sterilised either by filtering or 
autoclaving, then stored at room temperature 
 
1 M potassium phosphate buffer, pH 6.0 
132 ml 1 M K2HPO4 and 868 mL 1 M KH2PO4 were mixed together before confirming the pH 
to be 6.0 ± 0.1 (if the pH was adjusted, phosphoric acid or KOH was used). The solution was 
sterilised by autoclaving then stored at room temperature. 
 
Zeocin antibiotic 








Yeast Extract Peptone Dextrose Medium (YPD) (Zeocin as required) 
1% yeast extract 
2% peptone 
2% dextrose (glucose) 
2% agar 
100 mg/ml Zeocin 
 
For 1 L solution, 10 g yeast extract, 20 g peptone were dissolved in 900 ml water and 20 g of 
agar was added when making YPD plates. The solution was autoclaved for 20 min on a liquid 
cycle. The solution was cooled to ~60°C before adding 100 ml of a 20% dextrose stock 
solution. 1 ml stock of Zeocin (100 mg/ml) was added if required. 
 
Buffered Glycerol-complex Medium (BMGY) and Buffered Methanol-complex Medium 
(BMMY) 
1% yeast extract;  
2% peptone 
100 mM potassium phosphate, pH 6.0 
1.34% YNB 
4 x 10-5% biotin 
1% glycerol or 0.5% methanol 
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To make a 1 L solution, 10 g yeast extract and 20 g peptone were dissolved in 700 ml water. 
The solution was autoclaved for 20 min on a liquid cycle and then cooled to room temperature. 
The following was then added and mixed well; 100 ml 1 M potassium phosphate buffer (pH 
6.0), 100 ml 10X YNB, 2 ml of a 0.02% biotin stock and 100 ml 10% glycerol (for BMGY) or 
100 ml 5% methanol (for BMMY). The media were stored at 4°C and used for no longer than 
two months. 
 
2.2.2 P. pastoris storage 
For short term use, P. pastoris working stock were prepared by streaking a single colony of 
recombinant CD81 strain on to the YPD-Zeocin agar plates. The plates were incubated at 30 
°C for three days or until single colonies were visible. Plates were subsequently stored at 4 °C 
until use. Fresh plates were made by re-streaking Pichia colonies from -80 °C glycerol stock 
every three weeks. 
 
For long term storage and back-up stocks of P. pastoris, a single yeast colony was taken from 
the YPD-Zeocin agar plate and grown overnight at 30 °C and 220 rpm in 50 ml of YPD media. 
After incubation, 1 ml yeast culture was mixed with 1 ml of 50% glycerol stock and stored at -
80 °C until further use.  
 
2.2.3 Expression of recombinant CD81  
 
Shake flask culture 
For large scale recombinant CD81 expression, large scale yeast growth was performed using 
large baffled shake flasks. One colony of P. pastoris from YPD agar plates was added to a 
250 ml baffled flask containing 50 ml BMGY and incubated at 30 °C and 220 rpm for overnight 
growth. 5 ml of this seed culture were added into 200 ml of fresh BMGY media in separate 1 
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L baffled flask and grown for 22 - 24 h at 30 °C and 220 rpm. To induce recombinant CD81 
expression, cells were measure to OD600 of 1 and pelleted from BMGY media by centrifugation 
at 5000 x g for 10 min. The cells were resuspended in 500 ml of BMMY media  in  2 L baffled 
shake flask. Culture was grown for 22 h, supplemented with 5 ml of absolute methanol and 
further grown for 22 h. Cell pellet was harvested by centrifugation (5000 rpm for 20 min at 4 
°C) and stored at -80 °C until further use.  
 
Bioreactor culture 
A 2 L Applikon bioreactor was used to grow yeast cells on a large scale.  
Inoculum seed culture  preparation 
A single P. pastoris colony was added into a 250 ml baffled flask containing 50 ml BMGY 
media to prepare seed culture. The culture was incubated overnight at 30 °C at 220 rpm. After 
12 h growth, 1 L bioreactor BMGY media was inoculated with seed culture at an OD600=1 and 
grown at 30 °C at 220 rpm.  
 
Glycerol batch phase 
Media used in bioreactors: 
Basal salts medium (BSM) 
26.7ml 85% phosphoric acid, 0.93 g calcium sulphate, 18.2 g potassium sulphate, 14.9 g 
magnesium sulfate heptahydrate, 4.13 g potassium hydroxide and 40.0 g glycerol were 





PTM1 trace salts 
Dissolved 6.0 g cupric sulfate-5H2O, 0.08 g sodium iodide, 3.0 g manganese sulfate-H2O, 0.2 
g sodium molybdate-2H2O, 0.02 g boric acid, 0.5 g cobalt chloride, 20.0 g zinc chloride, 65.0 
g ferrous sulfate-7H2O, 0.2 g biotin and 5.0 ml sulphuric acid in water to a final volume of 1 L 
and filter sterilised. The solution was stored at room temperature. 
 
Yeast extract, peptone and glycerol (YPG) 
10 g yeast extract and 20 g peptone were dissolved in 900 ml water, added to a bioreactor 
and autoclaved. Separately, 10 g or 40 g glycerol were dissolved in 90 ml water, was 
autoclaved then added to an autoclaved bioreactor using a needle and syringe. 
 
Method: 
Bioreactor set up was performed using either BSM and PTM1 trace salts or using complex 
medium YPG. 1 ml of Antifoam J673A  was added to each bioreactor vessel using a needle 
and syringe. PTM1 trace salts (4.35 ml) were added in the same way  (if using a minimal 
medium). The dissolved oxygen  probe was allowed to polarise for > 6 h. Next, the stirrer (set 
to 700 rpm), the temperature (30°C) and aeration were applied to the system. The pH of the 
vessel, set to either pH 5 or pH 7 (later in the experiment), was controlled using 50% 
phosphoric acid and 28% ammonium hydroxide. The bioreactor media was inoculated with 
seed culture at OD600=1. The dissolve oxygen was maintained at ~30% by automatic addition 
of air from compressor. The culture was grown until the glycerol in the media was completely 
consumed; this was when the dissolve oxygen trace increased towards 100%. The culture 





Methanol fed batch phase 
Methanol was added in the bioreactor vessel at the feed rate of 4 ml/h. The feed rate was than 
increased to 8 ml/h for rest of the growth. The induction phase lasted for ~26 h before yeast 
harvest.  
 
2.3  Pichia pastoris membrane solubilisation 





5% glycerol, 2 mM EDTA, 100 mM sodium chloride, 50 mM sodium phosphate monobasic 
(NaH2PO4),   
50 mM sodium phosphate dibasic (Na2HPO4), pH 7.4 
For 1 L solution,  50 ml of 5 % glycerol, 4 ml of  0.5 M EDTA stock solution, 5.84 g NaCl, 11.3 
ml of I M NaH2PO4 stock solution and 38.7 ml of 1 M Na2HPO4 stock solution  were added in 
to 800 ml deionised water. The solution was mixed in 800 ml water and pH adjusted to 7.4 
before making up the final volume to 1 L with dH2O. The solution was autoclaved and stored 
at 4 ◦C. 
 
Resuspension buffer (Buffer A) 
20mM HEPES, 50mM sodium chloride, 10% glycerol, pH 7.0  
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For 1 L solution, 4.76 g of HEPES, 2.92 g of NaCl and 100 ml of glycerol were added in to 800 
ml of deionised water. The solution was mixed and pH was adjusted to 7.0, before making up 
the final volume to 1 L with dH2O. The solution was autoclaved and stored at 4 °C.  
 
Method: 
The cells from  large scale P. pastoris growth from shake flask or bioreactor were lysed using 
an Emulsiflex-C3 cell disrupter (Avestin)  to isolate  membranes. The cell pellet was mixed 
with ice-cold breaking buffer and protease inhibitor cocktail at the ratio of 1: 3: 0.001 (for 
example; 52 g cell pellet was mixed with 156 ml of breaking buffer and 52 µl of protease 
inhibitor cocktail). The cells were passed through the cell lyser for approximately 5 times (for 
~15 min) at 20,000 to 25,000 psi. Any unbroken cells and cell debris were removed by 
centrifugation (10,000 × g, for 30 min at 4 °C). The supernatant was collected and 
ultracentrifuged (100,000 × g, for 1 h at 4 °C). The pellet containing yeast membranes was 
collect, resuspended  in buffer A (at the wet pellet weight of 160 mg/ml) and homogenised 
using glass homogeniser. Membrane fraction was stored at 4 °C for immediate use or at -80 
°C for future analysis.  
 
2.3.2  P. pastoris membrane solubilisation  
 
SMA preparation 
The commercially available polymers (SMA 2000 and SZ25010 were provided as styrene 
maleic anhydride co-polymers and required to be converted to the styrene maleic acid by 
hydrolysis in sodium hydroxide by following previously published protocol (Rothnie, 2016). 
Briefly, a solution of each styrene maleic anhydride copolymers 10% (w/v) was dissolved in 1 
M sodium hydroxide, refluxed for 2 h and allowed to cool to room temperature. The polymers 
were precipitated by the addition of excess concentrated hydrochloric acid and washed 
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extensively with distilled water. Washed polymer was dissolved in 0.6 M sodium hydroxide to 
give a pH of 8, and freeze-dried. Styrene maleic acid co-polymer was stored at room 
temperature.  
 
10% of SMA 2000 and SZ25010 polymer stock was prepared by dissolving 10 g of polymer in 
80 ml of distilled water using magnetic stirrer and making the final volume of 100 ml. 
 
Detergent stock 





20 mM Tris-HCl, 150 mM sodium chloride, pH 8.0 
To make 1 L buffer, add 3.15 g of Tris-HCl and 8.76 g of sodium chloride  in 800 ml of dH2O. 
The solution was mixed and pH adjusted to 8.0 before making the final volume to 1 L 
 
HEPES buffer 
20 mM HEPES, 200 mM sodium chloride, 10% glycerol, pH 8.0 
To make 1 L buffer, add 4.76 g of HEPES, 11.68 g of sodium chloride and 100 ml of glycerol 
in to 700 ml of distilled water and mix well. Adjust pH using sodium hydroxide before making 





1x PBS (137 mM sodium chloride, 2.7 mM potassium chloride, 10 mM sodium phosphate 
dibasic, potassium phosphate dibasic, pH 7.4), 150 mM sodium chloride, 10% glycerol  
For preparing 1 L buffer, prepare PBS solution and add 8.76 g of sodium chloride and 100 ml 
of glycerol in 800 ml of distilled water. Adjust pH to 7.4 before making the final volume to 1 L. 
1% DDM and 0.1% CHS were added just before use. 
 
SMA co-polymer solubilisation 
Yeast membrane was solubilised with either SMA 2000 or SZ25010 polymer. Recombinant 
CD81 expressing P. pastoris membranes, at the wet pellet of 160 mg/ml were diluted four fold 
with either Tris-HCl or HEPES buffer and incubated with 2.5% of the SMA polymer for 1 h at 
room temperature on mild agitation. Insoluble material was sediment by ultracentrifugation 
(100,000 × g, 20 min at 4 ◦C) to yield supernatant containing solubilised CD81.  
 
Detergent solubilisation 
Yeast membrane expressing CD81 was solubilised with DDM (n-dodecyl-ß-D-maltoside) with 
either HEPES buffer or PBS solubilisation buffer, where fresh 1% DDM and 0.1% cholesterol 
hemisuccinate were added. The membrane fraction was solubilised for 1 h at 4 °C on magnetic 
stirrer prior to ultracentrifugation (100,000 x g for 1 h at 4 °C) to collect supernatant containing 
solubilised CD81.  
 
2.4 CD81 purification 
2.4.1 SMALP-CD81 purification 
Ni+2 NTA resin and buffers 
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Optimised protocol, using the solubilised fraction from 20 ml membrane preparation. 10 ml 
Ni+2 NTA resin was used.  
Wash 1 – 500 ml of HEPES buffer supplemented with 20 mM imidazole. 
Wash 2- 200 ml of HEPES buffer supplemented with 40 mM imidazole 
Wash 3- 10 ml HEPES buffer supplemented with 60 mM imidazole 
Elution buffer – 30 ml of HEPES buffer supplemented with 300 mM imidazole 
 
Method: 
The solubilised fractions were incubated with Ni+2 NTA agarose resin (washed twice with water 
and once with Tris/NaCl buffer) overnight at 4°C with mild agitation. The solution was poured 
into a chromatography column and the flow-through was collected. Resin was washed with 50 
bed volume of 20 mM imidazole containing Tris/NaCl buffer, a second wash with 20 bed 
volume of 40 mM imidazole buffer and a final wash with 3 bed volume of 60 mM imidazole 
buffer.  The bound CD81 were eluted with 300 mM imidazole buffer in six fractions. The elution 
fractions were pooled, buffer exchange to Tris buffer (without imidazole) via dialysis or using 
a centrifuge concentrator (Vivaspin 10 kDa cut-off, Sartorius). The IMAC purified and buffer 
exchanged SMALP-CD81 sample was then concentrated using centrifuge concentrator 
(Vivaspin 20 kDa cut-off, Sartorius) up to 500 µl.  
 
Harvest SMALP-CD81 was further analysed and purified through size exclusion 
chromatography (SEC) using AKTA Pure system (GE Healthcare) using a Superdex increase 





2.4.2 DDM-CD81 purification  
Ni+2 NTA resin and buffers 
The solubilised fraction from 20 ml membrane preparation. 2 ml Ni+2 NTA agarose resin was 
used. Where critical micelle concentration (CMC) of DDM is 0.0087% (0.0087% = 1 times 
DDM CMC) 
Wash 1- 10 ml PBS buffer supplemented with 50 mM Imidazole and 0.1% DDM  
Wash 2- 10 ml PBS buffer supplemented with 100 mM Imidazole and 0.1% DDM 
Wash 3 - 10 ml PBS buffer supplemented with 150 mM imidazole and 0.1% DDM 
Wash 4 – 10 ml PBS buffer supplemented with 200 mM imidazole and 0.1% DDM 
Elution buffer- 10 ml PBS buffer supplemented with 300 mM imidazole and 0.1% DDM 
 
Method: 
The solubilised fractions were incubated with Ni+2 NTA agarose resin (washed twice with water 
and once with Tris/NaCl buffer) overnight at 4°C with mild agitation. The solution was poured 
into a chromatography column and the flow-through was collected. Resin was washed four 
times with 5 resin bed volume of 50 mM imidazole, 100 mM imidazole, 150 mM imidazole and 
200 mM imidazole respectively.  The bound CD81 were eluted with 300 mM imidazole buffer 
in five fractions. The elution fractions were pooled, buffer exchange to PBS buffer (with 0.1% 
DDM but without imidazole) and concentrated using a centrifuge concentrator (Vivaspin 75 
kDa cut-off, Sartorius) to typically achieve 500 µl of 3 mg/ml concentrated SMALP-CD81 




Harvest SMALP-CD81 was further analysed and purified through size exclusion 
chromatography (SEC) using AKTA Pure system (GE Healthcare) using a Superdex increase 
200 10/300 GL SEC column.  
 
2.4.3 Protein concentration analysis 
Bicinchoninic acid (BCA) protein assay 
Protein concentration was determined using 1 mg/ml bovine serum albumin (BSA) as standard 
in a sterile 96 well flat bottom plate. A standard curve was generated by plating BSA standard 
in triplicate wells at concentrations of 0, 0.2, 0.4, 0.6, 0.8 and 1.0 mg/ml making up a total to 
10 μl volume with PBS. Samples were plated in triplicate to a total volume of 10μl. 200μl BCA 
reagent (a 50:1 ratio (v/v) between BCA solution and 4% (w/v) copper II sulphate solution) 
was added to all triplicate wells of standards and samples. The plate was incubated at 37 °C 
for 30 min. Absorbance values were measured on a Biotek EL800 microplate reader using a 
570nm filter. A standard curve was generated to calculate the protein content of samples, 
expressed as mg/ml. 
 
Gel based protein concentration determination 
Purified CD81 concentration were determined using SDS gel based protein assay (Rothnie 
2016). BSA stock of 1 mg/ml was made and used to prepare a series of BSA concentrations: 
0.25, 0.5, 0.75, 1.0 and 1.25 mg/ml (making up a total 15 µl volume with dH2O). Two CD81 
test samples, containing 10 µl and 20 µl protein, were also prepared. Each BSA concentrations 
and test protein samples were mixed with 5 µl 5 × LSB buffer with reducing agent and loaded 
in to 12 % SDS-PAGE gel. The gel was stained with Coomassie blue stain and the band 
intensity was calculated with ImageJ software. A standard curve was created by plotting BSA 
intensity as a function of mass, from which the CD81 concentration were calculated.  
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2.4.4 SDS gel electrophoresis  
Buffers 
Laemmli sample buffer 
A 4x Laemmli buffer was prepared using 2.4 ml 1 M tris pH 6.8,  0.8 ml  SDS stock, 4 ml 
glycerol,  0.01% bromophenol blue, 1ml β-mercaptoethanol and 2.8 ml dH2O. All the reagent 
were mixed together and the solution was stored at room temperature. 
 
Running buffer  
10x SDS-Tris buffer from National Diagnostics was used containing 0.25 M tris, 1.92 M 

















12% separating gel 
Volume to  prepare 
gel (x2) 
Polyacrylamide 30% 4.5 ml 
Distilled water 3.6 ml 
1.5 M Tris-HCl pH 5.5 3 ml 























4% staking gel 
Volume to prepare 
gel (x2) 
Polyacrylamide 30% 0.7 ml 
Distilled water 3.1 ml 
0.5 M Tris-HCl pH 6.8 1.3 ml 










Table 2.2: SDS-PAGE 4% stacking gel reagents.  
 
Method: 
Sodium dodecyl sulphate (SDS) polyacrylamide gel electrophoresis (PAGE) gels were 
prepared by making 12% separating gel, by mixing all the reagents stated in the Table 2.1, 
where TEMED was added last as it rapidly polymerises the gel solution. This was poured in 
the gel slide and topped with water. Once the gel had set, water was poured out and 4% 
stacking gel was added on top. The stacking gel was prepared by mixing all the reagents 
shown in the Table 2.2. A 10 well comb was inserted and then removed once the gel had set. 
 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was used to 
separate proteins from test samples according to their molecular weight. A 5 μl of 5x Laemmli 
sample buffer, with β-mercaptoethanol or without reducing agent, was mixed with 20 µl of test 
79 
 
sample. The samples were loaded in to the SDS-PAGE gels along with 5 µl of standard protein 
molecular weight marker (protometrics national diagnostics ladder - Fisher). 1 L of running 
buffer was added in the SDS tank prior to running of SDS-PAGE at 150 volts for ~1.5 h or until 
the dye reached the bottom of the gel.  
 
2.4.5 Western Blotting 
Buffers 
Western transfer buffer 
10x Tris buffer from National Diagnostics was used containing 0.25 M tris and 1.92 M glycine. 
100 ml of tris buffer and 200 ml of absolute methanol was mixed with 700 ml of distilled water. 
 
Phosphate buffered saline (PBS) 
The buffer was prepared by dissolving 10 PBS tablets (Fisher) in 1 L water 
 
Blocking buffer 




1 L of PBS buffer was prepared by dissolving 10 PBS tablets in 1 L distilled water. 2 ml of 






The antibodies shown in the Table 2.3 were used for the western blot analysis. 
 
Primary Antibody Dilution 
Anti-CD81`2s131 (Produced in-house; Grove et al. 
2017) 
1: 100 
Mouse Anti-His antibody (Cell Signalling 
Technology) 
1:5000 
Rabbit Anti-FLAG® antibody  (Sigma-Aldrich) 
       
     
1:5000 
Secondary Antibody   
Anti-rabbit HRP-linked Antibody (Cell Signalling 
Technology)      
      
1: 2000 
Anti-mouse HRP-conjugated IgG  (Sigma-Aldrich) 1: 2000 
 
Table 2.3: Primary and secondary antibodies used in Western blot analysis. Primary 
antibodies were used to identify CD81 EC2 epitope, C-terminus His6 tag or N-terminus FLAG 
tag. Secondary antibody was bound to primary to produce chemiluminescent signal through 




Following SDS-PAGE, immunoblot (western blot) was performed by transferring the proteins 
to PVDF membrane (Polyvinylidene Difluoride membrane, 0.2 µm, ThermoFisher Scientific; 




 Four fibre pads, four filter papers (Whatman 3 mm chromatography paper) were soaked in 
western transfer buffer. Next, using a colour coded cassette (Bio-Rad) a transfer insert was 
prepared by placing two fibre pads on the black side of the cassette and two filter papers on 
top. The SDS gel was carefully placed on top of the filter paper and covered with two more 
filter papers and fibre pads. The cassette was closed and locked and inserted into a colour 
coded electrophoretic western blotting cell.   The blotting cell and a Bio-ice cooling unit were 
placed in to a Bio-Rad PROTEAN 3 tank. Around 1 L of the western transfer buffer was added 
and ran for 100 V for 1 h.  
 
The PVDF membrane was removed and placed in a container containing 50 ml of blocking 
buffer and incubated for 1 h at room temperature with gentle shaking. The membrane was 
washes three times for 15 min with PBST buffer and stained with primary antibody and 
incubated at room temperature for 1 h. The membrane was rinsed three times for 15 min with 
PBST buffer and further stained with horse radish peroxidase (HRP) conjugated secondary 
antibody (prepared in blocking buffer) for 1 h. The membrane was washed 5 times for 25 min.  
4 ml of EZ-ECL Enhanced Chemiluminescence Detection Kit for HRP (Biological Industries) 
was poured on the membrane and protein bands were visualised with Gene-box (Syngene).  
 
2.5 CD81 biophysical analysis 
2.5.1 Circular Dichroism  
For circular dichroism (CD) analysis, the purified protein was buffer exchanged into 20 mM 
sodium phosphate buffer for CD81-SMALP. Sodium phosphate buffer was supplemented with 
0.1% DDM and 0.01% cholesterol hemisuccinate for CD81-DDM purified protein. Data was 
collected between 260 and 180 nm (far-UV wavelength region) at 0.2 nm intervals at 20°C 
using a Jasco J-1500 CD spectrometer. A 1 mm path length quartz cuvette (Starna UK) 
containing 200 µl of CD81-SMALP (0.05mg/ml) or CD81-DDM (0.09mg/ml) was used for each 
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analysis and 18 technical replicates were performed for each sample. For thermal melt 
analysis, temperature was increased from 25 - 90°C, with increments of 5°C. Structural CD 
data analysis was performed using Dichroweb (Whitmore and Wallace, 2004, Whitmore and 
Wallace, 2008) using CDSSTR, Contin-LL and Selcon3 algorithms (Sreerama and Woody, 
2000). For thermal melt analysis, 1 mm path length cuvette was used containing 200 µl of 
CD81 samples were used in sodium phosphate buffer. Each spectrum was collected with the 
data pitch of 0.1 nm. 18 technical replicate scans were taken at each temperature point for 
thermal melt assay.  
 
2.5.2 ELISA 
Enzyme linked immunosorbent assay (ELISA) was performed to detect CD81 binding with a 
functionally relevant antibody and to perform receptor ligand binding.  
 
Anti-CD81 ELISA 
For anti-CD81 binding ELISA, 50 µl of purified protein (100µg/ml) were added to a 96-well 
plate (Immulon II ELISA plate Bunc) in triplicate and incubated overnight at 4 °C. Unbound 
protein was removed by washing three times with PBS (200 µl/well). Plates were blocked with 
100 µl of 2%(w/v) BSA in PBS per well for 20 min at room temperature to reduce any 
nonspecific binding and washed three times with PBS. Samples were incubated with 50 µl 
primary anti-CD81 antibodies 1s337, 1s135 or 2s337, diluted 1:2 in PBS-Tween (0.05% v/v). 
After three PBS washes (200 µl/well), samples were incubated with HRP-conjugated anti-
mouse secondary antibody (Sigma-Aldrich) at a dilution 1: 1000 in PBS-Tween for 1 h at room 
temperature.  Three final washes were performed (200 µl/well) followed by the addition of 
SIGMAFAST™ OPD Tablets solution (Sigma-Aldrich) (100 μl/well) and incubated for 15 to 20 
min at room temperature. The stop reagent (1 M sulfuric acid from Sigma-Aldrich – 100 µl/well) 
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was used, once the solution started changing colour from colourless to pale orange. The 
absorbance was measured on a Fusion plate reader (Perkin-Elmer) at 450 nm. 
 
Receptor-ligand (CD81-E2)  ELISA  
An ELISA was also used to measure binding of HCV E2 glycoprotein to CD81. CD81 protein 
samples were bound to plates, blocked and washed as described above. Following this 
samples were incubated with 50 µl of 85 µg/ml purified streptavidin-tagged E2 protein for 1 h 
at room temperature incubation before three PBS washes. 50 µl primary anti-strep antibody 
(Progen #910STR) diluted 1:5000 in PBST and incubated at room temperature for 1 h with 
gentle shaking.  After three PBS washes (200 µl/well), samples were incubated with HRP-
conjugated anti-mouse secondary antibody (Sigma-Aldrich) at a dilution 1: 1000 in PBST.  
Wells were washed and developed as described above. 
 
2.5.3 Dynamic light scattering  
50 µl of CD81-SMALP (0.05mg/ml) or CD81-DDM (0.09mg/ml) were used for the DLS 
measurement. The data was collected using a Malvern Instruments ZetasizerNano S (633 
nm). Measurements were taken in disposable ultra-micro UV cuvettes (BrandTech Scientific) 
at 20 °C with 300 s equilibration time, where automated parameters were used. Each 
measurement was repeated seven times.   
 
2.5.4 Protein aggregation assay 
The aggregation of purified protein following heating at a range of temperatures from 20 °C to 
90 °C was assayed. 100 µl of purified protein samples (30 µg /ml) were heated for 10 min at 
selected temperature points followed by centrifugation at 10,000 g for 10 min to remove 
aggregation. Supernatant was collected and 20 µl sample from each were loaded on 12% 
SDS-PAGE gel following staining with Coomassie stain. The gel bands were analysed by 
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densitometry and amount of remaining protein in each temperature treatment was normalised 
with the 4 °C temperature treatment reading. 
 
2.5.5 Preparation of lipid only SMALPs 
The lipid only SMALPs was prepared using 15 mg of DMPC (1,2-dimyristoyl-sn-glycero-3-
phosphocholine) lipids from Sigma. Lipids were dissolved in 2:1 chloroform-methanol, rapid 
dried using nitrogen and placed under the vacuum for at least 1 h at room temperature. The 
lipid film was resuspended in sodium phosphate buffer to form a 2% (w/v) suspension. 2.5% 
(w/v) SMA 2000 polymer was added at a 1:1 ratio to solubilise lipids into SMALPs, the milky 
lipid suspension spontaneously clarifies indicating solubilisation. Excess polymer was 
removed by size exchange chromatography (SEC) using AKTA Pure unit (GE Healthcare) 
connected to Superdex 200 30/10 increase column (GE Healthcare).  
 
2.6 Pichia pastoris protoplast generation 
Buffers and reagent 
SED buffer 
1 M sorbitol; 25 mM EDTA; 50 mM  DTT 
To make 500 ml buffer, add 91 g of sorbitol, 7.3 g EDTA and 3.85 g of DTT (just before use). 
Dissolve in 400 ml of dH20 and make up the total volume of 500 ml.  
 
CG buffer 
20 mM trisodium citrate, 10% glycerol, pH 5.8, Protease inhibitor tablet 
To make 500 ml buffer, add 2.9 g of trisodium citrate, 50 ml glycerol. Adjust pH and add 





Zymolase 20 T (Amsbio, UK). Resuspended in water at 200 U/ml and stored at -20 °C. 
 
Method: 
A 24 g of Pichia pastoris cell pellet was taken forward to prepare protoplast. Wash the pellet 
in 400 ml of dH20 and centrifuged for 5 min at 5000 g. Supernatant discarded and pellet 
washed with 400 ml of SED buffer. Discard supernatant again and pellet was washed with 1 
M sorbitol.  The pellet was Resuspended in 300 ml of CG buffer and 1 ml of 500 U/ml Zymolase 
stock solution was added and incubated at room temperature for 15 min with gentle shaking. 
Protoplast was harvested by soft centrifugation for 5 min at 750 g. The protoplast pellet was 
gently Resuspended in 150 ml of solubilisation buffer and taken forward for the SMA 
solubilisation.  
 
2.7 CD81 microscopy analysis 
2.7.1 Negative staining EM to visualise SMALP-CD81 nanodiscs 
Uranyl acetate solution 
2% uranyl acetate solution was prepared. For 50 ml solution, 1 g of uranyl acetate was 
dissolved in 40 ml of distilled water, pH adjusted to 4.2 and the final volume was made up to 
50 ml. The solution was covered with foil and stirred overnight.   
 
To visualise SEC purified SMALP-CD81 nanodiscs 
The samples SEC purified SMALP-CD81 elution peaks and DMPC-CD81 nanodiscs were 
visualised through negative staining to identify isolated SMA lipid particles. The EM grids 
(copper grid with a formvar-carbon support film from Agar Scientific) were glow discharged for 
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2 min to distribute negative charge on the surface before for sample adsorption. 10 µl of 
sample drop was placed on each grid and incubated for 2 min at room temperature. Excess 
solution was blotted off and grids were washed three times with distilled water before gently 
drying using Whatman filter paper (Agar Scientific). 3 µl drop of uranyl acetate stain was 
placed on each grid and incubated for 4 min following three washed with distilled water. The 
grids were visualisation using JEOL 2100Plus super high resolution TEM-STEM at room 
temperature. The images were acquired at 60000x by Dr Saskia Bakker at Cryo-EM facility at 
the University of Warwick.  
 
Negative staining with Ni-NTA-Gold nanoparticle 
For the Ni+2-NTA conjugated 5 nm gold particle (purchased from Nanoprobes) binding to the 
His6 tagged CD81, SEC purified SMAL-CD81 peaks and SMALP-DMPC samples were used 
and visualised through negative staining EM. 10 µl of each sample was incubated on the glow 
discharged EM grids for 2 min at room temperature following three washes with distilled water. 
The grids were then placed upside down on a droplet of (10 µl) of 0.5 µM Ni+2-NTA-Gold 
particles for 30 min at room temperature. Excess solution was blotted off, washed with buffer 
three times and with distilled water three times. Samples were stained with 3 µl of uranyl 
acetate for 4 min following three distilled water washes. The grids were visualisation using 
JEOL 2100Plus super high resolution TEM-STEM at room temperature. The images were 
acquired at 60000x by Dr Saskia Bakker at Cryo-EM facility at the University of Warwick.  
 
2.7.2 Confocal microscopy 
Cells were grown in the microscopy compatible tissue culture dishes (Greiner cell view plates 
from VWR). The media was aspirated and washed twice with ice-cold PBS and cells were 
fixed with 4% paraformaldehyde (in PBS) for 15 min at 37 °C. Cells were washed three times 
with PBS and  incubated with 20% FBS for 1 h at room temperature. CD81 protein on the cells 
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were labelled with anti-CD81 antibody (2s131) as primary antibody at 1:700 dilution in 20% 
FBS (in PBS) incubated for 12 h  at 4 °C. Cells were washed with PBS three time before 
labelling with Alexa Fluor 488-conjugated secondary antibody (Sigma) for 1 h at room 
temperature. Excess antibody was removed by washing cells five times with PBS and washed 
once with DAPI diluted 1:100 (in PBS) for 3 min. Cells were further washed once with PBS. 
Nuclei were counterstain using Prolong Gold medium containing DAPI (20 µl). Cover slip was 
placed and live cells were visualised with a confocal laser scanning microscope SP5 TCS II 
MP by Leica (using ARCHA advanced imaging facility at Aston University, images taken by 
Charlie Clarke-Bland). 
  
2.7.3 Electron microscopy  
Cell processing for electron microscopy 
Fixation 
Cells were harvested through scraping and subsequent centrifugation (to obtain at least 1 mm 
size pellet). Cells were fixed using 2% EM grade glutaraldehyde (8% stock from Polysciences) 
for 1 h with 1 ml solution volume at room temperature. Cells were washed three times with 
PBS and once with dH20 before dehydration step.  
 
Dehydration 
After fixing, the cells were dehydrated to achieve 100% dehydration. Starting from 10% 
dehydration, 1 ml of 10% ethanol was mixed with the cell pellet and incubated for 15 mins 
before harvesting the cells by centrifugation. Repeat this step six times with 10% ethanol 
concentration increments to achieve 70% dehydration. Cell pellet was stored in 100 µl PBS at 
4 °C before taking to Warwick University to perform 100% dehydration using ethanol and then 
into acetone for 20 mins. 
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Resin preparation and Embedding 
Epoxy resin was prepared using both araldite (Araldite 502) and epon resin (Embed812). 
Resin were prepared by Ian Hands-Portman at Warwick University. Briefly, 12.5 ml Embed 
812 and 7.2 ml Araldite 502, 27 ml DDSA and 1.3 ml BDMA were heated separately at 65 °C 
for 12 h followed by combining first three reagents and then BDMA was added. The 1:1 epoxy 
resin and acetone were incubated for 1 h. The diluted resin was replaced with 100% resin by 
curing (heating to 40 °C). The resin was then infiltrated into the sample overnight (~ 15 h) in a 
vacuum oven.  
 
Sectioning on ultramicrotome (performed at Warwick University) 
After embedding and curing the cells in the resin, the sample block was securely fastened 
onto the ultramicrotome holder. The stereomicroscope lenses over the microtome were 
adjusted to the lowest magnification and lighting were set to focus on the sample. A diamond 
knife was inserted in the knife holder for precise sample sectioning. Automated sectioning was 
selected to obtain ~100 nm sections, where the sectioning was performed at low speeds to 
produce thin sections. The sections were collected onto copper grids (copper EM grid with a 
formvar-carbon support film from Agar Scientific) and dried before placing the grid in a grid 
storage box. 
 
Immunolabelling the cell sections with gold labelled anti-CD81 antibodies 
The cell sections were labelled with two anti-CD81 antibodies: anti-CD81 2s131 conjugated 
with 15 nm gold particle (stock concentration 170 µg/ml), and anti-CD81 1s337 conjugated 
with 6 nm gold particle (stock concentration 70 µg/ml). The two custom conjugated antibodies 
were generated by Generon UK. The grid containing cell sections were blocked with 1% BSA 
in PBST for 30 min and rinsed twice with PBS. The grids were them incubated with 2 µg/ ml 
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of both 2s131 and 1s337 antibodies for 1 h at room temperature in 1% BSA/PBST, followed 
by three PBS washes and heavy metal staining.   
 
Uranyl acetate staining 
The EM grid was stained with 3 µl of 2% uranyl acetate for 10 min and washed three times 
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Table 2.4: List of some of the crucial cell processing steps performed to prepare cell 




The grids were visualised using JEOL 2100Plus super high resolution TEM-STEM fitted with 
Gatan OneView IS camera at room temperature. The images were acquired at 30000x by Ian 
Hands-Portman at Cryo-EM facility at the University of Warwick. 
 
2.8 LCP crystallisation trial of SMALP-CD81  
The crystallisation trials were performed at the University of Warwick in collaboration with Prof 
Alex Cameron. The two lipid cubic phase (LCP) crystallisation screens were used for 
crystallisation attempt,  MemGold and MemGoldMeso (Molecular Dimensions). The screens 
encompassed 96 crystallisation conditions each, containing various combinations of pH range, 
polyethylene glycol (PEG) concentrations and salt additives based on previous successful 
membrane protein crystallisation conditions.  The crystals trays were set up using Mosquito 
LCP robot (TTP Labtech), where 50 nl of the LCP suspension and 800 nl of the screen solution 
were dispensed robotically on the 96 well glass plates (Molecular Dimensions).  
 
2.9 Mammalian cells to study CD81 
2.9.1 Mammalian cell growth  
Cell reviving 
Defrost the cryo vial rapidly from the liquid nitrogen storage. Prepare T125 flask by adding 5 
ml of the media. Spray the cryo vial with 70% ethanol and warm the frozen cells by hands. 
Transfer the content of the vial into the flask slowly (drop-by-drop). Incubate at 37 °C in 5% 
CO2. It will take around 4 days to reach cell confluency of 80%. Standard cell culture protocol 





Warm media, PBS and trysin in 37 °C incubator. For HEK cells passage: tap the flask gently 
to dislodge cells from the flask surface. Centrifuge at 5000 rpm for 5 min to obtain cell pellet. 
Resuspend cells in fresh media. Divide cells 1:5 (for passage after 3 days) or 1:10 (for passage 
after 3 days) into new flasks by making up the total volume of 15 ml in each flask. 
 
For Huh 7 and HepG2 cells, trypsin was used to dislodge the cells from the surface. Remove 
the media from  the flask and cells were rinsed with 10 ml tissue culture grade PBS. A 2 ml 
trypsin (Merck) was added and incubated for 5 min at 37 °C. A 10 ml of media was added, 
cells were washed off from the bottom of the flask and centrifuged to spin down the cells. Cell 
pellet was harvested or resuspended with 10 ml of fresh media and divided 1:5 (for 2 days 
growth) or 1:10 (for 3 days) growth in new flasks, where each flask has the total volume of 15 
ml. 
 
For endogenous CD81 detection in HEK293 S and T cells, western blots analysis were 
performed. Cells were grown as an adherent monolayer in T75 flasks containing 15 ml DMEM 
medium at 37 °C until 80% confluent. Cells were harvested through scraping, washed with 
phosphate buffer, lysed and ultra-centrifuged to obtain membrane only fractions. HEK 293S 
and T membranes were then incubated with 2.5 % SMA polymer solution for 1 h at room 
temperature and soluble (supernatant) and insoluble (pellet) fractions were separated through 
ultracentrifugation. Solubilisation efficiency was tested through western blot analysis where 







Before dividing cells into new flask, cell concentration were counted using hemocytometer. A 
90 µl of cell suspension was taken in an Eppendorf tube and 10 µl of trypan blue was added 
and mixed well, where 10 µl of the suspension was loaded in the hemocytometer and number 
of cells per ml was calculated.  
 
Cryo-preserve mammalian cells 
The harvested cells were cryo freezed  in 90% FBS and 10% DMSO  . The cell pellet was 
resuspened in 1 ml of the freezing media in the sterile cryo-vial, which was placed in -80 °C 
freezer for 2 h and then in liquid nitrogen for long term storage.  
 
 
2.9.1 Preparation of whole cell lysate (WCL) 
1x Triton X-100 lysis buffer 
1% Triton X-100, 10 mM Tris pH 7.5, 150 mM sodium chloride, 1 mM EDTA and 0.02% sodium 
azide. 
For preparing 500 ml of the lysis buffer, 5 ml of Triton X-100, 5 ml of 1 M Tris, 15 ml of 5 M 
sodium chloride, 1 ml of 0.5 M EDTA stock and 0.1 g of sodium azide were mixed with 400 ml 
of dH2O and total volume was made upto 500 ml. Buffer was stored at 4 °C. 
 
Citrate saline buffer 
1.35 M potassium chloride and 0.15 M sodium citrate   
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Made 200 ml of 10x stock.  Added 20.12 g of potassium chloride and 6.42 g of sodium citrate 
and dissolve in 150 ml of dH2O. The total volume was then made up to 200 ml. The solution 
was filter sterilised and diluted 10 folds before use.  
 
Method: 
The old media was aspirated from the flask and cells were washed with 4 ml of PBS. 
Mammalian cells were scrapped off from each well and transferred to 1.5 ml Eppendorf tubes 
on ice. Cells were spun down at 5000 rpm for 3 min and supernatant was aspirated out. The 
tubes containing cell pellet were placed on ice for at least 2 min to chill. During the spin, 1 ml 
of 1% triton X-100 lysis buffer was taken in 1.5 ml Eppendorf tube and 10 µl of 100x protease 
inhibitor cocktail (Sigma) was added and vortexed. Cells were lysed by adding 150 µl of the 
ice-cold 1% Triton X-100 lysis buffer and vortexing for two  lots of 10 sec. Cells in lysis buffer 
were incubated on ice for 30 min before centrifuging at 14,000 rpm for 10 min at 4 °C to pellet 
down nuclei and other soluble material. Supernatant was collected and stored at -20 °C. 
 
2.9.2 Membrane preparation (for HEK and Huh-7 cells) 
 Homogenisation buffer 
10 mM Tris HCl; 250 mM Sucrose; 1 mM EDTA; protease inhibitor tablet (Sigma); pH 7.4 
To make I L buffer, add 85.5 g of sucrose, 1.57 g of Tris-HCl and 0.29 g of the EDTA dissolve 
in 800 ml of dH2O and make up the total volume to 1 L. Stored at 4 °C. 
 
Buffer-A 
20 mM HEPES, 50 mM sodium chloride, 10% glycerol, pH 7.0 
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For preparing 1 L of buffer A, 4.76 g of HEPES, 2.92 g of sodium chloride and 100 ml of 
glycerol were dissolved in 800 ml of dH2O. pH was adjusted with sodium hydroxide and the 
total volume was made up to 1 L.  
 
Method: 
The harvested cell pellet was washed in ice-cold PBS twice. Supernatant discarded and 5 ml 
of homogenisation buffer added per T75 cell pellet. The cells were lysed by titrating through 
fine needle twenty times before spinning at 4000 rpm to pellet down debris. Supernatant was 
spun at 45,000 rpm for 1 h to collect membrane only fraction in the pellet. The pellet was then 
weighted and resuspended to a suitable buffer-A volume to obtain wet pellet concentration of 
80 mg/ml. 
 
2.9.3 Mammalian membrane solubilisation 
SMA solubilisation 
For CD81 solubilisation, a 500 µl of 80 mg/ml of membrane preparation was taken in which 
13.125 mg of SMA 2000 or SZ25010 polymer and 11.8 µl of buffer A was added and incubated 
at room temperature for 1 h shaking. The membrane suspension was then ultracentrifuged 
(45,000 rpm for 1 h) to separate soluble fraction (supernatant) from the insoluble pellet.  
 
Detergent solubilisation  
The 500 µl of membrane preparation at 80 mg/ml was solubilised with 55 µl of either 10% 
DDM only stock or 10% DDM with 1% CHS stock to obtain final concentration of 1% DDM and 
0.1% CHS. The membrane suspension was incubated at 4 °C for 1 h before ultracentrifugation 




2.10 Transient transfection of recombinant CD81 
2.10.1  E-coli transformation 
Luria-Bertani (LB) broth and LB agar 
For 1 L media, 20 g of LB was dissolved completely into water and autoclave.  For preparing 
LB agar 20 g/L LB and 15 g/L agar was dissolved completely in water and autoclaved 
.Ampicillin antibiotic added fresh after cooling the media to ~40 °C before pouring media into 
sterile petri dishes.  
 
Ampicillin antibiotic 




The transformation of XL-Gold Ultracompetent E-coli cells were performed with pEF6.A 
plasmid DNA to produced four differently transformed groups: pEF6.A containing no CD81 
gene; pEF6.A containing wild type CD81; pEF6.A containing four cysteine residue mutated 
CD81; and pEF6.A containing all cysteine residue mutated CD81.  
 
Before transformation, LB agar plates were placed in the incubator to evaporate any 
condensation and water bath was turned on and set to 42 °C. One tube of XL-Gold 
Ultracompetent E-coli cells was thawed on ice and an empty 1.5 ml of Eppendorf tube was 
placed on ice to chill. 1 µl of 1 µg/µl of relevant DNA was added into Eppendorf tube containing 
50 µl of XL-10 Gold Ultracompetent E-coli culture. The tube was incubated on ice for 30 min 
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(maximum) following heat shock treatment for 45 s at 42 °C. The tube was placed back on ice 
for 2 min incubation following the addition of 1 ml LB broth (without Ampicillin) and incubation 
at 37 °C for 1 h shaking. The cell suspension was centrifuged at 5000 rpm for 5 min to collect 
the cell pellet. The cells were resuspend in 50 µl of LB broth and plated out on LB agar plates 
(containing Ampicillin). The plates were Incubate for 16 h at 37 °C to obtain single colonies of 
transformed cells. A single colony was picked on the next day and inoculated in 10 ml of LB 
broth containing 10 µl Ampicillin in 50 ml Falcon tube for 16 h incubation at 37 °C. The seed 




Mini and/or Maxi preparation was performed using QIAGEN® Plasmid Mini and Maxi Kits 
(following manufacturer’s protocol) to collect plasmid DNA for future transfection work. 
 
2.10.2  PEI transfection  
PEI solution 
Using a plastic Pasteur pipette, 0.1 g of PEI solution (from Sigma Aldrich) was taken into a 
beaker containing 80 ml of dH2O. Mixed well until the PEI dissolved completely. The pH was 
adjusted to 7.0 using hydrochloric acid. The total volume was made up to 100 ml and filter 
sterilised in the tissue culture hood using 0.22 µm syringe filter (Fisher Scientific). The PEI 






Method (for 6-well plates): 
On the day before transfection, 5 x 105 cells in 2 ml complete DMEM media were plated out 
in a 6-well plate. Next day, 100 µl of Opti-Mem serum free medium  (Thermofisher) was taken 
into 1.5 ml Eppendorf tubes. 2 µg of DNA was added and mixed by flicking the tubes. 8 µl of 
PEI stock solution was added in the tube and mixed by gently vortexing. Incubate for 10 min 
at room temperature before slowly adding the DNA/PEI complex to the cells with gently mixing. 
Cells were incubated for 48 h at 37°C before harvest.  
 
2.10.3 Lipofectamine (for 6-well plates) 
Lipofectamine™ LTX Reagent with PLUS™ Reagent from Thermofisher Scientific was used.  
On the day before transfection, cells were grown in 2 ml DMEM media to reach 1 million cells 
per ml on the day of transfection.    Two Eppendorf tubes were prepared per transfection.  In 
one tubes 150 µl of Opti-Mem medium and 7.5 µl of lipofectamine reagent was added, gently 
mixed and incubated for 5 min.  In the second tube  1 µg DNA and 14 µg PLUS reagent were 
diluted with 700 µl of Opti-Mem, which was mixed gently and incubated for 5 min at room 
temperature. The DNA suspension was added into the lipofectamine reagent solution and 
mixed gently before incubating for 5 min at room temperature. Add drop-by-drop of the DNA 










 Recombinant hCD81 solubilisation from Pichia pastoris using SMA 2000  
co- polymer 
 
Membrane proteins (MP) are crucial players in several biological processes, such as signal 
transduction, ion transport and electron transfer to name a few. In order to understand how 
they work, to comprehend their role in cell biology and to perform in depth structural analysis, 
it is essential to solubilise and purify MP to fully characterise them. Membrane proteins, such 
as tetraspanin CD81, are notoriously difficult to study as they are present in low levels and 
require detergents to keep them soluble in an aqueous solution (Homsi et al., 2014). In this 
chapter, recombinant tetraspanin CD81 MP was overexpressed in Pichia pastoris cells and 
attempts were made to solubilise it in SMALPs using SMA co-polymers to aid future 
biophysical, structural and lipidomic studies.  
 
Two different types of SMA co-polymers were used, in this chapter, to solubilise CD81 from 
the P. pastoris membranes. These were SMA 2000 and SZ25010 polymers: SMA 2000 
polymer has an average molecular weight of 7.5 kDa, consisting of 33% maleic acid subunits, 
while SZ25010 polymer is 10 kDa in size and consists of 25% maleic acid content (Morrison 
et al., 2016).  The polymer spontaneously inserts into biological membranes and forms small 
nanodiscs (~10 nm in size) of lipid bilayer that are surrounded by the polymer, therefore, 
extracting MP in their surrounding lipoprotein environment.  The small size of these nanodiscs, 
containing the protein of interest, can then be purified, whist retaining the lipid environment 
(Gulati et al., 2014, Dorr et al., 2015).  
 
P. pastoris is a methylotrophic yeast that is widely used as an eukaryotic expression system 
for the production of recombinant membrane proteins for scientific research and development 
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(Jamshad et al., 2006).  The increasing popularity of the P. pastoris expression system is 
attributed to its ease of growth compared to other higher eukaryotes as these cells can be 
grown on a large scale (using shake flasks and bioreactors) in simple medium. The yields can 
reach around 100 g of cell pellet from 1 L of the culture growth medium, corresponding to an 
optical density reading reaching greater than 500 OD600 units/ml (Byme, 2015).  Another major 
advantage of using P. pastoris is that it provides tightly controlled methanol-inducible 
transgene expression, where heterologous membrane protein expression will take place in 
the presence of an inducer.  
 
In this study, the P. pastoris X-33 strain was utilised to produce CD81 under tight regulation 
using the alcohol oxidase-1 (AOX1) promoter in the pPICZB vector. Expression of 
recombinant CD81 relies on the expression driven by the AOX1 promoter, which is supressed 
in the presence of glycerol that is added in the growth medium as a preferred carbon source 
for cell growth as well as a repressor of AOX1 transcription. Addition of methanol triggers the 
expression of the promoter gene, which in turn initiates the transcription and expression of the 
recombinant CD81 gene. 
 
To overexpress CD81 protein, a previously-established P. pastoris construct was used by 
Jamshed et al. 2008. Briefly, the coding sequence of the protein was tagged at the 3´ end (C-
terminus of the corresponding protein) with a hexa-histidine tag and cloned in the  P. pastoris 
expression vector pPICZB downstream of an AOX1 promoter sequence at the EcoR1 and 
XhoI restriction sites. To avoid potential CD81 aggregation after solubilisation, palmitoylation 
sites were eliminated by conserved point mutation. Six intracellular cysteines at residue 
numbers 7, 10, 81, 90, 228 and 229 were mutated to alanine (schematic of the construct is 
shown in Figure 3.1), where these variations in CD81 palmitoylation  null (CD81 p-null) 
sequence had been demonstrated to not affect the overall function and stability of CD81 
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(Berditchevski and Odintsova, 1999). An additional N-terminal serine in the coding sequence 




Figure 3.1: Schematic representation of recombinant hCD81 protein used in this 
project.  Possible palmitoylation sites (intracellular cysteine residues) at sequence position 7, 
10, 81, 90, 227 and 228 are mutated to alanine to prevent protein cross-linking (represented 
with white circles). Two extracellular loops are shown, the small extracellular loop (EC1) and 
the large extracellular loop (EC2), where EC2 contains conserved CCG motif that is important 
for disulphide bridge formation. The C-terminus contains His6 for ease of purification (shown 









Figure 3.2: Wild type CD81 protein sequence and recombinant sequence in pPICZB 
plasmid. The wild type sequence shown in black letters, while p-null sequence is shown in 
blue letters. The mutated palmitoylation sites (six Cys residues at 7, 10, 81, 90, 228 and 229 
are mutated to Ala) are indicated in pink boxes in the recombinant sequence, where an 
additional N-terminal Ser is also indicated in pink box. The C-terminus site contain hexa his-
tag (shown in blue box) for protein identification in western blots. Four transmembrane helices 







3.1 Recombinant CD81 expression in Pichia pastoris membranes 
Full-length recombinant CD81 has previously been produced in milligram quantities using P. 
pastoris  (Jamshad et al., 2008).  To confirm CD81 expression and to generate large cell 
biomass for subsequent studies, large scale growth was performed using shake flasks. 
 
 For P. pastoris growth, a 5 ml in seed culture was inoculated in a shake flask containing 200 
ml BMGY media and grown for 24 h. Optical density was measured after every 1 h for 6 h to 
monitor the increase in cell density, as shown in the Figure 3.3. The data show that after an 
initial lag phase of approximately 1.5 h, exponential growth of P. pastoris cells was achieved, 
with a predicted doubling time of 2 h.  
 
 
Figure 3.3: P. pastoris growth in glycerol medium. Large scale P. pastoris growth in BMGY 
medium was performed to increase cell biomass and repress CD81 gene expression. A single 
recombinant P. pastoris colony was inoculated in 50 ml of BMGY medium and grown for 24 h 
or until the OD600 reached 1.0, as a seed culture. Next, 5 ml of the seed culture was added to 
shake flasks containing 200 ml BMGY medium at a starting OD600 of 0.1. Flasks were 
incubated at 30 °C and 230 rpm for 24 h growth, where optical density at 600 nm were taken 
during the first 6 h of growth at 1 h intervals. Data analysed using GraphPad Prism. N=3. 
 
















After overnight growth, cells were pelleted from the BMGY medium, resuspended in 500 ml 
BMMY medium and cultured for 24 h to induce CD81 gene transcription. Figure 3.4 shows 
culture optical density analysis in BMMY medium, which indicates a  much slower doubling 
time compared to the cell growth in glycerol (BMGY) medium. This was expected as methanol 
is not ideal for cell growth; it was added to activate the AOX1 promoter that would induce 
CD81 expression.  
 
 
Figure 3.4: Pichia pastoris growth in methanol medium. Large scale P. pastoris growth 
was performed in methanol containing BMMY medium to induce CD81 gene expression. Cells 
were pelleted from the glycerol medium via centrifugation, resuspended in methanol medium 
(BMMY) and cultured for 24 h to aid CD81 protein expression at the membrane. OD600 
readings were taken immediately after cell inoculation in BMMY media and for the first 6 h 
growth at 1 h intervals. Data analysed using GraphPad Prism. N=3.  
 
 
After 24 h cell growth in methanol medium, the culture was supplemented with 1% pure 
methanol and further grown for 24 h before cell harvest.  OD600 readings of the culture were 
taken, post methanol supplementation, for 6 h at 1 h intervals, which is shown in Figure 3.5. 
The data indicate a much slower cell growth after supplementation compared to the initial 
BMMY growth.  


















Figure 3.5: Pichia pastoris growth after 1% pure methanol supplement in the media. 
After 24 h of cell growth in methanol medium, cultures were supplemented with 1% absolute 
methanol as final concentration. OD600 were taken for immediately after methanol 




A ~100 g cell pellet was collected at the end of large-scale growth from eight shake flasks, 
which was then  frozen at -80 oC until the membrane preparation step. The P. pastoris 
membrane fraction was obtained by lysing the cells under high pressure (maximum pressure 
of ~25,000 psi). Unbroken cells and cellular debris were separated through centrifugation, and 
the membrane only fraction was pelleted through ultracentrifugation. The presence of His6-
tagged CD81 protein was detected through western blot analysis using an anti-His6 primary 
antibody, as shown in Figure 3.6. The Western blot analysis confirmed the presence of a ~25 
kDa CD81 protein band. The expected CD81 size, as suggested in the scientific literature, is 
~ 26 kDa; the size difference observed in our samples was possibly due to palmitoylation site 
mutation. A lower protein gel band was also observed, which was assumed to be a truncated 
CD81 protein in the sample.  
 

















Figure 3.6: Western blot analysis to detect CD81 protein from shake flask and 
bioreactor membrane preparations. Western blot detection of recombinant CD81 from the 
membrane fraction using commercially-available monoclonal anti- His6 antibody as primary 
and horse radish peroxidase (HRP) conjugated anti-mouse antibody as secondary antibodies. 
Each lane contains 20 µl of membrane fraction mixed with 5 µl of LSB buffer with reducing 




3.2 CD81 solubilisation using SMA co-polymer 
The SMA co-polymers, SMA 2000 and SZ25010, were used to test CD81 solubilisation 
efficiency from the crude membrane preparation. This was to obtain CD81 in SMA lipid 
particles (SMALPs) to circumvent some of the stability issues with membrane proteins after 
extracting them from their surrounding lipid environment. The CD81 protein in SMALPs, i.e. in 
their lipo-protein membrane surroundings is expected to keep the protein more stable than 
conventional detergent based membrane protein solubilisation methods.  
 
The membrane preparation with a wet pellet protein concentration of 40 mg/ml was incubated 
with 2.5% SMA co-polymer for 1 h at room temperature with gentle agitation to solubilise CD81 
in SMALPs. The n-dodecyl-β-D-maltoside (DDM) solubilisation was used as a positive control, 
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as this has previously been shown to extract CD81 from P. pastoris membranes with high 
efficiency (Jamshad et al., 2008). For the negative control, the membrane preparation was 
tested with the same experimental conditions except for the addition of any solubilising agent.  
 
The membrane preparation from cells was a viscous and turbid suspension. After the addition 
of SMA co-polymers, SMA 2000 or SZ25010 as solubilising agent, the membrane turbidity 
dropped dramatically after 1 h incubation, suggesting the breakdown of large lipoprotein 
chunks of plasma membrane into small pieces, as shown in the optical density (OD600) 
analysis in Figure 3.7. No change in turbidity was observed in the negative control sample. A 
significant drop in membrane turbidity was observed in both SMA 2000 and SZ25010 
solubilisations, and also in DDM solubilisations. This suggested that both SMA co-polymers 
were able to solubilise P. pastoris membranes with high efficiency that was comparable to 
detergent CD81 solubilisation. However, OD600 analysis only measured total protein 









Figure 3.7: Membrane preparation image and optical density analysis of SMA co-
polymer membrane solubilisation. SMA co-polymer extraction efficiency compared to 
detergent solubilisation. Two polymer samples were prepared containing 150 µl of 160 mg/ml 
membrane fraction each and 150 µl of either 10 % SMA2000 or SZ25010 solution in Tris/NaCl 
buffer and made to total concentration of 2.5% SMA in 600 µl total volume.  A positive control 
sample was prepared by adding 60 µl of 10 % DM, 60 µl glycerol, and 150 µl of 1 M NaCl 
solution, 60 µl 10 × PBS and 150 µl membrane prep into 120 µl of deionized water to make a 
total volume of 600 µl. The negative control sample contained 150 µl membranes and 450 µl 
of Tris/NaCl buffer. Samples were incubated on a bench-top rocker for 1 h at room 
temperature. Optical density of the samples were measured at 600 nm and analysed using 
GraphPad Prism. N=3.   
 
 
In order to test for specific CD81 solubilisation efficiency, western blot analysis and 
quantification were performed on the solubilised and insoluble membrane fractions, as shown 
in the Figure 3.8. The western blot clearly displays CD81 monomeric bands in both polymers 
and detergent samples. The soluble SMA2000 and SZ25010 CD81 bands appeared fuzzy 
and less pigmented, which is a known feature of SMA co-polymers that hinder the antibody 
detection system (Rothnie, 2016). To quantify solubilised CD81 monomer amounts from the 
western blots, band intensities were measured using ImageJ software. Readings were 
converted into percentages, where the DDM-CD81 band intensity readings were taken as the 
positive control (100%). The quantification of the western blot, also shown in the Figure 3.8, 
shows the percentage of solubilised CD81 protein in SMA2000 and SZ251010 samples, which 
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appeared comparable to that of DDM solubilised CD81, indicating efficient CD81 solubilisation 
with the SMA co-polymers. The actual SMA polymer solubilisation efficiency for CD81 was 
predicted to be higher, but due to poor staining of SMALP-CD81 bands in western blots, due 
to SMA polymer hindrance with antibody detected system, not all SMALP-CD81 protein was 
quantified.   
 
Overall, this work indicated that SMA polymer extracts recombinant CD81 from the P. pastoris 
membranes with high efficiency that was comparable to detergent solubilisation. 
 
 
Figure 3.8: Western blot analysis and quantification of CD81 solubilisation using SMA 
co-polymers. Two SMA co-polymers were used, SMA 2000 and SZ25010, where detergent 
(DDM) solubilisation was used as a negative control. CD81 was detected through anti-CD81 
(2s131) as primary antibody and HRP-conjugated anti-mouse secondary antibody. Each lane 
contains 20 µl of sample and 5 µl of LSB buffer. The quantification of Western blot was 
performed using ImageJ software, where DDM-CD81 band intensity reading was set at 100% 






3.3: Rate of CD81 solubilisation using SMA co-polymers 
In order to determine the optimal SMA co-polymer solubilisation time, various incubation time-
points were tested from 15 min to 4 h. Optical density readings were taken at each time-point 
to calculate the decrease in membrane turbidity, associated with protein solubilisation. 
Western blot analysis was also performed to quantify the amount of CD81 obtained at each 
time-point.  
 
Figure 3.9 shows a photograph that was taken before and ten minutes after addition of SMA 
2000 polymer into a crude P. pastoris membrane preparation.  The membrane preparation 
was a bright orange opaque and turbid suspension, becoming a clear pale orange suspension 
after 10 min of polymer addition, suggesting rapid break down of the membrane. Both samples 
were compared at the same dilution to perform optimal comparison.  
 
Figure 3.9: Crude membrane image before and 10 min after SMA 2000 polymer addition. 
An image of a crude membrane was taken before the addition of any solubilising agent and 
after ten minutes of SMA polymer addition and room temperature incubation. Before = 
membrane only sample without any solubilising agent. After= membrane fraction with 2.5% 





The optical density readings at 600 nm were taken before polymer addition and at each time 
point after polymer addition. Figure 3.10 show a sharp drop in OD600 reading within 15 min of 
incubation that further decreased after 30 min. The OD600 reading did not change after that 
and remained constant at subsequent time point readings. This suggested that the maximum 
solubilisation efficiency was reached after 30 min or the spectrophotometer was not sensitive 
enough to detect further smaller changes in membrane turbidity. From this, it was concluded 
that the SMA polymer was able to solubilise P. pastoris membranes rapidly where most 
solubilisation was achieved within 15 min. However, specific CD81 solubilisation was 
predicted to be much slower, possibly due to the formation of manometer sized particles after 




Figure 3.10: Optical density analysis of SMA 2000 polymer solubilisation at various time 
points. Six time points were tested, these were: 15 min, 30 min, 1 h, 2 h and 4 h and a negative 
control (membrane only fraction without polymer addition, plotted as 0 min reading). Samples 
were incubated at room temperature with gentle shaking. Each contained 150 µl of membrane 
preparation, 150 µl of 10% SMA 2000 solution (to achieve a final 2.5% polymer concentration) 
and 300 µl Tris/NaCl buffer. The negative control contained 150 µl membrane preparation and 
450 µl buffer. Optical density of the samples were measured at 600 nm and analysed using 
Graph Pad Prism. N=3. 
 





























To determine the rate of specific CD81 solubilisation, Western blot analysis and quantification 
was performed, as shown in Figure 3.11. In the Western blot, the changes in insoluble CD81 
bands intensity were tested at each time points rather than soluble fraction as Western blot 
protein bands were found to be blurry and poorly pigmented for solubilised SMALP-CD81, 
which was unreliable for quantification and has previously been observed by Rothnie et al., 
2016. Therefore, in this work and subsequent analysis, CD81 amounts in insoluble fractions 
were quantified to calculate the increase or changes in the amount of soluble CD81.  
 
The quantification of Western blot protein bands suggested much slower CD81 protein 
solubilisation compared to the rapid membrane solubilisation. The analysis indicated that after 
15 min, around 80% CD81 remained insoluble. This was in marked contrast with the optical 
density data. After 1 h incubation, around 50% CD81 from the SMA 2000 co-polymer samples 
had been solubilised, whereas, optimum protein solubilisation efficiency was achieved after 4 
h when only ~30% protein remained insoluble, indicating that the majority (70%) of CD81 had 
been solubilised by the polymer. 
 
This work suggested that the P. pastoris membrane turbidity dropped rapidly after SMA 2000 
co-polymer addition and after just 15 min remained constant. However, although this bulk 
membrane disruption occurred quickly, the specific solubilisation of CD81 was much slower 




Figure 3.11: Western blot analysis and quantification of  SMA 2000 solubilistaion at 
various time points.  Western blot showing insoluble CD81 fraction after SMA 2000 
solubilisation at various time points. Insoluble CD81 (from the pellet fraction after 
ultracentrifugation) was detected with an anti-CD81 (2s131) antibody as primary antibody and 
HRP-conjugated anti-mouse as secondary antibody. Each lane contains 20 µl  sample and 5 
µl LSB buffer. Western blot protein bands were quantified using ImageJ software. Protein band 
intensity readings were reported as a percentage, where insoluble CD81 at 0 min was taken 
as 100%. Graphs were plotted using GraphPad Prism. N=3.  (S)= soluble fraction. 
 
 
3.4: Optimisation of SMA 2000 co-polymer concentration  
Further analysis were performed using SMA 2000 co-polymer to optimise protein solubilisation 
conditions for subsequent downstream processing. The CD81 solubilisation at varying SMA 
2000 polymer concentrations were tested, which were: 0% (negative control), 0.5%, 1%, 1.5%, 
2%, 2.5% and 5%. Each of the seven test samples were incubated at room temperature for 1 
h after polymer addition.  
 
The optical density data is shown in Figure 3.12.  The optical density reading significantly 
dropped, from the 0% polymer concentration, even with the addition of 0.5% polymer 
suggesting that only a small amount of the polymer was needed to breakdown larger 
lipoprotein complexes. The OD600 readings of rest of the conditions also remained at the low 




Figure 3.12: Optical density analysis of membrane solubilisation at various SMA 2000 
co-polymer concentrations. Seven test samples were prepared, containing 0%, 0.5%, 1%, 
1.5%, 2%, 2.5% and 5% polymer concentrations.  Each of the seven samples contained 150 
µl of membrane preparation and either no SMA polymer (negative control), 30 µl, 60 µl, 90 µl, 
120 µl, 150 µl or 300 µl of 10 % SMA 2000 solution respectively in Tris/NaCl buffer to make 
total volume of 600 µl. Optical density of the samples were measured at 600 nm and analysed 
using Graph Pad Prism. N=3. 
 
 
However, western blot quantification of CD81 protein from the insoluble fractions, shown in 
Figure 3.13, suggested less efficient CD81 solubilisation compared to the breakdown of the 
membranes (optical density data, Figure 3.12). The insoluble CD81 protein amount steadily 
decreased with an increase in polymer concentrations suggesting an increase in solubilisation 
efficiency at higher polymer concentrations. Around eighty percent CD81 remained insoluble 
in 0.5 % polymer concentration, whereas, only less than 40% CD81 remained in the insoluble 
fraction in 1.5 % polymer concentration. More than half of the CD81 protein appeared to 
solubilise in 2.5 % polymer and nearly 80% of the protein was solubilised after a 1 h incubation 











































From these data, higher polymer concentration (5%) was shown to be most successful for 
CD81 solubilisation. However, high polymer quantity in solubilised fractions might have 
negative effects on subsequent downstream purification steps due to excess polymer 
hindrance with His-tag binding to nickel NTA resin, as predicted by Morrison et al. 2016. For 
this reason, 2.5% polymer concentration, displaying more than 50% CD81 solubilisation 




Figure 3.13: Western blot analysis and quantification of insoluble CD81 at various SMA 
2000 concentrations. The insoluble CD81 fractions at each of the seven polymer 
concentrations were detected using Western blot analysis. Anti-CD81 (2s131) antibody was 
used as primary and HRP-conjugated anti-mouse antibody was used as secondary antibody. 
Each lane contain 20 µl of sample and 5 µl of LSB buffer. Western blot protein bands were 
quantified using ImageJ software. Protein band intensity readings were reported as a 
percentage, where insoluble CD81 at 0% polymer comcentration was taken as 100%. Graphs 
were plotted using Graph Pad Prism. N=3.  (S)= soluble fraction. 
 
 
This work suggested that an SMA 2000 polymer concentration of 2.5% with 1 h room 




3.5: Pichia pastoris growth and CD81 expression in bioreactors 
 
In order to upscale recombinant CD81 production from shake-flasks, bioreactor growth was 
performed. Membrane fractions were prepared using the same methodology as shake flasks 
(as described in chapter 2). Figure 3.14 shows the difference in bioreactor and shake flask 
membrane appearance. The bioreactor membrane preparation appeared pale orange in 
colour compared a bright orange coloured shake flask membrane fraction. Also the total 
protein concentration was lower in bioreactor samples, which was 10 mg/ml in comparison to 




Figure 3.14: An image of crude membrane preparations from the shake flask and 
bioreactor. Comparison of the bioreactor membrane preparations from the shake flasks. 
Each Eppendorf tubes contained 1 ml of membrane preparation. 
 
 
Moreover, western blot detection and quantification, as shown in Figures 3.15, detected less 
CD81 in bioreactor-produced cell membranes compared to two independent shake flask 
membranes. Around 40% less CD81 was detected in bioreactor samples than shake flask 
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membrane fractions. A lower order protein band was also observed in shake flask membranes, 




Figure 3.15: Western blot analysis and quantification to detect and compare CD81 
protein expression from the shake flask and bioreactor membrane preparation. Western 
blot was performed to check and compare CD81 expression, where two independent shake 
flask membrane samples were compared to test CD81 expression in the bioreactor membrane 
preparation. The protein was detected through anti-His6 antibody as primary antibody and 
HRP-conjugated anti-mouse antibody as secondary antibody. Quantification of CD81 
monomeric bands from the Western blot was also performed.  Monomeric CD81 western blot 
band intensity was calculated using ImageJ software. Shake flask band intensity was used as 
positive control (100 %) to compare percentage CD81 obtained from bioreactor preparation. 
Data was analysed using Graph Pad Prism, where N=2. 
 
 
To determine CD81 solubilisation efficiency from the bioreactor produced cell membranes, 
both shake flask and bioreactor membranes were solubilised side-by-side with SMA 2000 co-
polymer. Three test samples were prepared: two test samples containing 1 ml of either 
bioreactor or shake flask membrane preparation that were solubilised with 2.5 % SMA 2000; 
one negative control sample (bioreactor membrane) with no solubilising agent.  Each sample 
was incubated at room temperature for 1 h before collecting soluble and insoluble CD81 
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fractions through ultracentrifugation. Western blot analysis and quantification were performed, 
as shown in Figure 3.16. Quantification of CD81 bands detected a very low percentage of 
soluble CD81 from the bioreactor sample compared to the shake flask sample. The amount 
of insoluble CD81 from the bioreactor samples were also very low. This suggested a possible 
low CD81 expression in bioreactor-produced P. pastoris membranes compared to shake flask 
membranes, or difficulty in western blot detection of the solubilised SMALP-CD81 from the 
bioreactor membrane preparation (due to polymer hindrance). As relatively intense insoluble 




Figure 3.16: Western blot analysis and quantification to detect SMA 2000 solubilised 
CD81 from the bioreactor membrane preparation. The CD81 polymer solubilisation 
efficiency from the bioreactor membrane was compared with the shake flask membranes. 
Three samples were prepared: first sample contained 150 µl of shake flask membrane and 
150 µl of 10 % SMA 2000 solution; the second sample contained 150 µl of bioreactor 
membrane and 150 µl of 10 % SMA 2000 polymer solution; the final sample contained 150 µl 
of bioreactor membrane with no solubilising agent. The CD81 protein was detected with anti-
His6 antibody as primary antibody and HRP-conjugated anti-mouse antibody as secondary 
antibody. Quantification of CD81 solubilisation from the shake flask and bioreactor 
membranes was also performed. Western blot monomeric CD81 band intensity was reported 
as percentages. Soluble CD81 intensity from shake flask membranes was converted to 100% 
to compare CD81 solubilisation from bioreactor membrane fractions. Data were analysed 





An enzyme-linked immunosorbent assay (ELISA) was performed to detect CD81 protein in 
bioreactor and shake flask membrane preparations, using various CD81 specific antibodies 
that had been previously raised against recombinant CD81. A total of eight antibodies was 
tested, out of which three antibodies (2s131, 1s337 and 1s135) had been previously shown to 
bind to full length detergent solubilised P. pastoris membrane expressing CD81 (Grove et al. 
2017), as listed in Table 3.1. Also, according to the epitope mapping studies from Grove et al. 
2017,  the antibody 2s131 recognises a continuous region in the helix D of the CD81 EC2 (not 
structurally sensitive), whereas, antibodies 1s337 and 1s135 recognises discontinuous  
regions (epitope) of EC2 across helices A, B and C (structurally sensitive antibody). The 
remaining five antibodies does not show binding affinity with the full length detergent 
solubilised and purified CD81 from P. pastoris (unpublished data from Dr Michelle Clare), as 


























Table 3.1: Table showing binding ability of eight of in-house produced monoclonal anti-
CD81 antibodies.  The binding affinity of various antibodies were tested by performing ELISA 
with the full length detergent (DDM) solubilised CD81. ELISA plates were coated with different 
concentrations of CD81 and titrated the antibodies against it. CD81 used was 0.1, 0.2 and 0.4 
µg/µl. Antibodies (suspended in RPMI medium supplemented with 10% FCS) were diluted 
1:100, 1:500, 1:1000, 1:2000 and 1:5000. Data generated by Dr Michelle Clare.  
 
 
Both shake flask and bioreactor derived CD81 were tested by ELISA using a total of eight anti-
CD81 antibodies. BSA protein was used as a negative control. Figure 3.17 confirmed CD81 
binding (from both shake flasks and bioreactor membrane preparations) to three of the anti-
CD81 antibodies (Ab 2s131, 1s337 and 1s135) that were known to bind to detergent purified 
CD81. However, the binding intensity, measured through colorimetric detection, in bioreactor 
membrane preparations was low compared to shake flask membrane preparations. This 
indicated that bioreactor membrane preparations had lower CD81 expression than shake flask 
membranes, thus, suggesting the superiority of shake flask growth to obtain higher CD81 
expression. Table 3.2 compares findings from shake flask and bioreactor growth, CD81 
expression and polymer solubilisation efficiency, where bioreactor growth appeared to be 
 














superior for obtaining higher cell biomass. On contrary, higher total protein concentration and 
efficient SMA co-polymer CD81 solubilisation were observed in shake flask grown P. pastoris 
membranes. 
 
Hence, this work unexpectedly suggests that although P. pastoris growth can be scaled-up 





Figure 3.17: ELISA to detect and compare CD81 protein from the shake flask and 
bioreactor membrane preparations using a range of anti-CD81 antibodies. Seven in-
house produced anti-CD81 antibodies were used for this analysis, mAb 21139, 1s73, 2s131, 
2s20, 2s48, 1s337, 1s135 and 1s201. BSA protein was used as a negative control. Primary 
antibodies were bound to HRP-conjugated anti-mouse secondary antibody and visualised 

















































Total culture volume 4 L 1 L 
Growth time 56 h 56 h 
Harvested cell-pellet 100 g per 4 litre 100 g per litre 
Membrane fraction 12 g 12 g 
Total protein 
concentration 
17 µg/µl 10 µg/µl 
CD81 expression in 
Western blot 
Dark and thick band ~40% less than shake flask 
membrane 
CD81 SMA solubilisation 
efficiency 
Comparable to DDM Less efficient than DDM 
 
Table 3.2: Comparison of shake flask and bioreactor P. pastoris growth and CD81 p-















Purification, biophysical and biochemical analysis of SMALP-CD81 
After the success of SMA co-polymer solubilisation of CD81 from P. pastoris membranes, 
subsequent purification of recombinant CD81 protein was attempted and optimised to aid 
biochemical studies. For this, immobilized metal-affinity chromatography (IMAC) was 
employed in which the His6 peptide affinity tag (fused to the C-terminus of the CD81 protein) 
was exploited based on its strong interaction between transition metal ions, such as Ni+2. 
However, affinity purification alone is usually not sufficient for obtaining highly homogenous 
membrane protein samples.  Therefore, size exclusion chromatography (SEC) was also used 
where the separation of proteins is based on the size of the analytes in the solution.  
 
The detailed biophysical and biochemical analysis of the IMAC and SEC purified SMALP-
CD81 to determine secondary structure integrity and function compared to detergent (DDM) 
solubilised and purified CD81 is described in this chapter. The presence and abundance of 
correct protein in the purified samples were identified using mass spectrometry protein 
identification along with the detection of any contaminant proteins.  
 
Lastly, attempts were made to extract only mature and correctly folded membrane bound 
CD81 to take forward to future structural studies. For this, yeast protoplasts were prepared by 
enzymatic cell wall removal and subsequent analysis were performed to determine the quality 
of the harvested CD81 protein.  The yeast protoplast were prepared to directly solubilise intact 
cell membranes instead of making membrane preparations prior to polymer solubilisation. This 
method was predicted to favour extraction of correctly folded membrane proteins that have 




4.1 SMALP-CD81 purification and optimisation of purification protocol 
In order to isolate SMALP-CD81 from other solubilised membrane proteins in P. pastoris 
membrane, IMAC was performed by exploiting His6-tag affinity with Ni+2 ions. For initial 
purification trials, a previously-established method for SMALPed membrane proteins was 
used (Gulati et al., 2014). Briefly, 1 ml of membrane preparation was solubilised with 2.5% 
SMA 2000 solution and incubated at room temperature for 1 h. The soluble fraction containing 
solubilised CD81 was collected after ultracentrifugation and incubated with Ni NTA resin at 
the ratio of 1 ml membrane preparation to 100 µl resin at 4 °C for 12 h with gentle shaking. 
The suspension was then poured into a chromatography column and the flow through was 
collected. The resin was washed with buffer containing low imidazole concentration (20 mM 
imidazole at 10 times resin bed volume), to wash-out any nonspecifically bound proteins.  
SMALP-CD81 was eluted with Tris/NaCl buffer containing 200 mM imidazole in six fractions. 
The 20 µl fractions from the wash and elution fractions were loaded on SDS gels to perform 
western blot analysis to detect the presence of SMALP-CD81 protein.  
 
In Figure 4.1, prominent CD81 gel bands at ~25 kDa were seen in all six elution fractions in 
coomassie stained gels showing the presence of SMALP-CD81 in purified samples. However, 
high amounts of an unknown contaminant protein were also observed at around 100 kDa in 
most of the wash and elution fractions, indicating the presence of a contaminant protein at 
higher concentrations than SMALP-CD81. Also, weak CD81 bands were present in the wash 
fractions (containing 20 mM, 40 mM and 60 mM imidazole concentrations), indicating loss of 




Figure 4.1: SDS-PAGE analysis of the SMALP-CD81 IMAC purification. The SMA co-
polymer soluble, purification flow through along with washes and elution samples were 
visualised through SDS-PAGE analysis to determine CD81 content in each fraction.  20 µl of 
samples with 5 µl of LSB buffer were loaded on each well of the 12% SDS-PAGE gel where 
proteins were stained using Brilliant Blue stain. The image is representative of N=3. A) SDS-
PAGE analysis of the SMA 2000 solubilised (S), insoluble pellet (P), IMAC flow through (FT) 
and the 20 mM imidazole washes. B) SDS-PAGE analysis of the 40 mM (40) and 60 mM (60) 
imidazole washes and all six elution fractions with 200 mM imidazole containing elution buffer. 
 
 
Western blot analysis on the soluble, insoluble, flow through, all wash samples and elution 
fractions in Figure 4.2 display the presence of CD81 bands in all samples. However, the 
intensity of CD81 appeared highest in elution fractions indicating the presence of most protein 
in these fractions. Similar to the SDS gel image, a higher order CD81 band or a contaminant 
was also detected in all elution fractions in the western blot analysis. This suggested that 
despite the success in purifying CD81 through nickel affinity purification, optimisation of the 
purification protocol was needed to further reduce contaminant proteins and prevent loss of 






Figure 4.2: Western blot analysis of the IMAC purified SMALP-CD81. The western blot 
analysis was performed using anti-His6 antibody to detect CD8 in soluble, purification flow 
through, wash and elution fractions. The HRP-conjugated anti-mouse antibody was used as 
secondary antibody. Each lane contained 20 µl of the sample and 5 µl of LSB buffer. The 
image is representative of N=3. A) Western blot analysis of the SMA 2000 solubilised (S), 
insoluble pellet (P), IMAC flow through (FT) and the 20 mM imidazole washes. B) Western 
blot analysis of the 40 mM (40) and 60 mM (60) imidazole washes and all six elution fractions 
with 200 mM imidazole containing elution buffer.  
 
 
To optimise the purification protocol for CD81 and eliminate the unknown ~100 kDa 
contaminant protein, further purification trials were performed with an increase in the number 
of buffer washes (20 mM imidazole wash was increased from 10 times to 50 times resin bed 
volume). Moreover, a five fold increase in sample to resin ratio from 1:10 to 1:2 (1 ml of 
membrane preparation to 500 µl of resin slurry) was used. The resin bound CD81 was eluted 
with 300 mM imidazole (instead of 200 mM imidazole) to make sure to elute the majority of 
the protein. Figure 4.3 shows SDS gel analysis of the optimised purification conditions. This 
shows a significant reduction in the ~100 kDa contaminant protein bands. Moreover, the 
majority of the SMALP-CD81 was detected in the first three elution fractions, and a minimum 
loss of SMALP-CD81 in the wash fractions was also observed suggesting the superiority of 
the tested purification conditions. Therefore, for subsequent purification work, a membrane to 
Ni+2 NTA resin ratio of 1:2 was used for SMALP-CD81 purification, and 50 times resin bed 
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Figure 4.3:  SDS-PAGE analysis of the optimised IMAC purification conditions. SDS-
PAGE analysis was performed on the optimised purification conditions using more Ni+2 NTA 
resin (at a membrane to resin ratio of 1:2) and with an increased number of low imidazole (20 
mM) containing buffer washes. Each lane contained 20 µl of sample and 5 µl of LSB buffer. 
Image is representative of N≥3. A) SDS-PAGE analysis of the SMA 2000 solubilised (S), 
insoluble pellet (P), IMAC flow through (FT) and the 20 mM imidazole washes. B) SDS-PAGE 
analysis of the 40 mM (40) and 60 mM (60) imidazole washes and all six elution fractions with 




After the success of small scale CD81 purification trials using 1 ml membrane preparation, a 
larger volume (10 ml) of membrane sample was used to attempt to purify CD81 using 
optimised purification conditions.  Consistent with the small scale purification, purified SMALP-
CD81 was successfully detected in the elution samples at ~25 kDa (shown in Figure 4.4), also 
very low levels of other contaminating proteins were observed. These conditions were also 
tested for large scale purification work using 50 ml of P. pastoris membrane preparation as a 




Figure 4.4: SDS-PAGE analysis of larger scale IMAC purification trial of SMALP-CD81. 
The SDS-PAGE analysis was performed to purify SMALP-CD81 protein from the 20 ml of P. 
pastoris membrane preparation.  Each lane contain 20 µl of sample and 5 µl of the LSB buffer. 
Image is representative of N≥3. A) SDS-PAGE analysis of the SMA solubilised, IMAC flow 
through (FT), 20 mM and 40 mM imidazole washes and the first elution fraction. B) SDS-
PAGE analysis of the remaining five IMAC elution fractions. 
 
 
Therefore, partially pure SMALP-CD81 protein sample was obtained after SMA co-polymer 
solubilisation and IMAC purification, where purification quality was improved by using higher 
amounts of Ni+2 NTA resin and increasing the 20 mM imidazole buffer wash to 50 times the 
resin bed volume. Hence, for subsequent purification work these conditions were used.  
 
4.2: Antigen-antibody binding ELISA  
After successfully purifying SMALP-CD81, the IMAC elution fractions from the medium scale 
purification (starting from 10 ml membrane preparation) were pooled, buffer exchanged into 
Tris/NaCl buffer without imidazole, and concentrated to 1 ml to obtain a concentrated protein 




The SDS-PAGE and Western blot analysis confirmed the presence of monomeric CD81 in the 
buffer-exchanged and concentrated samples, as shown in Figure 4.5. Possible dimeric CD81 
bands were observed by both SDS-PAGE and western blot above 35 kDa, along with other 
higher order unknown contaminating protein gel bands. A gel based BSA protein concentration 
determination assay (A. Rothnie et al., 2014) was used and CD81 concentration was 
determined to be 0.1 mg/ml with an average purity of 54% (calculated from three independent 
replicates).   
 
β-mercaptoethanol is usually added in the Laemmli sample buffer (LSB) buffer prior to running 
the samples on SDS-PAGE to reduce/cleave intermolecular disulphide bonds. In this and 
subsequent analysis, β-mercaptoethanol was omitted from the LSB buffer in order to retain 
cysteine-cysteine interactions to determine an approximate size of a single subunit and the 





Figure 4.5: SDS-PAGE and Western blot analysis of the purified, buffer exchanged and 
concentrated SMALP-CD81. Each lane contains 20 µl of sample and 5 µl of LSB buffer 
without β mercaptoethanol, where the reducing agent (β-mercaptoethanol) was omitted to 
preserve potential intermolecular disulphide bonds between CD81 subunits. 12%   SDS-PAGE 
gel was prepared and imaged using a Syngene G-box, where images are representative of 
N=3. A) Western blot analysis of IMAC purified and concentrated sample. Anti-His6 antibody 
was used as primary and anti-mouse HRP-conjugated antibody as a secondary antibody. B) 
SDS-PAGE analysis of IMAC purified and concentrated sample. Gel was stained with brilliant 
blue dye to visualise protein bands.  
 
 
The enzyme-linked immunosorbent assay (ELISA) was also performed to test CD81 binding 
with a panel of in-house produced monoclonal antibodies that are specific for CD81 large 
extracellular loop (EC2), as discussed in Chapter 3. Figure 4.6 shows that the purified and 
concentrated SMALP-CD81 was able to bind to three of the antibodies that had previously 
detected CD81 in crude membrane preparations (see Figure 3.17).  The detection of SMALP-
CD81 by both conformational antibodies (mAb 1s337 and 1s135) and the non-
conformationally sensitive antibody (mAb 2s131) confirmed the presence of structurally 
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relevant CD81 protein in the IMAC concentrated samples.  This was promising, as these three 
antibodies have also shown binding affinity with the detergent solubilised CD81 as well as to 
the CD81 present in crude shake flask and bioreactor derived P. pastoris membranes.  The 
fact that these antibodies binds to SMALP-CD81 after IMAC purification, indicated that 





Figure 4.6: ELISA to detect SMALP-CD81 with a range of monoclonal anti-CD81 
antibodies. The Ni+2 affinity purified, buffer exchanged and concentrated SMALP-CD81 was 
detected through antigen-antibody binding ELISA. Eight CD81 mAb were used for this 
analysis, mAb 21139, 1s73, 2s131, 2s20, 2s48, 1s337, 1s135 and 1s201, where BSA protein 
was used as a negative control.  Primary antibodies were detected with secondary horse-
radish peroxidase antibody and visualised by SIGMAFASTTM OPD tablet. Optical density 













































Table 4.1 lists the antibodies (provided as hybridoma supernatant) and their binding ability 
with SMALP-CD81 compared to the CD81 in crude P. pastoris membranes and detergent 
purified CD81. A similar binding pattern was observed in all three samples with the exception 
of mAb 1s135 mAb, where lower binding ability of SMALP-CD81 and crude membrane bound 

















Table 4.1: Table showing binding ability SMALP-CD81 with eight in-house produced 
monoclonal anti-CD81 antibodies. The ELISA binding affinity of IMAC purified and 
concentrated SMALP-CD81 with several monoclonal CD81 antibodies are listed in the table. 
SMALP-CD81 mAb binding data was also compared to detergent purified CD81 and to the 















CD81 in crude 
P. pastoris 
membranes 
21139 No No No 




No (very low 
binding) 
2s131 Yes Yes Yes 
2s20 No No No 
2s48 No No No 
1s337 Yes Yes Yes 
1s135 Yes Yes Yes 
1s201 No No No 
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4.3 Mass spectrometry CD81 identification of CD81 
In order to detect the presence of CD81 protein in the IMAC purification samples and to identify 
contaminant proteins, mass spectrometry analysis was performed using LC-ESI-QUAD-TOF 
Mass Spectrometry (using the Mass Spectrometry and Proteomics facility at The University of 
St. Andrews). The proteins in the IMAC samples were separated by SDS-PAGE and visualised 
using Coomassie stain. The gel bands at ~25 kDa (potential CD81 monomer), ~35 kDa and 
~100 kDa, were excised and sent for analysis.  The liquid chromatography mass spectrometry 
(LC-MS) data from the in-gel tryptic digest from the three bands were searched against the 
NCBI database (all sequences in the public domain). The gel band at 25 kDa gave a good 
score for monomeric human CD81; the gel band at ~35 kDa was identified as alcohol 
dehydrogenase protein from P. pastoris, and CD81 protein. Whereas the gel band at ~100 
kDa was identified as plasma membrane ATPase, as shown in Figure 4.7. Table 4.2 shows 
the mass spectrometry protein hits and their corresponding peptide scores for all three gel 








Figure 4.7: Mass spectrometry analysis confirms the presence of monomeric CD81 at 
25 kDa. An SDS-PAGE gel was prepared containing 15 µl of purified and concentrated 
SMALP-CD81 sample loaded with 5 µl of 5 X LSB buffer. The gel was stained with Coomassie 
dye to visualise proteins. Three gel band samples at 23 kDa, ~35 kDa and 100 kDa were sent 
for LC-MS protein identification. The samples were trypsinised and fragmented then analysed 
using an ESI-QUAD-TOF MS instrument. Peptides with fixed carbamidomethyl (C) and 
variable oxidation (M) modification were searched for using MS/MS Ion search on NCBI 
database. Mass spectrometry data were tested three times with independent sample 






































Table 4.2: Mass spectrometry protein hits with their corresponding peptide scores. 
Three protein bands from Coomassie stained SDS gels were analysed. These were the gel 
bands at ~25 kDa; ~35 kDa and ~100 kDa. Average peptide score enabled initial filtering of 
database search results in addition to providing a useful measure of confidence for the 
proteins identified. This parameter is widely applied to results from the analysis of multi-protein 
complexes using a two-dimensional LC/MS/MS workflow (Chepanoske et al., 2005). 
 
 
Overall, around 54% purity was achieved with IMAC purification and concentration. The 
presence of structurally sensitive CD81 protein was confirmed by antigen-antibody ELISA 
using a range of anti-CD81 antibodies; mass spectrometry protein identification further 





 4.4 Circular Dichroism analysis to determine SMALP-CD81 secondary structure  
Circular Dichroism (CD) spectroscopy is a well established biophysical technique to 
structurally characterise biomolecules such as proteins and nucleic acids. CD is a type of light 
absorption spectroscopy that depends on the differential absorption of left- and right-handed 
circularly-polarised light by the chromphores of chiral molecules (Miles and Wallace, 2016). 
Proteins  naturally contain several chromophores that can give rise to the CD signal,  such as 
amide chromophores of the peptide bonds between two amino-acid residues (Kelly et al., 
2005). The alpha-helix, beta-sheet and unordered secondary structure features are calculated 
using the absorption pattern of the far-UV wavelength region from 240 to 180 nm, where the 
two types of electron transitions are responsible for the CD signal, the transition at around 222 
nm and a second transition at ~208 and 190 nm wavelength (Miles and Wallace, 2016). 
 
For the CD spectroscopy of membrane proteins, the secondary structure falls into two major 
groups, alpha helical bundle, beta-barrels or unordered as shown in Figure 4.8 . The far-UV 
spectrum for an alpha helical protein, such as CD81, shows two characteristic negative peaks 
of similar magnitude at 208 and 222 nm and a positive transition (peak) at 190 nm wavelength. 
A beta-barrel protein has a characteristic negative peak at 218 nm and a positive peak 
between 200 and 190 nm. Unordered proteins have a negative peak under ~200 nm but no 
significant positive electron transition. 
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Figure 4.8: Characteristic far-UV CD spectra for an alpha-helix, beta-sheet and random 
coil in membrane proteins. The alpha-helical protein has two negative peaks at 222 and 208 
nm and a positive peak at 190 nm wavelength. The beta-sheet spectrum has a general 
negative peak between 210-220 nm and a positive peak at around 195 to 200 nm. The 
spectrum of a random coiled (disordered) protein has a negative peak at around 200 nm 
(Whitmore and Wallace, 2008).  
To investigate the intact secondary strutcure feature of purified SMALP-CD81, CD analysis 
was performed. The detergent (DDM) purified protein was also used in this study to compare 
CD81 secondary structure profile with SMALP-CD81. The far UV wavelength region of 240 to 
180 nm were studied using  a Jasco J-1500 CD spectrometer at the University of Warwick, 
Chemistry Department.  
Before performing protein CD spectroscopy, various buffer only conditions were tested to 
check for optimal buffer composition for the analysis. Besides keeping the protein stable and 
soluble, the ideal CD buffer must not include any optically-active particles and should be as 
transparent as possible. The total absorbance reading of the sample, including the buffer, 
should be around  1 absorbance  for obtaining high quality data (Greenfield, 2006). Several 
low wavelength absorbing buffers are routinely used but sodium phosphate is the most 
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recommended buffer for CD studies (due to the least absorbance at far-UV wavelength 
region). Therefore, for this study sodium phosphate buffer was used and three different sodium 
phosphate buffer compositions were tested:  20 mM sodium phosphate with 2.5% SMA 2000 
co-polymer; 20 mM sodium phosphate with 0.1% DDM and 0.01% CHS; 20 mM sodium 
phosphate with 150 mM sodium chloride, 10% glycerol, 0.1% DDM and 0.01% CHS, in order 
to check for background signal (noise) from the SMA co-polymer and detergent molecules. A 
20 mM HEPES buffer was also tested, as a control, as HEPES is known to have strong 
absorbance at the far-UV wavelength region, therefore, not ideal for the CD studies.  
 
The CD analyis of the four buffer conditions is shown in the Figure 4.9. The two detergent-
containing sodium phosphate buffer conditions showed the least interference in the CD 
spectrum (Panel A of Figure 2.9) as shown by the minimum base line value throughout 180 to 
300 nm wavelength. This was in marked contrast with SMA co-polymer containing sodium 
phosphate buffer where noise was observed from 180 to 240 nm that was similar to the 
HEPES buffer spectrum, indicating a high background signal. The high tension (HT) and 
absorption (Abs)  values for SMA co-polymer containing buffer was also much higher than  the 
recommended maximum levels of HT ≤ 700 and Abs ≤ 1, respectively.  Therefore, from this 
work, sodium phosphate buffer supplemented with 0.1% DDM and 0.01% CHS (showing 
minimum absorbance interference) was used for DDM-CD81 protein buffer excahange and as 
a baseline correction. While, for SMALP-CD81 work further tests were performed in an attempt 





   
Figure 4.9: CD spectroscopy analysis of different sodium phosphate buffers. Four buffer 
conditions were tested: 20 mM HEPES; 20mM sodium phosphate with 2.5% SMA 2000; 20 
mM sodium phosphate with 0.1% DDM and 0.01% CHS; 20 mM sodium phosphate with 
sodium chloride, glycerol, DDM and CHS. A 200 µl of each buffer conditions was tested in a 
1 mm path length cuvette. Maximum absorbance of 300 nm and minimum absorbance of 180 
nm was used for CD analysis at 0.2 nm intervals at 20 °C; 18 technical replicates were 
performed for each sample, where N=2. CD [mdeg] = CD ellipticity reported in millidegrees; 
HT [V]= High Tension - the voltage applied to the photomultiplier tube to amplify the CD 
detector's sensitivity where HT higher than 700 Volts must be avoided. Abs= CD is reported 










A range of SMA co-polymer concentrations in the sodium phosphate buffer was tested in an 
attempt to reduce polymer inteterference with the CD signal. Six polymer concentrations were 
tested, which were: 0.125% ; 0.25%;  0.5%; 1%; 1.5%; 2.0% along with a buffer condition 
without any polymer as a control. Figure 4.10 indicated strong interference in  all SMA co-
polymer containing buffers even in the lowest polymer concentration (0.125%) conditions, 
whereas no background signal was observed in the buffer only sample (without any polymer). 
This suggested strong optical activity of the linear SMA co-polymer between 180 to 240 nm 
wavelength even at the low concentration.  This observation was consistent with a previously- 
published article by Lee et al., 2016, where a small but significant absorbance of the free 
polymer in the UV wavelength region was suggested, which could impede UV detection 
methods for proteins. However, once the free polymer was removed from the solution/buffer, 
this problem was reduced. Therefore, insead of measuring free SMA polymer to determine 
SMALPs base-line interferance, lipid only SMALPs were utilised.  
 
For subsequent CD studies, excess polymer was removed from the purified SMALP-CD81 
samples prior to the analysis  through buffer exchange in 20 mM sodium phosphate only 
buffer. Additionally, rather than using free SMA co-polymer for the background signal 
correction (baseline correction), lipid-only SMALP solution was prepared, using 1,2-
dimyristoyl-sn-glycero-3-phosphocholine (DMPC) lipid, to substract possible nanodiscs and 
lipid noise from the CD spectrum.   
 
The amount of lipid only SMALPs required as a control for CD analysis was calculated using 
the absorbance peak at 260 nm wavelength of DMPC-SMALP and then diluting it to 






Figure 4.10: CD spectroscopy analysis  of the chosen phosphate buffer containing a 
range of SMA 2000 concentrations. Six SMA 2000 polymer concentrations were tested: 
0.125% ; 0.25%;  0.5%; 1%; 1.5%; 2.0% along with a buffer condition without any polymer as 
a control. 200 µl of each buffer condition was used in a 1 mm path length cuvette. Maximum 
absorbance of 300 nm and minimum absorbance of 180 nm was used for CD analysis at 0.2 
nm intervals at 20 °C; 18 technical replicates were performed for each sample, where N=2. 
CD [mdeg] = CD ellipticity reported in millidegrees; HT [V]= High Tension - the voltage applied 
to the photomultiplier tube to amplify the CD detector's sensitivity where HT higher than 700 
Volts must be avoided. Abs= CD is reported in units of absorbance or ellipticity where Abs 











To examine the folding of the protein CD spectroscopy was used. Figure 4.11 shows that both 
CD81-SMALP and CD81-DDM display two negative peaks at 222 nm and 208 nm and a 
positive peak at 190 nm in the CD spectrum. This indicates alpha-helical secondary structure, 
which suggests that protein in both samples is folded and abundant in alpha-helical secondary 
structure. However, there is a clear difference in the shape of the CD81-DDM curve compared 
to CD81-SMALP, particularly at the 208 nm peak. After Dichroweb CD data analysis and 
taking the average alpha helical abundance from three secondary structure databases 
(CDSSTR, Contin-LL and Selcon3 – Table 4.3), the CD81-SMALP appears to comprise 71% 
alpha helical structure and around 28% of the protein was classified as unstructured. This is 
in marked contrast to CD81-DDM where approximately 58% of the protein was alpha helical 
and 37% protein was classified as unstructured. This suggests that SMA solubilised and 
purified CD81 was better able to retain its correct structural conformation, since a previously 
published CD81 crystal structure (PDB file 5TCX) indicated that approximately 68% of the 








Figure 4.11: Circular dichroism spectra of CD81 in SMALPs and detergent micelles. CD 
spectra of purified CD81 either encapsulated within SMALPs (black) or within DDM micelles 
(grey). Purified CD81-SMALP and CD81-DDM was buffer exchanged into 20 mM sodium 
phosphate buffer pH 8, at concentrations of 0.05 mg/ml and 0.09 mg/ml respectively. 200 µl 
of each sample volume was used in a 1 mm path length cuvette and measured using a Jasco 
J-1500 instrument. Maximum absorbance of 260 nm and minimum absorbance of 180 nm was 
used for CD detection at 0.2 nm intervals at 20 °C; 18 technical replicates were performed for 

































Analysis Secondary structure 
α-
helices 






CDSSTR 75 6 18 99 
CONTIN 65 3 32 100 
SELCON3 74 -4 34 104 
average 71 2 28 100 

















CONTIN 54 6 40 100 
SELCON3 59 3 40 102 
average 58 6 37 101 
     
       
 
Table 4.3: Parameters from Dichroweb analysis of CD spectroscopy data. Baseline 
corrected data was analysed using Dichroweb using CDSSTR, Contin-LL and Selcon3 
algorithms. A mean weight residue of 109.8 was used. For SELCON3 analysis of CD81-
SMALP the data was truncated from 190 nm.  For all CD81-DDM analysis data was truncated 
from 185 nm to avoid the increase in CD due to absorbance from the detergent. 
 
 
4.5: DLS analysis to determine particle size of the SMALP-CD81 
After confirming intact CD81 secondary structure, further biophysical analysis was performed 
to determine size distribution profile of  SMALP-CD81 nanodiscs and DDM-CD81 micelles in 
IMAC purified samples. For this, dynamic light scattering (DLS) analysis was performed. As a 
biophysical techniques, DLS was performed to determine average diameter of the SMALP 
nanodiscs and DDM-CD81 micelles suspended in sodium phosphate buffer.  The DLS data 
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were obtained through a Brookhaven NanoBrook 90plus Zeta instrument (640 nm) at Warwick 
University using a 1.0 cm path length disposable cuvette.  
 
Figure 4.12 shows an average size of ~10 nm for the purified SMALP-CD81, which was 
consistent with previous studies on SMALPs size determination (Lee et al., 2016). CD81 
detergent micelles appeared to have an average diameter of just under ~7 nm. The DDM-
CD81 micelle size calculated in this anaysis was comparable to  previously published studies 
by the Bill group, where ~6 nm of OG-CD81 micelle size was determined through DLS analysis 





Figure 4.12: Particle size analysis of SMALP-CD81 and DDM-CD81.  DLS analysis of 
purified CD81 either encapsulated within SMALPs (black) or within DDM micelles (grey).   
Obtained using a Malvern Instruments Zetasizer Nano S (633 nm) with  1.0 cm path length 




4.6: Thermostability analysis of SMALP-CD81  
The thermostability of purified CD81 was investigated next, using three different approaches. 
Firstly, CD spectroscopy was used to monitor protein secondary structure stability over a 
temperature range from 20°C to 90°C. The changes in protein folding were measured by 
analysing the entire spectrum at the far-UV  wavelength region with increasing temperature at 
each  5 °C increment. Detergent- extracted CD81 was also analysed to determine the protein 
unfolding pattern at higher temperatures and to compare it with SMALP-CD81 nanodiscs.  
 
A 1 mm path length cuvette containing 200 µl of either 0.05 mg/ml SMALP-CD81 or 0.09 
mg/ml DDM-CD81 sample was used for the analysis using a Jasco J-1500 CD spectrometer. 
Eighteen repeat scans at each temperature were taken as technical replicates. At 
temperatures up to 40°C minor unfolding was observed, with CD81-SMALP possibly being a 
little more stable than CD81-DDM. However at temperatures above 40°C the ellipticity 
reduced at each temperature increment. Despite the initial spectral differences observed 
between CD81-SMALP and CD81-DDM (Figure 4.13), little difference was seen between 
them in resisting heat treatment. 
 
Therefore, minor unfolding was detected at initial heat treatments (upto 40 °C) after which the 
ellipticity was considerably reduced, indicating rapid unfolding of the alpha-helical structure at 
each temperature increment. Both SMALP-CD81 and DDM-CD81 appeared comparable in 






Figure 4.13: Thermal melt analysis of SMALP-CD81 and DDM-CD81 using CD 
spectroscopy. Two purified CD81 samples from SMA and detergent solubilisation were used 
where samples were buffer exchanged into 20 mM sodium phosphate buffer pH 8 (for 
detergent protein buffer was supplemented with 0.1% DDM and 0.01% CHS). The protein 
concentration was calculated through a gel based BSA protein concentration determination 
assay (Rothnie et al. 2014) which indicated 0.05 mg/ml  and 0.09 mg/ml of CD81 respectively. 
Maximum absorbance of 260 nm and minimum absorbance of 180 nm was used for CD 
detection at 0.2 nm intervals from 25 °C to 90°C temperature range with 5° C increment. 
Eighteen technical replicates were taken at each condition. N=2. 
 
 
Next, thermostability was monitored by binding to a conformationally sensitive antibody to 
heat-treated CD81 protein in SMALPs and detergent samples. The antigen-antibody ELISA 
using a structurally sensitive anti-CD8 antibody (mAbs 1s337) that specifically recognises an 
EC2 epitope (as discussed in Chapter 3.5).  To test for functional integrity at higher 
temperatures, both SMALP-CD81 and DDM-CD81 samples were treated with various 
temperature points from  20 °C to 90°C with 10 °C increaments for 10 mins, where protein 
incubated at 4 °C was taken as the starting point. Samples were centrifuged to remove 




In Figure 4.14, CD81-SMALP showed very little change in binding at increasing temperatures 
up until 60°C, suggesting intact conformation of CD81. At temperatures of 70°C and above a 
gradual decrease in antibody binding was observed, likely due to heat-induced unfolding of 
the extracellular loop 2 epitope. In contrast CD81-DDM antibody binding decreased following 
incubation at 20°C and continued to decrease at each increased temperature, indicating lower 
protein stability in detergent micelles at this important extracellular loop than when CD81 is 




Figure 4.14: Affect of increasing temperature on the binding of CD81 to a 
conformationsensitive anti-CD81 (mAb 1s337) antibody, using an ELISA assay. ELISA 
was performed using an in-house anti-CD81 antibody that is specific to the large-extracellular 
loop secondary structure (mAb 1.337). 50 µl of purified protein (100µg/ml)  from both polymer 
and detergent solubilised samples were treated for 10 min at 4 °C and at various temperatures 
from 20 °C to 90 °C at 10 °C increment.  Samples were centrifuged to remove aggregates and 
immobilised on a 96-well plate, in triplicates, for ELISA detection. HRP-conjugated secondary 
antibody was bound to the primary anti-CD81 antibody, which was then visualised with 
SIGMAFASTTM OPD tablets as soluble substrate for the detection of peroxidase activity in 
the CD81 immunoassay. Optical density readings at 492 nm were taken for each test 
condition. Three technical replicates were taken per condition. Black solid circles are CD81-
SMALP, open grey squares are CD81-DDM. Data are mean±sem, N=3. 
 























The final approach examined protein aggregation upon heating, as shown in Figure 4.15. After 
heating (from 10 °C to 80 °C with 10 °C increaments), samples were centrifuged to remove 
large aggregates before visualising by Western blot using a non-conformational anti-CD81 
antibody (2s131). CD81-SMALP appeared unaffected up to temperatures of 40-50 °C., after 
which the monomer intensity began to decrease. The increase in heavier CD81 bands were 
also observed at 50 °C and above, indicating aggregation in these samples. The DDM-CD81 
western blot displayed negligible changes in CD81 monomer band intensity up to 
temperatures of 40-60 °C. Some decrease in CD81 band intensity was observed at 70-80 °C 
samples. A putative dimeric CD81 above ~45 kDa size was also seen in all samples without 





Figure 4.15: Western-blot analysis of heat-treated SMALP-CD81 and DDM-CD81 
samples. Each well contained 20 µl of sample and 5 µl of 5 X LSB buffer. Protein was detected 
with anti-CD81 antibody mAb 25131  (produced in-house) as primary antibody and anti-mouse 





4.7: Size exclusion chromatography (SEC) of SMALP-CD81 
Further to biophysical characterisationn of IMAC purified SMALP-CD81, the protein 
distribution in the sample was analysed through a high-resolution size based separation. This 
was to determine the quality of the sample and to investigate the presence of monomeric 
protein, multimolecular complexes and/or protein aggregates. Most importantly, the SEC 
seperation of SMALP-CD81  was performed as a second step purification to further eliminate 
potential contamination and/or aggregates in order to obtain monodispersed SMALP-CD81 
fraction to take forward to potential structural analysis.  
 
For this work, purified SMALP-CD81 sample was analysied through size exclusion 
chromatography (SEC), also known as gel filtration.The ÄKTA pure protein purification system 
(with 24 ml SuperdexTM 200 Increase 10/300 GL column), image shown in Figure 4.16, was 
used to determine how proteins in the  sample separates according to its size ,where larger 






Figure 4.16: An image of the gel filtration unit (AKTA pure protein purification system) 
used for SMALP-CD81 studies.  
 
 
To perform SEC analysis, 30 ml of P. pastoris membrane preparation was solubilised with 
2.5% SMA co-polymer for 1 h. The SMALP-CD81 was then purified through affinity 
chromatography and concentrated to obtain 500 µl of  1.13 mg/ml CD81. Figure 4.17 shows 
an SDS-gel of purified CD81 from 30 ml membrane preparation and a SDS-PAGE with range 
of BSA amounts as  standard (0.25 µg to 1.25 µg) to determine CD81 concentration for 





Figure 4.17: SDS-PAGE analysis of SMALP-CD81 affinity purification and 
concentration. Each lane contain 15 µl sample and 5 µl LSB buffer without reducing agent. 
SMALP-CD81 was eluted with 300 mM imidazole in six fractions (15 ml per fraction). Images 
are representative of N=3. A) IMAC flow through (FT), 20 mM and 60 mM imidazole washes 
and six elution fractions were analysed on the Coomassie stained SDS-gel. B)  BSA standards 
(0.125 to 1.25 µg) were run on the SDS-PAGE gel along with IMAC purified and concentrated 
SMALP-CD81 fraction. Densitometry analysis using ImageJ was performed to determine 
CD81 concentration.   
 
 
Purified CD81-SMALP was concentrated and loaded on a size exclusion chromatography 
column, as shown in Figure 4.18A this resulted in two major elution peaks as measured by 
the absorbance at 280 nm. Peak 1 was very close to the void volume of the column (~8 ml) 
suggesting the presence of larger complexes or potential protein or SMALP aggregates. Peak 
2 eluted at ~13 ml column elution volume suggesting extraction of smaller molecules (potential 
isolation of individual CD81 SMALPs) in this region. DLS analysis on each of the two peaks, 
as shown in Figure 4.18B, suggested the average particle size in Peak 1 (void peak) was ~30 
nm, whereas, ~10 nm particles were detected in Peak 2 fractions that was consistent with 
predicted SMALPed proteins using the SMA 2000 co-polymer (Rothnie et al, 2016). Peak 2 
particle size was also consistent with the size of SMALP-CD81 after first step affinity 







Figure 4.18: Size exclusion chromatography elution profile of the SMALP-CD81.A) SEC 
profile obtained on a Superdex 200 10/300 GL SEC column with absorbance measured at 280 
nm. SEC enables the separation of 500 µl of 1 mg/ml SMALP-CD81 into two main peaks 
named Peak 1 and Peak 2. N ≥ 3. B) DLS particle size analysis of IMAC purified SMALP-
CD81, SEC Peak1, SEC Peak 2 of SMALP-CD81 and DDM-CD81. Brookhaven NanoBrook 
90plus Zeta instrument (640 nm) was used along with 1.0 cm path length disposible cuvette. 
Six technical replicates were performed for each samole. N=2.  
 
 
Next, all the elution fractions from  both peaks were analysed by  SDS-PAGE to  detect the 
presence of CD81 (at ~25 kDa) and to check for the presence of higher order bands or 
contamination.  Moreover, receptor-ligand binding ELISA using CD81 ligand E2 glycoprotein 
was also performed to test for CD81 binding ability with E2.  
 
Figure 4.19 indicated the presence of CD81 (~25 kDa) and a higher order protein band (~45 
kDa) in all Peak 1 fractions. The CD81 gel bands were also detected in Peak 2 fractions with 
faint higher order gel bands. Receptor-ligand binding of CD81 with HCV glycoprotein E2 
indicated that only Peak 2 fractions bind to the ligand, as shown in Figure 4.20. This indicated  
that only Peak 2 samples were able to bind to purified HCV E2 glycoprotein (suggesting intact 
 A B 
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binding site on the CD81 EC2 for viral binding) . Therefore we became interested in Peak 2 




Figure 4.19: SDS-PAGE analysis of the Peak 1 and Peak 2 fractions. The SEC elution 
fractions from each of the two peak were visualised on 12% SDS- PAGE gel. Each lane 
contain 20 µl of sample and 5 µl of Lammeli sample buffer.  N=3. A) Individual Peak 1 fractions 









Figure 4.20: Receptor-ligand binding of Peak 1 and Peak 2 SMALP-CD81 fractions with 
HCV E2 glycoprotein. Functional integrity of SEC elution samples were detected using E2 
glycoprotein that acts as CD81 receptor ligand. 100 µl of eluted samples were used to test E2 
binding ability. E2 protein was bound to anti-Strep antibody as primary antibody  and Horse 
radish peroxidase conjugated antibody as secondary antibody, which was then visualised with 
SIGMAFASTTM OPD tablets as soluble substrate for the detection of peroxidase activity in 
the CD81 immunoassay. Optical density readings at 492 nm were taken for each sample. N=3 
 
 
Peak 2 stability was tested by re-analysing it by SEC. The Peak 2 fractions were collected and 
pooled together to obtain ~1.5 ml of 0.3 mg/ml sample, where 500 µl of this was reloaded on 
SEC. Figure 4.21A shows the SEC spectrum obtained from the IMAC purified samples and 
Figure 4.21B shows the SEC Peak 2 reloaded sample. Surprisingly, the analysis displayed a 
similar bimodal protein separation where a large and small peak were observed at the same 
elution volumes. This might suggest either lower Peak 2 stability where aggregation occurred 
after harvest or a dynamic equilibrium between larger and smaller SMALP-CD81 particle 






































Figure 4.21: SEC elution profiles of the SMALP-CD81 and SEC Peak 2 re-run. Profile 
obtained on a Superdex, increase 200 10/300 GL SEC column with absorbance measured at 
280 nm. A) Typical SEC elution profile of the SMALP-CD81. 500 µl of SMALP-CD81 was 
used. B) Re-analysis of the SEC Peak 2. Peak 2 fractions were pooled and concentrated using 
20 kDa concentrator and re-analysed by SEC. 500 µl of the sample was used. N=2.  
 
 
So far all the SEC elution profile was monitored at 280 nm to check protein elution. In an effort 
to detect polymer elution, the UV trace at 260 nm was also monitored because the SMA 
polymer absorbs at 260 nm. Figure 8.4 show the SEC spectra at both 280 nm (shown in black) 
and 260 nm (shown in green). Consistent with previous analysis, the 280 nm spectrum 
displayed bimodal peak distribution, while three peaks were identified in the 260 nm polymer 
analysis. The same elution profile was observed for ~ 8 ml peak, whereas a much larger peak 
height was observed in 260 nm for Peak 2 despite eluting out at the same elution volume.  
This suggested more polymer in the Peak 2  fraction than CD81 protein. A third peak was also 







Figure 4.22: SEC profile at 280 nm and 260 nm. The SEC analysis was performed at 280 
nm (green) to detect proteins and  260 nm (black) to detect SMALP nanodiscs. Profile obtained 
on a Superdex, increase 200 10/300 GL SEC column with absorbance measured at 280 nm 
and 260 nm. N ≥ 3. 
 
 
As Peak 2 on the gel filtration trace appeared to contain relevent viral binding site and 
potentially non-aggregated CD81 (Figures 4.18 and 4.20), efforts were made to try to increase 
the proportion of CD81 in this peak. Firstly P. pastoris growth conditions were changed: lower 
cell biomass was taken forward for large scale growth in methanol medium (OD600 ≤ 1) instead 
of starting growth at high cell density (OD600 ˃ 5). This was to try to produce less but possibly 
better quality P. pastoris cells that expressed propery folded CD81 protein. Secondly, HEPES 
buffer was used for solubilisation, purification and gel filtration work, supplemented with 200 
mM sodium chloride and 10% glycerol, instead of the standard Tris/sodium chloride buffer. As 
HEPES  buffer is known to efficiently maintain pH of the solution, thus preventing pH related 
SMALPs or protein aggregation and glycerol is often reported to aid stability of memrbane 
proteins. Finally, CD81-SMALP elution fractions from affinity purification were concentrated 
less before analysing on the SEC, to minimise aggregation due to heavy concentration of the 






















protein. A like-for-like comparison of the results obtained before and after optimisation, as 
shown in Figure 4.23. After applying these changes, an increase in Peak 2 was observed in 
the SEC spectrum (shown in Figure 4.23B). SDS-PAGE analysis of the SEC fractions show 
considerably less protein in the void fractions (Peak 1) and more in ~13 ml elution fractions 










Figure 4.23 Size exclusion chromatography elution profile of the SMALP-CD81 before 
and after optimisation. Profile obtained on a Superdex, increase 200 10/300 GL SEC column 
with absorbance measured at 280 nm. The “before optimisation” condition (top SEC spectrum 
and SDS-gel) used 500 µl of SMALP-CD81 concentration of 6.02 mg/ml. Whereas,  1.64 
mg/ml SMALP-CD81 concentration was used for “after optimisation” SEC analysis (bottom). 
The Peak 1 and Peak 2 fractions were pooled and concentrated using a 20 kDa cut off 
concentrator and visualised on 12% SDS- PAGE gel. Each lane contains 20 µl of sample and 




The secondary structure profile of the Peak 1 and Peak 2 from the optimised protocol was 
tested in order to check for intact structure and to compare the two peaks. For this, CD 
spectroscopy was performed. The pooled and concentrated fractions from each peak were 
buffer exchanged from HEPES buffer to 20 mM potassium phosphate only buffer and diluted 
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to ~0.05 mg/ml each. A 200 µl sample was taken from each of the two samples in a 1 mm 
path length cuvette and tested at the far-UV wavelength regions of 180 to 240 nm. In Figure 
4.24A, both Peak 1 and Peak 2 samples display characteristic negative alpha-helical peaks at 
222 nm and 208 nm and a positive peak at 190 nm in the CD spectrum with similar elipticity. 
This indicates intact secondary structure and a abundance of alpha-helix folding of CD81 in 
both Peak 1 and Peak 2 samples, suggesting that protein in both samples were correctly 
folded and have similar α-helical profile.  Unexpectedly from the CD analysis, Peak 1 (void 
peak) was therefore  anticipated to contain folded and possibly aggregated CD81 protein or 
nanodiscs.  Moreover, consistent with previous work, Peak 1 and Peak 2 SDS-PAGE analysis 
(shown in Figure 4.24B) appeared similar (in terms of protein band profile), with more intense 
protein bands observed in Peak 2 samples suggesting the presence of more SMALP-CD81 








Figure 4.24: Circular dichroism spectra of SMALP-CD81 SEC Peak 1 and Peak 2. A) SEC 
purified Peak 1 and Peak 2 fractions were used for CD secondary structure analysis. SEC 
purified fractions were buffer exchanged into 20 mM sodium phosphate buffer pH 8, at the 
concentration of ~0.05 mg/ml (Peak 1)  and ~0.05 mg/ml (Peak 2). 200 µl of each sample 
volume was used in a 1 mm path length cuvette. Maximum absorbance of 260 nm and 
minimum absorbance of 180 nm was used for CD detection at 0.2 nm intervals at 20 °C; 18 
technical replicates were performed for each sample, where N=2. B) SDS-PAGE analysis of 
IMAC purified SMALP-CD81, SEC Peak 1 and SEC Peak 2 samples used for CD analysis. 
12% SDS-PAGE was used. Each lane contained 15 µl of sample and 5 µl of LSB buffer. Image 













4.8: Mass spectrometry protein identification  
Liquid chromatography MS/MS  using collision-induced dissociation (CID) fragmentation is a 
well-established proteomic technique that allows the detection of individual proteins from the 
complex mixture (Andre et al., 2006). This technique was utilised in this study to identify and 
quantify component proteins in  affinity and SEC purified protein and solubilised P. pastoris 
membrane extracts. Five samples were tested for mass spectrometry total proteome 
identification, these were: affinity purified SMALP-CD81;  SEC Peak 1; SEC Peak 2; affinity 
purifed DDM-CD81 (as control); and SMA co-polymer solubilised membrane. This work was 
performed with Dr Ivana Millic (Aston University) and using the Mass spectrometry and 
Proteomic facility at The University of St. Andrews.  
 
30 µg of total protein from each of the five  samples were separated on a 12% SDS gel. Each 
gel lane was cut in three fractions: fraction 1 was from 10 kDa to 25 kDa where one prominent 
CD81 protein band was observed; fraction 2 was from 25 kDa to 45 kDa where a ~40 kDa 
protein band was detected in each sample; and fraction 3 was from 45 kDa to 180 kDa where 
several faint protein bands were observed, as shown in Figure 4.25 (SMA solubilised 
membrane gel not shown). The proteins in each gel fraction were trypsin digested and 
analysed through a bottom-up mass spectrometery approach to quantitatively and qualitatively 
investigate the peptides from digested proteins. The mass-to-charge ratio (m/z) of individual 
molecules were determied, where protein identification and characterisation were performed 
by MASCOT and NCBI database searching against signature MS/MS data for each protein. 
The search was limited to Komagataella phaffii (Pichia pastoris) and Homo sapiens database 







Figure 4.25: SDS-PAGE gel for mass spectrometry analysis. The samples were run on 
12% SDS-PAGE gel for protein separation according to the size, where each lane contain 30 
µg of total protein in 40 µl sample volume and 10 µl of LSB buffer. The gel was stained with 
brilliant blue dye to visualise proteins. For mass spectrometry analysis, each  gel lane was 
divided in three fractions: fraction 1 contained gel piece from 10 kDa to 25 KDa as shown in 
green; fraction 2 contained gel area fron 25 kDa to 45 kDa shown in orange; fraction 3 include 
the gel area from 45 kDa all the way through 180 kDa.  
 
 
Table 4.4 lists total proteome analysis data along with the average abundance values, 
including p-values and confidence scores of MS/MS data hits, of identified proteins in each of 
the five test samples.  The CD81 antigen (from Homo sapiens) was detected in all three gel 
fractions with high abundance  indicating the dominance of CD81 protein, where SEC Peak 2 
fractions contained the most CD81 after the SMA co-polymer solubilised membrane  samples. 
The alcohol oxidase 1 protein (AOX1), from P. pastoris, was also identfified as a dominant 
contaminant with high abundance in fraction 3 (from 45 kDa to 180 kDa) gel samples, 
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however, with two and a half times less abundance value than CD81 protein in SEC Peak 2 
samples, indicating some reduction of AOX1 during purification steps. Other contaminant 
proteins with noticeable presence were 40S ribosomal protein  and actin from P. pastoris. The 
detergent affinity purified sample was used as a control, where total protein identification 
pattern was similar to that of affinity purified SMALP-CD81 with an exception of low abundance 
value for CD81 protein in this sample.  
 
The mass spectrometry analysis suggested that CD81 was present and dominant in all 
samples, particularly in solubilsed membrane and SEC Peak 2 samples. Moreover, several 
other yeast expressed soluble and RNA-associated proteins were also identified as 















Table 4.4: List of protein hits with their corresponding average abundance in total 
proteome mass spetrometry analysis of SMA solubilised, affinity and SEC purified 
samples. Three gel band fractions from each of the five samples were tested for LC-MS 
protein identification. The samples were trypsinised (in-gel digestion) and fragmented then 
analysed using an ESI-QUAD-TOF MS instrument. Peptides with fixed carbamidomethyl (C) 
and variable oxidation (M) modification were searched for using MS/MS Ion search on 
MASCOT and NCBI databases. Mass spectrometry data was tested three times with 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.9: Pichia pastoris protoplast  preparation for isolating membrane bound CD81  
P. pastoris protoplasts are cells without cell wall which has been removed through enzymatic 
treatment. In this work, a lytic enzyme called zymolyase was used for yeast cell wall digestion 
as it contains an active enzyme called β-1,3 glucanase  (a hydrolase) that hydrolyzes the 
glucose polymer of the cell wall into small pentose products, thus breaking down the yeast cell 
wall.  This method favours extraction of correctly folded membrane proteins that have been 
targeted to the plasma membrane and limits solubilisation of misfolded proteins stored in 
internal membrane compartments. Protoplasts were then directly subjected to SMA co-
polymer solubilisation to extract membrane associated CD81. The expected benefit of using 
P. pastoris  protoplast in this study was that it favoured extraction of correctly folded proteins 
present in plasma membrane as it limits solubilisation of proteins stored in internal membrane 






Figure 4.26: Schematic of protoplast generation and CD81 solubilising process. P. 
pastoris cells expressing hCD81 was firstly treated with Zymolase for cell wall digestion. The 
protoplasts formed were directly used to perform SMA co-polymer solubilisation following 
ultracentrifugation step tp recover solubilised fraction for subsequent purification steps. Image 







For protoplast work, a previously published protocol was used by  Hartmann et al., 2017. 
Briefly, 12 g of P. pastoris cell pellet was  washed with sorbitol (1 M) and trisodium citrate (20 
mM) buffers to prepare the yeast cell wall for enzymatic treatment. The cells were treated with 
Zymolyase at room temperature under gentle shaking following slow speed centrifugation to 
harvest protoplasts. The CD81 protein on the protoplast membrane was solubilised using 
2.5% SMA co-polymer for 30 mins at RT following IMAC and SEC purification stages.  
 
Figure 4.27 show a typical SEC spectrum obtained after protoplast SMA co-polymer 
solubiliation and IMAC purification. A sharp peak at around 14 ml column elution volume was 
observed suggesting the presence of a homogenous protein sample. No void peak (at around 




Figure 4.27: Size exclusion spectrum of protoplast solubilised and purified SMALP-
CD81. Profile obtained on a Superdex increase 200 10/300 GL SEC column with absorbance 
measured at 280 nm. The 500 µl of ~3 mg/ml IMAC purified SMALP-CD81 sample was loaded 
on the AKTA unit, where individual fractions were collected in 250 µl volume. Graph was 
prepared using GraphPad Prism, where N=2.   
























The individual elution fractions from SEC purification along with concentrated 14 ml peak 
sample were analysed through SDS-PAGE and western blot (using anti-His6 antibody), as 
shown in the Figure 4.28. In SDS-PAGE analysis, a higher order band close to ~45 kDa was 
detected in all elution fractions and in concentrated SEC peak sample. A very faint potential 
monomeric CD81 gel bands was also detected at 25 kDa. This suggested the presence and 
dominance of a higher order protein (a possible contaminant or dimeric CD81 protein). The 
western blot analysis, using the C-terminus His-tag, detected monomeric CD81 protein at ~25 




Figure 4.28: SDS-PAGE and western blot analysis of concentrated ~14 ml SEC peak and 
individual elution fractions. Each individual SEC fraction lane cotain 20 µl of sample and 5 
µl of LSB buffer, while 10 µl of concentrated SEC peak with 2.5 µl was added in concentrated 
sample lanes. Both SDS-PAGE and Western blot images are representative of N=2. SEC 
conc.= concentrated SEC 14 ml peak sample. A) Coomassie stained SDS-PAGE analysis of 
individual peak fractions along with pooled and concentrated SEC peak sample. B) Western 
blot analysis of indiviual peak fraction as well as pooled and concentrated SEC peak sample. 
Anti-His6 antibody was used as primary and HRP-conjugated anti-mouse antibody was used 






Finally, in order to determine the presence of CD81 protein in the SEC purified sample, mass 
spectrometry protein identification analysis was performed. The proteins  in the SEC sample 
was separated by SDS-PAGE, where two protein bands were visualised  and sent off for mass 
spectrometry identifictaion, as shown in Figure 4.29. The MS data predicted the most 
dominant protein (at ~45 kDa) in the sample was an alcohol dehydrogenase protein from the 
P. pastoris origin. Only small amounts of CD81 protein was identified in the second band at 
~35 kDa, suggesting low CD81 abundance in the SEC purified samples.  Therefore, this study 
suggested that P. pastoris protoplast preparation and direct solubilisation was not an optimal 











Figure 4.29:  SDS-PAGE and western blot analysis of concentrated ~14 ml SEC peak 
and individual elution fractions. SDS-PAGE gel was prepared containing 5 µl of SEC 14 ml 
peak  sample loaded with 1.25 µl of 5 X LSB buffer. The gel was stained with brilliant blue dye 
to visualise proteins. Two gel band samples at ~35 kDa and ~45 kDa were sent for LC-MS 
protein identification. The samples were trypsinised and fragmented then analysed using an 
ESI-QUAD-TOF MS instrument. Peptides with fixed carbamidomethyl (C) and variable 
oxidation (M) modification were searched for using MS/MS Ion search on NCBI database. 

















Chapter 5  
Structural studies: visualisation of SMALP-CD81 nanodiscs through negative 
stain electron microscopy and X-ray crystallisation trials 
 
Obtaining high-resolution structures is a cornerstone of the membrane protein research. The 
SMA co-polymer solubilisation and purification of CD81 shown in the previous chapters 
enabled the yield of superior protein samples that could facilitate structure determination. 
Therefore, initial negative staining cryo electron microscopy (cryo-EM) and X-ray 
crystallography structural analysis are discussed in this chapter.  
 
The recent cryo-EM revolution has enabled the structural organisation of several membrane 
proteins that had previously remained elusive to X-ray crystallisation techniques (Wan et al., 
2019, Basore et al., 2019). The suitability of the SMALP method for structural analysis through 
EM has previously been shown by (Parmar et al., 2018) where a ~340 kDa trimeric form of 
AcrB protein was solved at 8.8 Ӑ resolution using Cryo-EM.  The major limitation that prevents 
CD81 Cryo-EM studies is the small size of the protein (~25 kDa)  and the fact that there is 
very little peptide biomass protruding from the plasma membrane ( the EC2 domain protrudes 
~ 3 to 5 nm outside of the plasma membrane), thus, making it currently an impossible target 
for cryo-EM structural investigation, unless a CD81 complex could be generated using an 
antibody or a ligand. Therefore, in this study, negative stain electron microscopy analysis was 
attempted in an effort to visualise SMALP-CD81 in the SEC purified samples to confirm the 
presence of isolated nanodiscs. The tetraspanin literature has suggested the presence of 
tetraspanin enriched microdomains on the plasma membrane to exert their biological function 
(Bailey et al., 2011); this provides an opportunity to capture CD81 dimers or higher order 
structures using SMA. Negative staining analysis could potentially be taken forward for Cryo-




Membrane protein crystallisatio in lipidic cubic phase (LCP) has been successfully applied to 
obtain a high resolution structure of SMA polymer solubilised and purified microbial rhodopsin 
by (Broecker et al., 2017). As CD81 protein is an important pharmaceutical drug target due to 
its association with several clinical pathologies including various types of cancer and in HCV 
infection, obtaining structural information will be invaluable for therapeutic discovery. Further 
to EM analysis, this chapter will also discuss large scale CD81 preparation to obtain 
concentrated and homogenous SMALP-CD81 for lipidic cubic phase formation and protein 
crystallisation for X-ray crystallography. P. pastoris and Sf9 overexpressed recombinant CD81 
was investigated for the large scale preparation of suitable protein.   
 
5.1: Negative stain electron microscopy to visualise SEC Peak 1 and Peak 2 fractions 
In order to visualise isolated SMALP nanodiscs, negative staining electron microscopy 
analysis was performed on both SEC Peak 1 and Peak 2 samples. 
 
A 10 ml P. pastoris membrane preparation was solubilised using SMA and purified using IMAC 
and SEC purification. Figure 5.1 show the SEC profile obtained after affinity purification and 
concentration that indicated the presence of a large peak (Peak 1) at ~8 ml elution volume 
and a small peak (Peak 2) at ~12 ml elution volume, which was similar to previous work 
discussed in chapter 4. The SDS-PAGE analysis, also shown in Figure 5.1, confirmed the 
presence of SMALP-CD81 in both SEC peaks (Peak 1 and Peak 2), with the majority of the 
protein in the concentrated Peak 2 fraction. The SEC fractions from each peak were pooled 
and concentrated to obtain 0.23 mg/ml Peak 1 sample and 0.25 mg/ml Peak 2 sample 






Figure 5.1: Preparatory SEC and SDS-PAGE analysis for negative staining EM.  Size 
exclusion chromatography elution profile of SMALP-CD81 after IMAC purification. SEC 
spectrum obtained on a Superdex 200 10/300 GL SEC column with absorbance measured at 
280 nm. SEC enabled the separation of 500 µl of 0.7 mg/ml SMALP-CD81 into two main 
peaks. SDS-PAGE analysis was performed on the pooled and concentrated fractions from 
each of the two peaks. 12 % SDS-gel was prepared where each lane contained 15 µl sample 
and 5 µl LSB buffer. Image shown as representative image. N ≥ 3. Conc. SMALP-CD81= 
before SEC sample. 
 
 
After collecting the SEC peaks, the samples were taken to Warwick University Imaging Facility 
to perform negative stain Cryo-EM for nanodiscs and protein visualisation. The EM copper 
grids were glow-discharged to obtain a negatively-charged surface where sample was added 
and incubated for 3 minutes following washing and staining with 2% uranyl acetate.  The grids 
were imaged using a JEOL2100+ TEM instrument at 60,000 X magnification. The first few 
negative staining EM analyses did not work as the EM images only showed big blobs of protein 
(possibly due to high sample concentration). Optimisation of the analysis was attempted by 
diluting SEC peak samples: a serial dilution was prepared taking 5, 10, 25, 50 and 100 fold 




Figure 5.2 show micrographs from the SEC Peak 1 and Peak 2 samples indicating good 
particle distribution and no obvious aggregation. A high purity and monodispersity of SMALP-
CD81 nanodiscs was observed in 100 fold sample dilution.  Sparsely distributed and larger 
particles were observed in Peak 1 samples, while, smaller and numerous nanodiscs were 
observed in Peak 2 samples with an average size of ~10 nm (according to EM software 
measurement). The particle sizes observed through EM were consistent with the DLS analysis 
of SEC purified samples as discussed in chapter 4. The larger particle size observed in Peak 
1 is  predicted to be a possible consequence of nanodisc interaction with one another forming 
a higher order structure. 
 
Therefore, negative staining cryo-EM analysis indicated the presence of monodispersed 
SMALP-CD81 in SEC Peak 2 sample, whereas larger particles were observed in the SEC 








Figure 5.2: Negative stain micrographs of SMALP-CD81 nanodiscs from SEC Peak 1 
and SEC Peak 2.  The micrographs shows highly pure and monodispersed SMALP-CD81 
nanodiscs in both samples. The 3 µl of  92 µg/ml and 100 µg/ml  of each SMALP-CD81  SEC 
Peak 1 and Peak 2 samples, respectively, were immobilised on negatively-charged copper 
grids and stained with 2% uranyl acetate before imaging on the  JEOL2100+ TEM at 60,000 
X magnification (at Warwick University; operator: Dr Saskia Bakker). Images are the 













5.2: CD81 detection through Ni-NTA-Gold particle binding 
Further to the successful visualisation of SMALP nanodiscs in both Peak 1 and Peak 2 
samples, the localisation of CD81 protein was detected through high resolution imaging. So 
far no protein biomass was observed in the nanodiscs possibly due to small size of CD81 
protein. Attempts were made in this study to label CD81 proteins encapsulated in SMALPs to 
identify them through negative staining EM.  
 
A reagent comprising nickel (II) nitrilotriacetic acid (Ni-NTA) conjugated with a monofunctional 
gold nanoparticle was utilised for the site specific and covalent labelling of histidine residues 
(His-tag) on the protein terminus. The binding occurs due to the affinity of histidine residues 
to Ni+2 NTA complex ions bound to gold nanoparticles, as shown in Figure 5.3. The precise 
location of Ni-NTA-Gold labelled proteins could then be determined by electron microscopy.  
 
Inspiration of this work was from (Swainsbury et al., 2014), where  electron microscopy of 
SMALP nanodiscs containing His6-tagged protein was performed after binding with 
functionalised nanogold  particles (conjugated Ni NTA  functional group). Pre-treatment of the 
SMALPs with nanogold particles allowed the detection of the bacterial reaction centers (a 
class of integral membrane proteins) His6-tag. Also, this technique could potentially identify 









Figure 5.3: The interaction between histidine tagged protein with Ni-NTA-gold. The Ni-
NTA functional group attached to the 5 nm gold particle interacts and form stable complexes 
with the histidine residues of the recombinant protein for easy electron microscopy detection 
for the gold labelled protein. Image adapted from www.nanoprobes.com. 
 
 
For this work, three test samples were prepared. The first two sample were SEC Peak 1 and 
Peak 2 obtained from a 10 ml of P. pastoris membrane SMA solubilisation and IMAC 
purification. This was followed by the SEC separation of the two distinct peaks, Peak 1 and 
Peak 2, as shown in Figure 5.4. The third sample was lipid-only SMALPs as a negative control. 
This was to test for any non-specific binding of the Ni-NTA-Gold particles with the polymer or 









Figure 5.4: Preparatory SEC spectrum for nanogold particle SMALP-CD81 labelling.  
Size exclusion chromatography elution profile of the SMALP-CD81 after IMAC purification, 
where two distinct peaks, Peak 1 and Peak 2, were collected and pooled separately before 
subsequent analysis.  SEC spectrum obtained on a Superdex 200 increase10/300 GL SEC 
column with absorbance measured at 280 nm. The SEC enabled the separation of 500 µl 0.8 
mg/ml SMALP-CD81 into two main peaks. N≥3. 
 
 
For the lipid-only samples, a 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) 
suspension was solubilised in SMALPs using 2.5% SMA co-polymer following excess polymer 
removal and homogenous suspension isolation through SEC, as shown in the Figure 5.5, 
where ~11.2 ml elution peak fractions were collected, pooled and used for subsequent work.  
 


















Figure 5.5: Typical SEC spectrum of SMALP-DMPC samples. The lipid only SMALP was 
prepared by firstly dissolving DMPC lipid in methanol-chloroform solution before solubilising 
with the SMA2000 polymer. The SEC separation was performed to collect ~11.7 ml elution 
peak fractions for the EM imaging work. SEC spectrum obtained on a Superdex 200 10/300 
GL SEC column with absorbance measured at 280 nm. SEC enabled the separation of 500 µl 
SMALP-DMPC into three main peaks. N=2. UV1_280= UV trace at A280, shown in blue; Cond= 
Conductivity, shown in orange; UV2_ 260= UV trace at A260, shown in purple.  
 
 
Each of the three samples (SEC Peak 1, SEC Peak 2, and SMALP-DMPC) were analysed 
with and without Ni-NTA-gold particle incubation. Therefore, a total of six samples were 
imaged, where three control samples were without the nanogold particle, while test samples 
were incubated with the Ni-NTA-gold particles. The control samples were treated in the 
following manner: SMALP solution was applied to glow-discharged carbon grids and left for 2 
min. Excess solution was blotted off and the grid washed 3x in water. The grid was stained for 
4 min in 2% uranyl acetate. For gold particle binding, the SMALP sample was applied to glow-
discharged grids as before. The grids were then incubated for 30 min in Ni-NTA-gold according 
to the manufacturer’s instruction, and stained as before.  
181 
 
The Figures 5.6 show the images from the lipid-only SMALPs with and without nanogold 
particle binding. Figure 5.6A indicated the presence of monodispersed SMALP nanodiscs 
(indicated with black arrowheads), whereas, Figure 5.6B showed the presence of isolated 
SMALP-DMPC nano discs (black arrow heads) as well as monodispersed 5 nm gold particles 
(indicated with white arrow heads). Some non-specific nanogold particle binding with SMALP-
DMPC discs was also observed (indicated with blue arrow heads). This suggested some 
nonspecific interaction between lipids only SMALPs and nanogold particles.  
 
 
Figure 5.6: Negative stain micrographs of SMALP-DMPC nanodiscs with and without 
Ni-NTA-Gold particles. A 2,500 fold diluted SMALP-DMPC peak ~11.7 was used to check 
for non-specific nanogold particle binding. Samples were analysed using JEOL2100+ TEM at 
60,000 X magnification (at Warwick University; operator: Dr Saskia Bakker). 3 µl sample was 
immobilised on the negatively charged EM grid and stained with uranyl acetate before TEM 
visualisation. Images are the representative images of N=2. Black arrowhead: SMALP-DMPC 
nanodiscs; White arrowhead: Ni-NTA-gold particles; blue arrowhead: Ni-NTA-Gold particles 





Figures 5.7 and 5.8 show SEC Peak 1 and Peak 2 micrographs, respectively. In both analyses, 
the SMALP-CD81 nanodiscs were clearly visible in control and test images. However, no 
obvious Ni-NTA-gold particle association with the CD81 protein in SMALP-CD81 nanodiscs 
was observed. While some gold particles were seen adjacent to nanodiscs, many more were 




Figure 5.7: Negative stain micrographs of SMALP-CD81 SEC Peak 1 sample with and 
without Ni-NTA-Gold particles. A 100 fold diluted SMALP-CD81 SEC Peak 1 sample was 
used to determine nanogold particle binding to the CD81-His6 tag. Samples were analysed 
using JEOL2100+ TEM at 60,000 X magnification (at Warwick University; operator: Dr Saskia 
Bakker). 3 µl 92 µg/ml sample was immobilised on the negatively charged EM grid and stained 
with uranyl acetate before TEM visualisation. Images are the representative images of N=2. 
Black arrowheads: SMALP-DMPC nanodiscs; White arrowheads: Ni-NTA-gold particles; blue 






Figure 5.8: Negative stain micrographs of SMALP-CD81 SEC Peak 2 sample with and 
without Ni-NTA-Gold particles. A 100 fold diluted SMALP-CD81 SEC Peak 2 sample was 
used to determine nanogold particle binding to the CD81 His6 tag. Samples were analysed 
using JEOL2100+ TEM at 60,000 X magnification (at Warwick University; operator: Dr Saskia 
Bakker). 3 µl 100 µg/ml sample was immobilised on the negatively charged EM grid and 
stained with uranyl acetate before TEM visualisation. Images are the representative images 




Overall, no binding of the functionalised gold nanoparticle was observed with the CD81 
proteins in both SEC Peak 1 and Peak 2 fractions. Only some non-specific binding was 
observed in the negative control (lipid only SMALPs). To troubleshoot this, the binding of the 
Ni-NTA-gold particle with His-tagged CD81 protein was assessed in solution by gel filtration 







5.3: In-solution analysis of Ni-NTA-Gold particle association with SMALP-CD81 
Further to EM analysis of Ni-NTA-gold particle binding to His6 tagged CD81, labelling of the 
CD81 protein with Ni-NTA-gold particles was attempted in solution rather than directly on the 
EM grid. The SMALP-CD81 Peak 2 sample was incubated with 10 molar excess of 5 nm Ni-
NTA-gold overnight at 4 °C following centrifugation to pellet out aggregates, shown in Figure 
5.9. The change in supernatant from colourless to red indicated the presence of dispersed 




Figure 5.9: Image showing SMALP-CD81 Peak 2 sample incubated with functionalised 
5 nm gold particles.  A ~350 µl 0.25 mg/ml SEC Peak 2 was incubated with 100 µl 0.5 µM 
Ni-NTA-gold particles overnight. Samples were centrifuged for 2 min at 12,000 rpm before the 
SEC run. The unaggregated gold nanoparticles have a red colour in solution, as seen in the 
supernatant. While, the aggregated particles appeared dark blue/purple as shown in the pellet 







The specific binding of Ni-NTA-gold particles to SMALP-CD81-His6 was assessed by 
analytical SEC. Ni-NTA-gold complexed with SMALP-CD81- His6 was monitored at 280 nm 
and 520 nm to detect both protein and gold nanoparticles. The Figure 5.10 show SMALP-
CD81 labelled with Ni-NTA-gold particles at 280 nm and 520 nm. Both spectra show a sharp 
peak at ~ 11.5 ml column elution volume indicating the presence of the protein and nanogold 
particle complexes. The SEC Peak 2 shift observed from the original peak elution volume of 
~13 ml (discussed in Chapter 4 Section 4.6) to ~11.5 ml peak indicated the presence of Ni-
NTA-Gold particles complexed with SMALP-CD81. The small SEC peak size was due to low 
protein concentration of the sample (~0.125 mg of protein was initially used) and some protein 
aggregation after overnight incubation with nanogold particles and subsequent centrifugation 








Figure 5.10 Binding of Ni-NTA-gold particles with SMALP-CD81 Peak 2 samples. 
SMALP-CD81 Peak 2 incubation following analytical SEC  with Ni-NTA-gold nanoparticles. 
Two absorbance spectra were taken: 280 nm (black) for identifying protein elution, and 520 
nm (blue) for the gold nanoparticle absorbance. The SEC enabled the separation of 350 µl of 
0.25 mg/ml SMALP-CD81 into one dominant peak at ~11.7 ml column elution volume. 












The SEC ~11.5 ml peak fractions were collected, pooled and evaluated through SDS-PAGE 
and Western blot analysis as shown in Figure 5.11. The analysis further confirmed the 
presence of relatively pure CD81 monomeric protein in the SEC peak fraction after incubation 
with nanogold particles.  
 
 
Figure 5.11:  SDS-PAGE and Western blot analysis of SEC peak at ~11.5 ml column 
elution volume containing Ni-NTA-gold particle labelled SMALP-CD81. The elution peak 
fractions were collected and pooled before loading on 12% SDS gels where each lane 
contained 20 µl sample and 5 µl LSB buffer. SDS-PAGE gel was stained with brilliant blue dye 
to visualise protein bands. For Western blot protein staining, anti-CD81 antibody was used as 
primary and anti-mouse HRP-conjugated antibody as secondary antibody. Both SDS-PAGE 
gel and Western blot images were taken using Syngene G-box, where images are 








5.4: Large-scale hCD81 preparation for LCP crystallisation trials 
One aim of this study was to obtain high quality protein samples in an attempt to obtain high 
quality of crystals of CD81 for structure determination by X-ray crystallography.  
 
For the CD81 crystallisation work, a large scale CD81 preparation was performed in order to 
obtain homogenous and concentrated protein sample for lipidic cubic phase reconstitution for 
crystal nucleation and growth. P. pastoris cells were cultured on a large-scale using shake 
flasks (total culture volume = 5 L). Around 80 g of cell pelleted was harvested and membrane 
only fraction was collected after cell lysis and ultra-centrifugation. 50 ml 160 mg/ml membrane 
preparation was diluted 3 fold and solubilised with 2.5% SMA 2000 polymer. The SMALP 
CD81 was purified through IMAC purification, as shown in Figure 5.12. ~ 3.5 L of low imidazole 
containing buffer washes (to wash 50 ml resin with 2.5 L of 20 mM imidazole wash;  1 L 40 
mM imidazole wash; and 50 ml 60 mM imidazole wash) were performed before eluting the 







Figure 5.12: SDS-PAGE analysis of the IMAC fractions. The IMAC flow through, washes 
and elution fractions were analyses on 12% SDS-PAGE. 2.5 L 20 mM imidazole buffer was 
used as the first wash; 1 L of 40 mM imidazole buffer as second wash; 50 ml of 60 mM 
imidazole buffer as the final wash before protein elution. The protein was eluted in 150 ml of 
300 mM imidazole elution buffer in six fractions. Each lane contain 15 µl of the sample and 5 
µl of LSB buffer. Image is the representative image of N≥3.  
 
 
The IMAC elution fractions appeared to contain high purified protein amounts, therefore in 
order to prevent protein aggregation due to high concentration, elution fractions were divided 
into two separate tubes. The elution fractions E1, E2 and E4 were pooled together, while E3, 
E5 and E6 were pooled separately and concentrated using 20 ml Vivaspin 10 kDa 
concentrators. The high protein containing elution fractions E2 and E3 were kept in separate 
concentrators to prevent aggregation due to high protein concentration. The 75 ml total volume 
in each  of the two tubes were concentrated to 1 ml, where protein concentration of 2.5 mg/ml 
190 
 
was achieved from the E1,E2 & E4 fraction and 3.01 mg/ml from the E3,E5 & E6 fractions , 
according to NanoDrop protein concentration determination 
 
Four preparatory SEC purifications were performed using 500 µl per SEC run. Figure 5.13 
shows a typical spectrum obtained after IMAC purification and concentration, which was 
similar to the SEC work discussed in Chapter 4. The SMALP-CD81 sample separated into 
one dominant peak at ~8 ml elution volume and a shoulder at ~12 ml column elution volume. 
The size of Peak 2 was much smaller this time, possibly due to heavy protein concentration 
post IMAC purification where only a small fraction of the nanodiscs was left in monodispersed 
form. Bigger aggregates were removed prior to the SEC run by centrifugation and pelleting 
them out.  
 
 
Figure 5.13: Preparatory SEC spectrum of IMAC purified SMALP-CD81 protein for 
subsequent crystallisation work. Size exclusion chromatography elution profile of the 
SMALP-CD81 after IMAC purification, where two characteristic peaks were harvested. SEC 
elution fractions from Peak 1 and Peak 2 were collected and pooled separately for future 
analysis.  A Superdex 200 increase10/300 GL SEC column was used to determine sample 
absorbance at 280 nm, where 500 µl of 3.01 mg/ml SMALP-CD81 sample was injected. N=4. 
 





















The SEC fractions between 11 to 14 ml column elution volume, from all four runs, were pooled 
and concentrated heavily to obtain ~40 µl of highly concentrated SMALP-CD81 protein (18.84 
mg/ml according to the NanoDrop) to use in the subsequent crystallisation trials. The SEC 
Peak 1 fractions from 8 ml to 10 ml column elution volume were also pooled and concentrated 
to ~40 µl where the protein concentration was calculated to be 4 mg/ml.  
 
Although large peak size was seen for the Peak 1, protein content was lower compared to the 
smaller looking Peak 2. May be large particles were absorbing highly which was shown by the 
large size of the peak  but it does not correlate to the higher amount of the CD81 protein as a 
lot more CD81 protein was harvested from the Peak 2. 
 
After the two step purification of SMALP-CD81-His6, X-ray crystallisation trials were performed 
using lipidic cubic phase consisting of monoolein (1-monooleoyl-rac-glycerol, C18:1c9) as the 
host lipid.  The LCP was prepared by using protein to monoolein ratio of 2:3 (40% to 60%), 
where 6 µl of the SMALP-CD81 protein solution and 9 µl of warm monoolein (at 45 °C) were 
used. Two Hamilton syringes were taken, one was filled with monoolein and another one with 
concentrated SMALP-CD81 protein suspension, and connected together through syringe 
coupler. The syringe plunger were then pushed alternatively in an attempt to mix the protein 
and lipid together, where initially the protein-monoolein mixture appeared cloudy but after 
mixing it few times (by pushing plungers back and forth) the lipid mesophase became 
homogenous.  This indicated the formation of lipidic cubic phase of monoolein with the CD81 
protein, as shown in the Figure 5.14. Formation of the LCP was verified by its transparent and 






Figure 5.14:  Image showing Hamilton syringes in which SMALP-CD81 and monoolein 
LCP was prepared. The clear LCP suspension (indicated with blue arrows) was formed after 
mixing the lipid (9 µl) in one syringe with the protein (6 µl). The LCP was prepared with the 
help of Professor Alex Cameron  University of Warwick. 
  
 
After reconstituting CD81 into the LCP, crystallisation trials were set up. Four LCP glass plates 
were prepared for automated LCP matrix screening per 96-well plate, using two bestselling 
membrane protein screens, called MemGold and MemGoldMeso, as these screens were 
developed to test several crystallisation conditions that were previously used to successfully 
crystallise membrane proteins.  
 
The protein-monoolein suspension was transferred to a syringe attached to a dispense needle 
and mounted on the Mosquito robot. The Mosquito robot is an automated nanolitre pipettor 
used for precise drop-to-drop placement of the LCP suspension onto the glass plate, as shown 
in the Figure 5.15. A 50 nl drop of the LCP suspension was placed in each of the 96 wells 
robotically, which was then covered with 800 nl of the screen solution. Four LCP plates were 
prepared, where LCP drops of two plates were screened with MemGold screen and the other 
two with MemGoldMeso screen. The plates from each of the two screens were incubated at 






Figure 5.15: An image of the Mosquito LCP crystallisation robot used for protein 
crystallisation screening. The robot was used to accurately dispense viscous LCP 
suspension and test screen drops (50 nl and 800 nl, respectively) on the glass plates for CD81 
crystallisation screening. The equipment belongs to the University of Warwick in the School of 
Life Sciences.  
 
 
After 72 h incubation, some wispy crystals were observed in one of the screen conditions of 
32% PEG 400; 0.1 M HEPES pH 8.0 and 0.07 M ammonium fluoride at 20 °C. The crystals 
were only observed in one condition that appeared to be growing in the middle of the well (not 
on the edge of the tray, a tell-tale sign of salt crystals). This seemed promising at first, however, 
further observation (after 10 days) hinted at possible false positive crystals that were coming 
up in the mother liquor (screen solution) that was indicative of salt rather than protein. The 
crystals were harvested after three weeks, flash frozen and sent to the Diamond Light Source 
for synchrotron beamline X-ray data collection, where the initial diffraction pattern confirmed 





Another large scale CD81 preparation was performed employing the same purification and 
concentration conditions in an attempt to perform additional crystallisation trials. A ~25 µl of 
15 mg/ml concentrated Peak 2 sample was harvested and taken to the Warwick University for 
crystal trays set up. The LCP mesophase was successfully formed after mechanical mixing of 
the monoolein and the SMALP-CD81 solution using  Hamilton syringes. Two plates were set 
up using MemGold and MemGoldMeso screens that were incubated at 20 °C for three weeks.   
 
Another novel approach was utilised to crystallise CD81 where the SMA 2000 polymer in 
SMALP-CD81 nanodiscs was precipitated using 50 mM magnesium chloride during LCP 
formation. This was to remove the polymer from SMALPs and capture CD81 protein on the 
monoolein to form cubic phase. Two crystal trays were set up after LCP formation (where clear 
mesophase was achieved after mechanical mixing) using MemGold and MemGoldMeso 
crystallisation screens and incubated at 20 °C for three weeks. 
 
No visible protein crystals were detected in these conditions at regular check-ups under the 











5.5: Crystallisation trials using Sf9 overexpressed CD81 
Insect cells (SF9) overexpressing recombinant CD81 were also used in this study (established 
in-house by Dr Michelle Clare and Raman Dhaliwal) to obtain large scale CD81 protein 
preparation. The protein of interest was solubilised using SMA 2000 polymer, purified by 
employing the two step purification method (as before), and subsequently used for the LCP 
crystallisation trials to obtain CD81 crystals. 
 
A 45 g cell pellet harvested from 3 L SF9 cultures (72 h growth) were used in this study (cell 
pellet was kindly provided by Dr Deborah Brotherton from The University of Warwick). The 
membrane only fraction was harvested by lysing the cells following ultracentrifugation to 
collect the membrane pellet.  A 70 ml membrane preparation was used which was solubilised 
with 2.5% SMA 2000 polymer at the room temperature for 1 h following ultracentrifugation to 
collect the soluble fraction. The SMALP-CD81 from the soluble fraction was purified using 
IMAC purification, as shown in the Figure 5.16. The protein was eluted with 150 ml 300 mM 





Figure 5.16: SDS-PAGE analysis of IMAC purified SMALP-CD81 from Sf9 cells. The SMA 
soluble and insoluble fractions along with IMAC flow through, wash and elution fractions were 
analysed by 12% SDS-PAGE. Where 2.5 L of 20 mM imidazole buffer was used as the first 
wash; 1 L of 40 mM imidazole buffer as second wash; 25 ml of 60 mM imidazole buffer as the 
final wash before protein elution. The protein was eluted in 150 ml 300 mM imidazole elution 
buffer in six fractions. Each lane contains 15 µl sample and 5 µl LSB buffer. N=1. 
 
 
The IMAC elution fractions were pooled in three tubes: E1& E2; E3 & E4; E5 & E6 as three 
separate fractions. These were then concentrated to 700 µl each with the concentration of 
2.16 mg/ml, 4.33 mg/ml and 2.82 mg/ml, respectively. Four SEC runs were performed using 
500 µl protein sample per run. Figure 5.17 shows a typical SEC spectrum obtained from SF9 
overexpressed and purified SMALP-CD81. One major peak at ~8.5 ml column elution volume 
and a shoulder at ~12 ml elution volume were harbested. Fractions from ~8.5 to 10 ml (called 
Peak 1) and from 11 to 14 ml (called Peak 2) were collected and pooled in two individual 
fractions. The SDS-PAGE analysis of the IMAC purified and concentrated fractions and SEC 




Figure 5.17: SEC spectrum of Sf9 overexpressed CD81 in SMALPs. SEC elution profile of 
the SMALP-CD81 after IMAC purification, where one dominant peak was observed at ~8.5 ml 
column elution volume and a Peak 2 shoulder at ~12 ml. SEC elution fractions from Peak 1 
and Peak 2 were collected and pooled separately for future analysis.  A Superdex 200 
increase 10/300 GL SEC column was used to determine sample absorbance at 280 nm; 500 





Figure 5.18:  SDS-PAGE analysis of concentrated samples before and after SEC 
separation. IMAC purified SMALP-CD81 was pooled in three separate fractions and 
concentrated before SDS-PAGE analysis. SEC Peak 1 and Peak 2 concentrated samples (up 
to 1 ml volume) were also used to analyse the quality of the harvested protein. Each lane 
contains 15 µl of the sample and 5 µl of LSB buffer. N=1. 
 
 
The SEC Peak 2 fractions (from four SEC runs) were concentrated using 0.5 ml Vivaspin 
concentrators, where 40 µl of ~57 mg/ml concentrated SMALP-CD81 solution was collected. 
The concentrated SMALP-CD81 solution was stored at 4 °C until subsequent use. The 
harvested protein precipitated after 72 h storage at 4 °C prior to the crystallisation trail. This 
was unexpected, as SMALP-CD81 previously appeared stable even at higher temperatures 
(as discussed in chapter 4). A reduced SMALP-CD81 stability observed here might be a 




Overall, large scale CD81 preparation from SF9 host cells using SMA 2000 polymer as 
solubilising agent proved successful. IMAC and subsequent SEC purification gave a relatively 
homogenous and highly concentrated SMALP-CD81 solution that was suitable for CD81 
crystallisation work.  Further studies are required to improve SEC protein separation and 
stabilisation at higher concentrations to obtain a highly pure fraction to aid subsequent protein 



















Chapter 6  
Mammalian cell imaging to study endogenous CD81 expression on the plasma 
membrane 
 
The spatial organisation of tetraspanin CD81 is vital for HCV interaction, cell communication 
and membrane trafficking (Levy et al. 1998). Tetraspanins are well-known for organising 
functional higher-order protein complexes called “tetraspanin-enriched microdomains” (TEMs) 
through interactions with partner proteins and other tetraspanin molecules (Kitadokoro et al., 
2001). Despite this, the nano scale organisation of CD81 on the plasma membrane has not 
been resolved. This is due to challenges posed by a relatively subtle changes in the 
architecture of membrane proteins clusters, where these changes are dynamic and likely to 
depend on the local membrane environment (Homsi et al., 2014). As such, ultra-high-
resolution imaging techniques, such as confocal and electron microscopy, offer some of the 
finest tools to study CD81 biology as they can uncover detailed molecular distribution on the 
cell surface. Therefore, attempts were made in this chapter to perform imaging analysis to 
reveal details of CD81 nano scale distribution.  
 
The principle interest in this chapter is to study CD81 protein expression and organisation on 
the native plasma membrane. So far all the discussed work in previous chapters was 
performed using yeast or insect cells that overexpressed exogenous and recombinant CD81. 
Here the study set out to observe natively expressed CD81 in human cell lines to firstly confirm 
endogenous expression, and then to investigate CD81 nanoscale distribution on the cell 
membrane. Therefore, aim of this study is to elucidate CD81 nano scale distribution on cell 






6.1 Overview of the mammalian cell lines 
The main interest in CD81 is in the context of hepatitis C virus entry that particularly target 
liver cells. For this reason, two human liver cell lines were chosen, namely, Huh-7 and HepG2 
cell lines, to determine CD81 expression level, distribution and clustering on the plasma 
membrane. HEK 293 cell line was also used to test for any changes in protein expression and 
distribution in these cells from hepatocytes. 
  
Huh-7 cells were originated from a well differentiated hepatocytes derived carcinoma cell line. 
The cells were originally taken from the liver carcinoma of a 57 year old Janpanese male, 
which was then grown and established for scientific research by Nakabayashi, H. and Sato, J 
(Tokiwa et al., 1979, Nakabayashi et al., 1982). Huh-7 is an immortal cell line of epithelial-like, 
tumorigenic cells, which grow typically as an adherent 2D monolayer on the surface of tissue 
culture plates or flasks, as shown in Figure 6.1A. It contains many mutations and INDELS 
(insertion or deletions of bases in the genome), most notable is the point mutation in the 
tumour suppressor p53 gene (Hsu et al., 1993, Iwao and Shidoji, 2015). Presence of 
endogenous CD81 in Huh-7 has been reported in many studies (Bruening et al., 2018, Sasaki 
et al., 2003, Delgrange et al., 2007). Therefore, Huh-7 cell line is a valuable research tool for 
studying hepatocyte-derived CD81 to further scientific research on endogenous CD81 
expression, membrane distribution and structural organisation. 
 
HepG2 is an another type of epithelial-like, immortal human liver cancer cell line that was 
established from the hepatocellular carcinoma of a 15 year old white male. HepG2 cells 
proliferate as small 2D aggregates on tissue culture plastic (as shown in Figure 6.1B) and 
could easily be grown successfully on a large-scale for the secretion of many plasma proteins 
such as fibrinogen and albumin (Goepfert et al., 2009, Zhu et al., 2016).  HepG2 cells do not 
express CD81 endogenously, and are thus used in many CD81- HCV studies as a negative 
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control or as a model liver cells to knock-in exogenous CD81 (Sasaki et al., 2003, Mee et al., 
2009).   
 
HEK 293 stands for human embryonic kidney cell line 293, originated from foetus kidney cells 
that are grown in culture (as shown in Figure 6.1C). HEK293 is a well-established and easy to 
grow adherent cell line that is highly transfectable and routinely used for the over expression 
of membrane proteins and viral vectors using transient transfection methods (Rodrigues et al., 
2011). In this chapter, HEK 293 cells were used to firstly test for endogenous CD81 expression 
and then utilised to compare CD81 expression and membrane distribution with liver cell lines, 
such as Huh-7 and HepG2. HEK 293 cells were used in this study along with more relevant 
liver cell lines (for HCV infection) because HEK 293 cells were easy to grow and transfect with 




















Figure 6.1: Images of Huh-7, HepG2 and HEK 293 cells. Image taken from inverted 
monocular metallurgical microscope at 10, 20 and 40 times magnification. Cells grown for 48 





















6.2 CD81 is expressed endogenously in Huh-7 and HEK 293 cells  
Firstly, the presence of endogenous CD81 expression in Huh-7 and HepG2 cell lines was 
tested. Two sub-types of HEK 293 cells were also tested for protein expression, these were 
HEK 293 T and HEK 293 S. Western blot analysis and quantification of protein bands were 
performed to determine the presence and relative amounts of CD81 in each cell line. Each 
cell type was grown in a 35 mm well of a 6-well tissue culture plate containing 2 ml DMEM 
medium. Cells were grown until approx. 70% confluent (~48 h) before harvesting using trypsin 
cell detachment. Whole cell lysates (WCLs) were prepared for Western blot analysis.  For this, 
20 µg of total protein from each sample was loaded in individual gel wells (protein 
concentration of WCLs were determined through BCA assay). In-house produced primary 
anti-CD81 antibody 2s131 (Grove et al., 2017) was used and HRP conjugated mouse antibody 
was used as secondary antibody to detect the presence of CD81 in the blot. ImageJ software 
was used to quantify protein amounts from the blot. Figure 6.2A, clearly confirms the presence 
of CD81 protein bands, at ~23 kDa, in the WCLs of Huh-7, HEK 293 S and HEK 293 T cell 
lines. No protein band was observed in the HepG2 lane, confirming the absence of CD81 
receptor in this cell line, which is consistent with the literature (Sasaki et al., 2003). 
Quantification of CD81 protein, shown in figure 6.2B, indicated higher endogenous CD81 
expression in both HEK 293 sub-types compared to Huh-7 cells. This was surprising as only 
low levels of the protein was initially predicted in HEKs especially when comparing with Huh-
7 cells where CD81 protein is known to be prevalent. Therefore, for subsequent studies in this 
chapter, both Huh-7 and HEK cells are taken forward for confocal microscopy analysis, where 








Figure 6.2: Western blot analysis of endogenous CD81 expression in Huh-7, HepG2, 
HEK 293T and HEK 293 S cell lines. A) Western blot to detect endogenous CD81. Four cell 
lines, Huh-7, HepG2, HEK 293S and HEK 293 T, were tested. 20 µg of total protein was loaded 
in each well, where samples were diluted using PBS. Total volume of 20 µl of sample 
preparation was added in each well, containing 15 µl of whole cell lysate and 5 µl of LSB 
without reducing agent. Anti-CD81 2s131 was used as primary and HRP conjugated anti-
mouse antibody was used as secondary antibody. Image is representative of N=2. B) 
Quantification of western blot analysis. ImageJ software was used to quantify CD81 protein 
gel band intensity. N=2. 
 
 
Confocal microscopy was performed to visualise the CD81 expression pattern on the plasma 
membranes of the mammalian cell lines. As anti-CD81 antibodies (1s337 and 2s131) that 
recognise the large extracellular domain of CD81 had already been validated in the lab (Grove 
et al., 2017), the plan was to fix the cells with paraformaldehyde (4%) and perform 
immunostaining. Alexa Flour 488 was used as it is the most used green fluorophore, with an 
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staining.  The cells were then viewed by confocal microscope, to allow visualisation of live 
cells and CD81 distribution on the membrane. Figure 6.3 indicated strong and even green 
fluorescent distribution across the plasma membranes of Huh-7 and HEK 293 cells, whereas, 
no cell membrane localisation of the green fluorophore was observed in HepG2. Although 
some intense, green blobs were seen in HepG2 micrographs, these were interpreted to be 
non-specific laser excitation of the intracellular vesicles that absorb and emits light at green 
fluorescent wavelength.  
 
Confocal microscopy further confirmed the Western blot data for the endogenous CD81 
expression in Huh-7 and HEK 293, and HepG2 as CD81 negative cell line. This work also 
indicated uniform CD81 distribution on the membrane in both CD81 positive cell lines. 
Therefore, this work using an in-house, conformationally-sensitive primary antibody, indicated 












Figure 6.3: Endogenous CD81 expression in Huh-7 and HEK 293 cells. Confocal 
microscopy analysis were performed on fixed and stained Huh-7, HEK 293 and HepG2 cells. 
Cells were fixed using 4% paraformaldehyde and stained using anti-CD81 antibody (1.337) 
and Alexa Fluor® 488 as primary and secondary antibodies, respectively. Green= Alexa Flour 

















6.3 Determining effective cell harvest conditions to minimise CD81 damage 
After confirming endogenous CD81 expression, optimisation of cell harvest conditions were 
performed to minimise receptor damage (associated with enzymatic cell detachment methods 
that negatively affect surface proteins) during cell harvest. Several proteolytic enzymes are 
utilised to detach cells from the tissue culture plastic, of which trypsin is the most commonly 
used. It acts on the C-terminal side of amino acids lysine or arginine to break down the proteins 
that enable the cells to attach on the adherent surface. Long term incubation of cells with 
trypsin harms the cells by stripping cell surface protein, which is a serious drawback for 
membrane protein work (Iwasaki et al., 2009). Therefore, some of the most frequently used 
cell detachment methods were examined to determine which one suited the most for CD81 
recovery from the strongly adherent Huh-7 cells. For this, four conditions were tested, which 
include both enzymatic and nonenzymatic methods. These were: 2.5% trypsin, 1.25% trypsin 
(50% less trypsin concentration), cell scraping, and using citrate saline solution (135 mM 
potassium chloride, 15 mM sodium citrate) instead of trypsin. The nonenzymatic method of 
using citrate saline is gentler than trypsin detachment, and thus less damaging for membrane 
proteins (Zhang et al., 2012). Whereas, cell scrapers are designed to gently harvest the cells 
using soft pliable blade that scrapes out cells from the tissue culture surface.  
 
Huh-7 cells were tested for this analysis as these cells are strongly adherent cells. Cells were 
grown in four 35 mm wells on a 6-well plate containing 2 ml complete DMEM medium 
containing 5 x 105 cells per well. Cells were then grown for 48 h and harvested using four 
different harvest conditions, as mentioned above. Whole cell lysate was prepared and BCA 
protein concentration assay was performed. Table 6.1 shows total protein concentration of 
WCLs of the tested conditions, where Huh-7 cells harvested via 2.5% trypsin showed highest 
total protein concentration of 3.19 mg/ml, indicating highest protein yield. Protein yielded from 
scraping and 1.25% trypsin indicated much lower protein concentration of 1.9 mg/ml and 1.8 
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mg/ml, respectively. Lowest amount of total protein was obtained through citrate saline harvest 
that yielded only 1.4 mg/ml.  
 
 
Huh-7 cell detachment 
method 
 
WCL total protein 
concentration 
2.5% Trypsin 3.2 mg/ml 
Scraping 1.9 mg/ml 
1.25% trypsin 1.8 mg/ml 
Citrate saline buffer 1.4 mg/ml 
 
Table 6.1: Table showing total protein concentration of WCLs from each of the four 
harvest conditions tested in Huh-7 cells. 
 
 
Next, Western-blot analysis was performed where 20 µg of the total protein from each of the 
four conditions were loaded on individual SDS gel wells. CD81 bands were detected with anti-
CD81 antibody (2s131) and HRP-conjugated secondary antibody. Figure 6.4 indicates that 
despite big difference in total protein concentration of 2.5% trypsin and scraping conditions, 
the western blot CD81 protein band intensities were similar in these two conditions. Lower 
CD81 band intensity was observed in 1.25% trypsin and citrate saline buffer harvest. In 
addition, an unknown lower order protein band was also observed in citrate saline buffer 
harvest condition which could possibly be the truncated CD81 product. Quantification of 
western blot analysis through ImageJ indicated slightly more CD81 protein amounts in the 
scraping condition than the 2.5% trypsin condition. Using the standard trypsin condition at 
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2.5% was able to detach most cells (as indicative by highest total protein concentration in BCA 
assay), however, specific CD81 yield was lower than the scraping method. As trypsin is well 
known for damaging surface proteins, this might explain the lower specific CD81 yield in the 
Western blot analysis. Using 50% less trypsin (1.25% trypsin) also does not improve CD81 
protein yields. The scraping method was less effective at harvesting cells from the flask, as 
shown by less total protein concentration in BCA assay, however, highest CD81 protein was 
recovered using this method. Citrate saline buffer yielded lowest amounts and of CD81 
protein. Therefore, for subsequent electron microscopy work, the scraping method to detach 










Figure 6.4: Testing cell detachment conditions in Huh-7 cells. A) Western blot analysis. 
Four conditions were tested for higher CD81 yield. 20 µg of total protein was loaded in each 
well, where samples were diluted (if required) using PBS. Total volume of 20 µl of sample 
preparation was added in each well, containing 15 µl of whole cell lysate and 5 µl of LSB 
without reducing agent. Anti-CD81 2s131 was used as primary and HRP conjugated anti-
mouse antibody was used as secondary antibody. Image is a representative of N=2. B) 
Quantification of western blot analysis. ImageJ software was used to quantify CD81 protein 













6.4 Investigation of CD81 nanoscale organisation by immunogold scanning electron 
microscopy 
 
Further to confocal microscopy, to zoom in to CD81 distribution on the plasma membrane at 
nano meter resolution, electron microscopy analysis was performed. This is to understand the 
CD81 localisation pattern, in an attempt to determine whether CD81 is distributed as isolated 
monomers or as groups of higher order structures. Although even CD81 expression and 
distribution on the membrane were observed in Huh-7 and HEK 293 cells through confocal 
microscopy, the resolution required to determine the differences in CD81 higher order 
structures is not achievable by confocal microscope. Rather than distinguishing potential 
multiple CD81 proteins as two or more objects separately, confocal images blurred them 
together as a single smudge. To overcome this limitation, transmission electron microscopy 
(TEM) is used to further understand CD81 distribution in Huh-7 and HEK 293 membranes. In 
TEM, high resolution of 0.2 nanometers (nm) is achieved through firing a monochromatic 
beam of electrons through a specimen to generate a detailed image of an object.  
 
For our electron microscopy work (EM), we collaborated with Professor Corrine Smith from 
the EM facility at Warwick University to use their state-of-the-art Jeol 2100 LaB6, which is a 
transmission electron microscope capable of high resolution images. An image of the 
instrument is shown in Figure 6.5.  
 
The cell section samples were prepared for CD81 visualisation. Cells were grown in large T-
flasks (175 cm2 surface area): cells were harvested through scraping and pelleted down to 
obtain at least 1 mm sized cell pellet. Pellets were fixed and ethanol dehydrated and then 
embedded in the resin to preserve structure and for sectioning thin slices for subsequent 
electron microscopy. Before imaging, cells were mounted on the negatively charges EM 





Figure 6.5: Image of a Jeol 200 LaB6 transmission electron microscope. The TEM 





The Figure 6.6 shows 10,000 X magnification micrographs of Huh-7 and HEK 293 cell 
sections without immuno labelling to test for cellular preservation. Both cell types showed 
excellent cellular preservation after extensive EM sample preparation and processing, as 
shown by the visualisation of intact cell membranes and inner cellular organelles. Cell 
membrane folds and curvatures are also intact and visible, however, membrane contrast 
was poor as grids had only uranyl acetate staining to make gold particles easier to spot (for 
later gold labelled antibody staining work). Mitochondrial cristae, which are the inner 
mitochondrial membrane folds, are clearly visible along with the tube-like cisternae of the 
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endoplasmic reticulum. Optimal cell section preservation was achieved after swapping 
formvar resin to epoxy resin and using carbon coated grids instead of standard copper grids. 
Grid resin tearing was observed in many trials due to electron beam damage to the cellular 
structure, but it eventually was possible to retain cellular structure.  Once optimal cell 
processing protocols and cell section preservation were achieved, the next step was to 
















Figure 6.6: Images of Huh-7 and HEK 293 cell sections using electron microscope. Cell 
section preservation was tested. Huh-7 and HEK 293 cells were fixed, thin-sectioned, stained 
and analysed using TEM. Sections were stained with 2% uranyl acetate. Scale bars: 1 µm. 
Representative images to show excellent cellular preservation. A) Cell section images of Huh-















For immuno staining, two separate anti-CD81 antibodies were used, which were labelled with 
gold nanoparticles to aid EM visualisation. The antibodies 2s131, recognise a region centred 
around helix D of the EC2, whereas, antibody 1s337 recognises similar, possible 
discontinuous, epitopes across helices A, B and C of the protein (Grove et al. 2017). Moreover, 
earlier prediction from unpublished data from Prof Jane McKeating (University of Oxford) 
suggested that 2s131 antibody is able to selectively bind to monomeric CD81, while 1.337 is 
able to recognise dimeric or possibly oligomeric protein. This prediction gave opportunity to 
examine structural organisation of endogenous CD81 on the plasma membrane using these 
two antibodies. The bespoke gold labelled anti-CD81 antibodies were therefore generated to 
attempt to detect monomeric and/or possible dimeric CD81 distribution, where 2s131 was 
conjugated with 15 nm gold particle and 1s337 with 6 nm gold particle to distinguish between 
two antibodies binding. 
 
Figure 6.7 shows micrographs of Huh-7 and HEK 293 cell sections labelled with both gold 
labelled anti-CD81 antibodies (2s131 and 1s337).The antibody concentration of 2 µg/ml was 
used according to the previously published article using anti-CD81 antibody to detect CD81 
through SEM (Grove et al. 2017).  In this pilot experiment, cell sections were immunostained 
with equal amounts of both antibodies in order to test for any preferential antibody binding 
pattern. No distinguishable binding pattern was observed, only off target distribution of 15 nm 
and 6 nm gold particles (corresponding to 2s131 and 1s337, respectively) were observed 
throughout the cell section. With this approach it was difficult to distinguish random binding 
from on target membrane only labelling. Therefore, optimisation of labelling protocol was 







   
Figure 6.7: Immuno gold staining of Huh-7 and HEK 293 cell.  Two nanogold labelled anti-
CD81 antibodies were used. 2s131 conjugated with 15 nm gold and 1s337 with 6 nm gold 
nanoparticles. Image scale bar from 2 µm to 500 nm. Huh-7 and HEK 293 cells were fixed, 
thin-sectioned, stained and analysed using TEM. Sections were stained with 2% uranyl 
acetate. Scale bars: 1 µm. Representative images to show non-specific antibody labelling. A) 













To address the ‘off target binding’, on the assumption that antibody concentration was too high 
serial dilution of 1:10, 1:100, 1:500, 1:1000, 1:10000 were prepared. The dilutions 1:500 and 
1: 10000 did not show any labelling at all (possibly due to low antibody concentration), 
whereas, similar non-specific antibody binding pattern was observed across the 1:10, 1:100 
and 1:1000 fold dilutions. Moreover, addition of antibody blocking agent (BSA) did not reduce 
non-specific antibody labelling, suggesting that antibody concentration was not an issue. 
Overall, no clear antibody labelling pattern on to the cell membrane was observed.  
 
In order to troubleshoot non-specific antibody labelling, another approach was utilised. Cells 
were labelled with antibodies before fixing and EM processing steps. This was to prevent 
cytoplasmic binding observed with cell section antibody staining. Pre-fixed cell labelling with 
both anti-CD81 antibodies (10 µg/ml each) was performed straight after cell pellet harvest and 
phosphate buffer wash but before glutaraldehyde fixation.  This resulted in reduction of non-
specific binding. Gold particles, although sparse, but now entirely visiualised on the plasma 
membrane of both Huh-7 and HEK 293 cell sections, as shown in Figure 6.8 and 6.9 
respectively, where 15 nm gold particles are marked with black, and 6 nm gold particles are 
marked with white arrow heads. 
 
In Figure 6.8, images at 10000, 20000 and 40000 times magnification in Huh-7 sections were 
taken. 2s131 staining (containing 15 nm gold) revealed mainly monodispersed CD81, 
although gold particles doublets were also observed.  However, 1s337 staining identified 
mainly higher order CD81 assemblies as shown by tightly packed clusters indicating a 
potential enrichment of CD81. The observed pattern of CD81 distribution in Huh-7 sections, 
where monodispersed proteins are present along with tight clusters of putative higher order 
CD81 structures, was consistent with the current prediction in the tetraspanin literature. It 
indicates the presence of both monomeric and higher order tetraspanin (possible tetraspanin 
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enriched microdomains) organisation (Hemler, 2003, Zimmerman et al., 2016). In HEK 293 
sections (shown in Figure 6.9), 2s131 staining identified sparsely dotted monodispersed gold 
particles along with some gold doublets. A few small clusters of 6 nm gold particles (1s337 
staining) were visualised indicating the presence of higher order CD81 structure. These 
images are consistent with Huh-7 analysis where CD81 is distributed as monomeric as well 










Figure 6.8: Analysis of CD81 nanoscale organisation in Huh-7 cells by immunogold 
transmission electron microscopy. Huh-7 cell sections were analysed for endogenous 
CD81 organisation using TEM. Sections were stained with 2% uranyl acetate. Scale bars: 1 
µm. Representative images to show CD81 distribution on the plasma membrane. Pre-fixed 
cell labelling with both antibodies. 15 nm gold particle conjugated 2s131 antibody is indicated 
with black arrow heads, and 6 nm gold particle conjugate 1s337 anti-CD81 antibody is shown 
in white arrow heads. Representative images from two independent cell preparation and EM 








Figure 6.9: Analysis of CD81 nanoscale organisation in HEK293 cells by immunogold 
transmission electron microscopy. HEK 293 cell sections were analysed for endogenous 
CD81 organisation using TEM. Sections were stained with 2% uranyl acetate. Scale bars: 1 
µm. Representative images to show CD81 distribution on the plasma membrane. Pre-fixed 
cell labelling with both antibodies. 15 nm gold particle conjugated 2s131 antibody is indicated 
with black arrow heads, and 6 nm gold particle conjugate 1s337 anti-CD81 antibody is shown 
in white arrow heads. Representative images from two independent cell preparation and EM 





Chapter 7  
Solubilisation of endogenous and overexpressed CD81 in mammalian cell 
lines using SMA co-polymer 
 
A critical step for the in-vitro investigation of membrane proteins is the solubilisation of the 
plasma membrane to extract the protein of interest in stable and active form. This could be 
achieved by complexing membrane proteins with amphipathic surfactant molecules, such as 
SMA co-polymer, to obtain an aqueous solution containing the protein with its surrounding 
lipids (Rothnie, 2016). This chapter provide details on endogenous CD81 solubilisation trials 
from HEK 293 cell membranes using SMA co-polymer to aid future work on mammalian cell 
expressed protein. Previous work on yeast SMALP-CD81 (discussed in Chapter 3) has shown 
increased protein stability and functionality compared to detergent extracted protein, therefore, 
SMA solubilisation was taken forward to attempt CD81 extraction from HEK 293 cell 
membranes.  
 
To enable structural, functional and biochemical characterisation of a mammalian expressed 
CD81, expression and purification of high quality protein in sufficiently large quantities are 
required. To accomplish this, attempts have also been made in this study to optimise 
heterologous CD81 overexpression in HEK293 and Huh-7 cells to increase protein yield.  
Overexpression of exogenous CD81 DNA into host cells was performed using readily available 
transfection reagents, such as polyethylenimine (PEI) and lipofectamine, with pEF6.A plasmid 
DNA containing a FLAG-tagged CD81 gene. Overexpression of recombinant CD81-FLAG 
from mammalian cell membranes will enable future SMA solubilisation and purification 





7.1 Endogenous CD81 solubilisation using SMA polymers 
HEK293 S and HEK293 T cells were used for SMA polymer solubilisation trials as these two 
cell types were shown to express most endogenous CD81 protein compared to liver cells 
(discussed in Chapter 6). Human embryonic kidney 293 cells (referred as HEK293 S in this 
thesis) is the cell line originally derived from human embryonic kidney cells grown in tissue 
culture. While, HEK293 T is a cell line derived from HEK293 S cells that expresses a mutant 
version of the SV40 large T antigen as enhancers of expression vector to increase protein 
production. Both HEK293 S and T cell lines  are very commonly used in biology for exogenous 
protein expression (Ooi et al., 2016).  
 
The presence of CD81 bands in both HEK 293S and HEK 293T membrane preparations as 
well as in SMA 2000 soluble and insoluble fractions were seen in western blot analysis, as 
shown in Figure 7.1. However, the intensity of CD81 bands post solubilisation appeared much 
lower compared to membrane only samples. As lower CD81 band intensity in the insoluble 
sample indicates higher protein solubilisation efficiency, this suggested that more CD81 
protein should be present in the soluble fraction but due to polymer hindrance in the Western 
blot antibody detection system not all SMALP-CD81 in the sample had been detected. 
Therefore, it was concluded that endogenous CD81 had been successfully solubilised using 





Figure 7.1: Western-blot analysis of SMA 2000 solubilisation. The SMA polymer 
solubilisation assays were performed to extract endogenous CD81 from both HEK 293S and 
HEK 293T cells. 10 µl of sample with 5 µl of LSB buffer without reducing agent was added in 
each gel lane. Anti-CD81 antibody 2s131 was used as primary and HRP-conjugated anti-
mouse antibody was used as secondary antibody. Image is representative of N=3. Western 




Next, SMA solubilisation efficiency was compared with detergents. For this, four different 
solubilisation conditions were used for HEK S and T cell membranes: 2.5 % SMA 2000, 2.5% 
SZ25010, 1% DDM, 1% DDM with 0.1% cholesterol hemisuccinate (CHS). Figure 7.2 shows 
very low intensity protein bands in all insoluble CD81 conditions suggesting that the majority 
of the protein was in the soluble fraction. The intensity of the insoluble CD81 band in SMA and 
detergent conditions was similar, indicating comparable CD81 solubilisation. Low gel band 
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intensity of the SMA soluble samples was observed compared to DDM samples, which was 
assumed to be due to polymer interference with antibody-protein binding.  Therefore, the 
solubilisation efficiency of both SMA polymers (SMA 2000 and SZ25010) and detergent (DDM) 
appeared to be comparable, where adding 0.1% CHS did not appear to make any difference. 





Figure 7.2:  Western blot analysis to compare SMA co-polymer and detergent 
solubilisation in HEK 293 S and HEK 293 T cells.  Soluble and insoluble fractions after HEK 
membranes were visualised through western blot. Four solubilisation reagents were used: 
2.5% SMA 2000 polymer, 2.5% SZ25010 polymer, 1% DDM, and 1% DDM with 0.1% 
cholesterol hemisuccinate (CHS). 10 µl of sample with 5 µl of LSB buffer without reducing 
agent was added in each gel lane. Anti-CD81 antibody 2s131 was used as primary and HRP-
conjugated anti-mouse antibody was used as secondary antibody. Image is a representative 
of N=2. Western blots were prepared and visualised by Karen Cheung and Connor Marlow 






CD81 binding to its ligand E2 was tested using an indirect enzyme-linked immunosorbent 
assay (ELISA). All eight samples, from SMA and detergent solubilisation, including four 
soluble and four insoluble fractions were checked for E2 binding. The assay was performed 
on both HEK S and T samples independently. BSA and HepG2 cell membrane were used as 
negative controls, and hCD81 P. Pastoris membrane and SMA 2000 solubilised fraction were 
used as positive controls. Figure 7.3 shows high E2 binding in SMA 2000 and SZ25010 soluble 
and insoluble samples from both HEK 293S and HEK 293T cell types, indicating intact 
functional activity in SMALP-CD81. In contrast, low binding was seen in 1% DDM and 1% 
DDM with 0.1% CHS soluble samples, and comparatively higher E2 binding was observed in 
the insoluble fractions. This suggests possible obstruction of the E2 binding epitope of CD81 
in detergent micelles that had negative effect on receptor-ligand binding.  
 
 
Figure 7.3: E2 ELISA to determine CD81 binding affinity with its ligand. Soluble and 
insoluble fractions from the polymer and detergent solubilisations were tested. BSA protein 
and HepG2 membrane were used as negative controls, and yeast membrane and 2.5% SMA 
solubilised soluble fraction were used as positive controls. Anti-Strep antibody (1: 5000 
dilution) was used as primary antibody and HRP conjugated anti-mouse antibody was used 
as secondary antibody, which were then visualised by SIGMAFASTTM OPD tablets. Optical 
density reading at 492 nm wavelength was taken. Image is representative of N=2. 
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Overall, these data demonstrate that endogenous CD81 from HEK cells was successfully 
solubilised using SMA polymers where the polymer solubilisation efficiency was comparable 
to DDM detergent. Moreover, the solubilised SMALP-CD81 was able to retain its functional 
relevance as it binds to HCV E2 glycoprotein in contrast with detergent solubilised CD81. Low 
E2 binding to DDM solubilised CD81 was unexpected; it could suggest either denaturation of 
E2 binding epitope on CD81 after detergent solubilisation or hindrance in binding due to the 
presence of detergent micelles. It was concluded that SMA co-polymers were able to efficiently 
solubilise endogenous CD81 from mammalian membranes and retained E2 binding ability, in 
contrast with detergent solubilised CD81.  Therefore, in future SMA co-polymers could be 
utilised to efficiently solubilise endogenous CD81 from HEK 293 membranes. This will also 
enable lipidomics studies to identify crucial lipids that surrounds CD81 to maintain its functional 
and structural integrity.   
 
 
7.2 Heterologous CD81 expression in mammalian cells  
The overexpression of CD81 membrane protein in HEK 293 and Huh-7 cells was attempted 
in an effort to increase CD81 yields. Although CD81 is expressed endogenously in both cell 
lines, increasing in protein yield was attempted to aid large scale production of mammalian 
cell derived CD81 for subsequent solubilisation and purification work. For this, lipid mediated 
exogenous DNA transfection was performed in HEK 293 cells using mainly PEI and 
lipofectamine as transfection reagents.  
 
Four CD81 constructs were acquired, as a kind gift from Dr Mike Tomlinson (University of 
Birmingham). Each construct contained either FLAG-tagged wild type or mutant hCD81 in 
pEF6.A plasmid with an ampicillin resistant gene. The hCD81 gene was cloned in pEF6.A 
plasmid via BamHI and NotI restriction sites with the stop codon, and without CD81 start codon 
as the N-terminus FLAG sequence already has the ATG. The detailed map of pEF6.A plasmid 
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with its multiple cloning site is shown in Figure 7.4. The four constructs used in this study 
contained either a wild-type CD81, four intracellular cysteines mutated to serine (four 
palmitoylation site mutant or 4PM), all six cysteine residues mutated to serine (also called 





Figure 7.4: The pEF6.A plasmid map. pEF6 A is an 8980 bp vector containing the CD81 
gene. The vector was constructed by ligating a 3974 bp BamH I-Bsm I fragment containing a 
constitutive promoter, the human elongation factor-1 alpha (EF-1α), from pEF6.B to a 5006 
bp fragment containing the blasticidin resistance gene from the pcDNA6 plasmid. Image 













Figure 7.5: Schematic representation of recombinant hCD81 p-null protein used for 
mammalian transfection.  In CD81 p-null construct possible palmitoylation sites (intracellular 
cysteine residues) at sequence position 7, 10, 81, 90, 228 and 2298 are mutated to serine  to 
prevent protein cross-linking (represented with white circles). Two extracellular loops are 
shown, small extracellular loop (EC1) and large extracellular loop (EC2), where EC2 contain 
conserve CCG motif that is important for disulphide bridges formation. The N-terminus contain 





The XL-10 Gold E-coli ultra-competent cells (from STRATAGENE) were transformed with 
pEF6.A plasmids. Four transformation assays were performed to produce four E-coli 
transformants containing either wild type CD81, CD81 4PM, CD81 p-null or pEF6.A empty 
vector. After transformation, cells were grown in LB broth at two different culture conditions:  
two of the transformants, pEF6.A-CD81 WT and pEF6.A-CD81 p-null were grown in 500 ml of 
the LB broth, while the remaining two transformants were grown 100 ml of the LB broth.  This 
was to test whether increasing culture volume from 100 ml to 500 ml would increase plasmid 
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DNA harvest.  Plasmid DNA concentrations were quantified using a NanoDrop where DNA 
purity was measured by A260/A280 ratio ranging from 1.80 – 2.00. 
 
Figure 7.5 shows E-coli XL10-Gold growth on ampicillin containing agar plates. This indicated 
successful transformation of the cells with the pEF6.A-CD81 WT construct containing the 
ampicillin resistance gene. The same was observed with the other three E-coli transformation 




Figure 7.6: Selection of transformed E-coli cells on LB agar. E-coli XL10-Gold cells were 
transformed using heat-shock. E-coli cells transformed with pEF6.A-CD WT plasmid was 
grown on ampicillin (100 µg/ml) LB agar plates. N=3. 
 
 
Harvested plasmid DNA from all four constructs was visualised by agarose gel electrophoresis 
as shown in Figure 7.7A. All four linearized plasmid DNA samples were present at the correct 
molecular weight of around 8.9 kb, indicating the presence of full length pEF6.A DNA. 
Quantification of the bands on the agarose gel, shown in Figure 7.7B, indicated the highest 
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DNA band intensity from the pEF6.A empty vector and pEF6.A-CD81 4PM that were grown in 
100 ml of culture post transformation. Lower band intensities were observed in pEF6.A-CD81 




Figure 7.7: Bacterial preparation to obtain large amounts of CD81 DNA. E-coli XL10-Gold 
cells were transformed using heat-shock. A) Agarose gel electrophoresis of four CD81 
DNA constructs after DNA preparation. Empty pEF6.A and pEF6.A-CD81 4PM were grown 
in 100 ml LB broth after transformation, whereas, pEF6.A-CD81 p-null and pEF6.A-CD81 WT 
were grown in 500 ml culture volume. Each lane contain 5 ng of the DNA obtained after maxi-
preparation using Qiagen kit (for Maxi prep.). Undigested pEF6.A-CD81 WT plasmid was used 
as a control. P-null= all palmitoylation sites mutated; WT=wild type; 4PM= four palmitoylation 
sites mutated. Image representative of N=3. C) DNA quantification of agarose gel bands. 




Table 7.1 lists harvested DNA amounts from all four pEF6.A plasmids from either 100 ml or 

































DNA extraction - the NanoDrop DNA concentration ratio of A260/A280 ranging from 1.8 to 2.0 
was observed in each DNA preparation.  Table 7.1 shows higher DNA amounts were achieved 
from 100 ml bacterial cultures; around 1.5 µg/µl and 1 µg/µl of DNA were obtained from 
pEF6.A-CD81 4PM and pEF6.A empty vector, respectively, compared to lower DNA yields in 
the other two constructs (0.78 µg/µl in pEF6.A-CD81 WT and 0.85 µg/µl in pEF6.A-CD81 p-
null). This indicated a preference for growing pEF6.A plasmid in lower volumes of culture 
media, which could be a consequence of pEF6.A being a high copy number plasmid (meaning 
that each host cell could contain many copies of pEF6.A plasmid). Over growing or expanding 
transformants in larger volume might have negative impact that can cause loss of plasmid or 
lower plasmid replication. Therefore, to obtain superior DNA yields in subsequent work, 
transformed cell were grown in 100 ml culture before harvesting and DNA preparation.  
 
 




pEF6.A-CD81 4PM 1048.1 
 
500 ml LB culture plasmids 
 
DNA (ng/µl) 
pEF6.A-CD81 WT 780.9 
pEF6.A-CD81 p-null 858.4 
 
Table 7.1: Table listing average DNA amounts obtained from four different DNA 
preparations. Four E-coli transformants were produced and grown in either 100 ml or 500 ml 






7.3 Transient CD81 expression in HEK 293 cells 
HEK 293 S and HEK 293 T were transfected with one of the three pEF6.A plasmids containing 
CD81 gene to further increase protein yields for subsequent solubilisation and purification. 
Exogenous pEF6.A-CD81 DNA was introduced into the host cells by transfection with a stable 
cationic polymer called polyethylenimine (PEI) (Boussif et al., 1995). PEI works by condensing 
DNA into positively charged cationic particles that binds to the anionic cell membrane leading 
to endocytosis of DNA:PEI complexes and subsequent release of the DNA into the cytoplasm 
(Sonawane et al., 2003) 
 
HEK cells were seeded in 6-well plates to reach a cell density of 3 x 105 cells/ml at the time of 
transfection. A PEI working solution of 1 mg/ml was prepared from the frozen stock solution. 
DNA to PEI ratio of 1:7 was used for the transfection, where 5 µg of DNA and 35 µl of PEI 
solution were used for initial transfection trials (as recommended by other membrane protein 
work in the laboratory). Whole cell lysates (WCLs) of transfection conditions were analysed 
through Western blot using anti-CD81 and anti-FLAG antibodies separately as primary 
antibodies to determine the presence of exogenous CD81. A mock transfection condition 
containing no DNA or PEI was performed as a negative control. Empty vector pEF6.A 
transfection was also performed as an additional negative control. 
 
The first few transfection trials were not successful as no increase in CD81 gel band intensity 
from the mock or empty vector pEF6.A control (showing only endogenous CD81) to hCD81 
transfection conditions were observed using anti-CD81 antibody. As shown in Figure 7.8. Also, 
no CD81 bands were observed at ~25 kDa in an anti-FLAG antibody stained Western blot, 




Figure 7.8: Western blot analysis of initial transfection trials in HEK cells.  Five 
transfection conditions were tested using CD81 wild type DNA, CD81 4PM, CD81 p-null, 
empty vector pEF6.A and mock transfection. 5 µg DNA and 35 µl PEI solution were used in 
each conditions except for mock. Western blots were stained with anti-CD81 and anti-FLAG 
antibodies separately. Each lane contain 20 µl of WCL and 5 µl of LSB buffer without reducing 
agent. Blots were either stained with primary anti-CD81 2s131 (with anti-mouse HRP 
secondary antibody) or with anti-FLAG antibody (with anti-rabbit HRP secondary antibody). 
Whole cell lysates were prepared from each transfection condition using Triton X-100 
containing lysis buffer. Mock= a negative control condition where no DNA or PEI were added 
but grown at the same test conditions. Images are representative of N=2. 
 
 
To trouble shoot the transfection protocol, fresh PEI stocks were made at 1 mg/ml. Another 
cationic lipid formulation, called lipofectamine, was also tested as an alternative to PEI to 
increase transfection efficiency of pEF6.A-CD81 DNA in HEK cells.  Similar to PEI, 
lipofectamine comprises lipid subunits that can form liposomes in an aqueous environment 
and entrap plasmid DNA. Consequently it delivers the transfection payload to the cytoplasm 
through endocytosis. Additionally, various DNA: PEI and DNA: lipofectamine ratios were 
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tested to determine optimal transfection conditions.  These conditions were examined in both 
HEK 293S and HEK 293T cells using pEF6.A-CD81 wild type.  
 
 In Figures 7.9 and 7.10, PEI and lipofectamine conditions were tested to increase the 
transfection efficiency.  This included using two DNA:PEI test concentrations of 0.5 µg DNA 
to 2 µl PEI and 1 µg DNA to 4 µl PEI, or three DNA:lipofectamine concentrations of 0.5 µg 
DNA to 7.5 µl lipofectamine, 1 µg DNA to 7.5 µl lipofectamine and 0.5 µg DNA to 6 µl 
lipofectamine. Cells were seeded at higher cell numbers to reach densities of 5 x 105 cells/ml 
(in 2 ml of DMEM medium) for transfection.  The presence of CD81 protein was detected 
through western blot using anti-CD81 and anti-FLAG antibodies (as shown in Figures 7.9 and 
7.10 respectively).  
 
The anti-CD81 antibody stained western blots in Figure 7.9 clearly show an increase in CD81 
band intensity from mock and pEF6.A empty vector control transfections. Possible CD81 
doublets were observed at ~ 25 kDa in the PEI condition of 1 µg DNA to 4 µl PEI,  and in all 
lipofectamine conditions indicating the presence of both endogenous CD81 along with the 
heavier exogenous FLAG-tagged CD81 protein.   
 
The anti-FLAG antibody stained western blots in Figure 7.10 show the clear presence of CD81 
bands in the PEI condition of 1 µg DNA to 4 µl PEI and in all three lipofectamine trials, 
indicating successful transfection and expression of exogenous CD81 in HEK cells. However, 
only a faint CD81 band was observed in one of the PEI transfections compared to 
lipofectamine where intense gel bands were detected in all three conditions. This suggested 





Figure 7.9: Test for various transient transfection conditions in HEK cells – CD81 
detection through anti-CD81 antibody.  Western blot analysis to test for various transfection 
conditions using only pEF6.A-CD81 WT plasmid. PEI and lipofectamine were used to test 
eight transfection conditions in both HEK 293 S and HEK 293 T cells. Each lane contains 20 
µl of WCL and 5 µl of LSB buffer without reducing agent. Western blots were stained with 
primary anti-CD81 2s131 (with anti-mouse HRP secondary antibody). Whole cell lysates were 
prepared from each transfection condition using Triton X-100 containing lysis buffer. Mock= a 
negative control condition where no DNA or PEI were added but grown at the same test 












Figure 7.10: Test for various transient transfection conditions – CD81 detection through 
anti-FLAG antibody. Western blot analysis to test for various transfection conditions using 
only pEF6.A-CD81 WT plasmid. PEI and lipofectamine were used to test eight transfection 
conditions in both HEK 293 S and HEK 293 T cells. Each lane contains 20 µl of WCL and 5 µl 
of LSB buffer without reducing agent. Western blots were stained with with anti-FLAG antibody 
(with anti-rabbit HRP secondary antibody). Whole cell lysates were prepared from each 
transfection conditions using Triton X-100 containing lysis buffer. Mock= a negative control 
condition where no DNA or PEI were added but grown at the same test conditions. Lipo= 
lipofectamine. Images are representative of N=2. 
 
 
To improve PEI transfection efficiency, in order to use it for routine large scale transfection 
and exogenous protein expression work (as PEI is more cost effective compared to pricey 
lipofectamine reagent),  new PEI reagent was purchased and fresh aliquots were made for 
subsequent work. Lipofectamine transfection was used as a positive control as this has 
worked well in previous experiments. Three DNA to PEI concentrations were tested: 2 µg DNA 
to 8 µl PEI; 1 µg DNA to 4 µl PEI; 3 µg DNA to 12 µl PEI. Figure 7.10 shows the Western blot 
analysis of new conditions using the anti-FLAG antibody. The presence of CD81 bands in two 
238 
 
out of three PEI conditions was observed, where the gel band intensities were similar to that 
of lipofectamine (positive control).  Besides indicating successful transfection, the western blot 
data also show higher PEI transfection efficiency that was as high as the positive control.  
Therefore, for subsequent work, 2 µg DNA to 8 µl PEI and 1 µg DNA to 7.5 µl lipofectamine 
concentrations were used, where lower amount of successful PEI condition was selected as 




Figure 7.11: Transient transfection in HEK cells with pEF6.A plasmids. Optimisation of 
transfection protocol using PEI. Transfection was carried out in HEK 293T cells, where 
Western blot was stained with anti-FLAG antibody. Lipofectamine condition of 1 µg DNA and 
7.5 µl lipofectamine reagent was used as positive control as this conditions has worked well 
in both HEK 293S and HEK 293T cells.Each lane contain 20 µl of WCL and 5 µl of LSB buffer 
without reducing agent. Whole cell lysates were prepared from each transfection conditions 
using Triton X-100 containing lysis buffer. Mock= a negative control condition where no DNA 
or PEI were added but grown at the same test conditions. Lipo= lipofectamine. Image is 





7.4 Transient CD81 expression in Huh-7 cells 
Heterologous CD81 expression was performed in Huh-7 cells, as this was more relevant cell 
line (liver cell line) for studying HCV infection, by utilising optimised lipofectamine and PEI 
conditions in HEK cells. The concentrations of 2 µg DNA to 8 µl PEI and 1 µg DNA to 7.5 µl 
lipofectamine were used. Small scale transfection trails were performed using 6-well tissue 
culture plates containing 2 ml DMEM medium in each well. Huh-7 cells were seeded to reach 
cell densities of 5 x 105 cells/ml on the day of transfection. Cells were then incubated for 48 h 
post transfection at 37 °C and whole cell lysates were prepared. The CD81 protein was 
detected through western blot stained with anti-FLAG antibody. 
 
The presence of CD81 protein bands were observed in both lipofectamine and PEI 
transfections, as shown in Figure 7.12, indicating successful exogenous CD81 expression in 
Huh-7 cells. The HEK 293 S cell transfections were used as positive controls. The CD81 band 
intensity in Huh-7 appeared to be slightly lower then HEK 293, however, fewer non-specific 
bands were detected in Huh-7 compared to HEK cells.   The lower band intensity in Huh-7 
samples could be a consequence of slower growth of the cells in tissue culture plates 
compared to HEK 293. Total protein concentration analysis from the whole cell lysates of HEK 
293S and Huh-7 cells grown in 2 ml of DMEM medium detected around 7.02 mg/ml and 4.4 








Figure 7.12: FLAG-tagged CD81 transfection in Huh-7 cells. Western blot analysis was 
performed using anti-FLAG antibody as primary and HRP-conjugated anti-rabbit antibody as 
secondary antibody. Each lane contain 20 µl of whole cell lysates and 5 µl of LSB buffer 
without reducing agent. Mock= condition where no DNA or transfection reagent were added 


















































7.5 Upscaling of transient transfection in HEK cells 
After establishing small-scale transfection conditions for CD81 in HEK 293` cells, larger scale 
transfection trials were performed using 10 ml DMEM media in petri plates (10 cm diameter). 
Cells were seeded to reach density of 5 x 105 cells/ml for transfection. After 48 h growth post 
transfection, cells were harvested through scraping and membrane only fractions were 
prepared instead of making whole cell lysates. This was done by titrating cells 15 times with a 
fine needle before spinning lysed cells at ultrahigh speed of 100,000 g to pellet out cellular 
membranes. The membrane pellet was resuspended in buffer A at 80 mg/ml. These steps 
were performed to obtain a HEK 293 cell membrane suspension containing transfected CD81 
along with endogenous CD81 to use in future SMA 2000 solubilisation and purification work. 
The transfection conditions of 10 µg DNA to 40 µl PEI and 5 µg DNA to 37.5 µl lipofectamine 
were used (previously optimised conditions were scaled-up five times). All three CD81 
containing plasmids: pEF6.A-CD81 WT, pEF6.A-CD81 4PM and pEF6.A-CD81 p-null were 
used for this work. The previously prepared small-scale pEF6.A-CD81 WT transfection whole 
cell lysate was used as a positive control.  
 
Figure 7.12 shows a western blot analysis of HEK membrane samples containing CD81. The 
protein bands at ~25 kDa were observed in both PEI and lipofectamine membrane 
preparations for all three CD81 plasmids, indicating successful upscaling of transfection 
conditions for CD81 in HEK cells (from 2 ml to 10 ml culture volume). However, the band 
intensity in the positive control (whole cell lysate of CD81 WT transfection) was much higher 
compared to test samples. This suggested possible loss of CD81 protein during extra cell lysis 
and membrane preparation steps. The monomeric (~25 kDa) protein band in the PEI CD81 
WT and the positive control (containing CD81 WT) samples appeared to run slightly differently 
compared to CD81 4PM and CD81 p-null samples. This was due to the presence of wild type 
CD81 gene containing no cysteine to serine mutation, which made it separate differently than 




Figure 7.13: Upscaling of CD81 transfection conditions in HEK cells. Western blot 
analysis was performed using anti-FLAG antibody as primary and anti-rabbit HRP conjugated 
antibody as secondary antibodies. Each lane contained 20 µl test membrane preparation with 
5 µl LSB buffer without reducing agent. The positive control contains 20 µl of whole cell lysate 
prepared from the small scale pEF6.A-CD81 wild type transfection with 5 µl LSB buffer. Lipo= 




Overall, this chapter has shown successful endogenous CD81 solubilisation with SMA co-
polymer, where SMALP-CD81 appeared to retain its ligand binding ability with HCV E2 
glycoprotein. Also shown in this chapter, successful exogenous hCD81-FLAG transfection and 
expression (through Western blot analysis) in HEK 293 and Huh-7. This will enable future 
large-scale protein production work to be carried out using HEK 293 and/or Huh-7 cells to 









8.1 Solubilisation of CD81 with SMA co-polymer  
CD81 belongs to a diverse group of four-pass transmembrane proteins that is implicated in 
many vital cellular processes such as cell adhesion, cell proliferation and in immune system 
regulation (Levy et al. 1998). CD81 has also been associated in many clinical pathologies 
such as in cancer, malaria virus infection, and is also a major participant for mediating hepatitis 
C virus infection by regulating HCV entry into the liver cells (Marukian et al., 2008). Therefore, 
conducting in-depth studies on CD81 structure and function is of paramount medical 
importance.  
 
In this study we have shown that recombinant CD81 expressed in P. pastoris yeast can be 
effectively solubilised and purified using SMA polymer. It was previously shown that another 
member of the tetraspanin family, TSPAN7, could also be extracted with SMA from the yeast 
Sacchromyces cerevisiae. However this was not the case for several other tetraspanins 
expressed in S. cerevisiae (Skaar et al., 2015). Interestingly, we found that monitoring 
membrane turbity was not a good measure for CD81 solubilisation. Membrane turbity is quick 
and easy to measure and has been used previously to monitor kinetics of solubilisation 
(Bersch et al., 2017, Logez et al., 2016). However we found that turbity decreased much more 
quickly and at lower concentrations of SMA than were needed for CD81 solubilisation (Figure 
3.11). This contrasts with a previous report where SMA was used to solubilise the ABC 
transporter MRP4/ABBC4 (multidrug resistance protein 4) from insect cell membranes, where 
the changes in turbity were mirrored by protein specific solubilisation (Hardy et al., 2019). 
Secondly the kinetics of CD81 solubilisation were much slower than that observed for MRP4 
(Hardy et al., 2019), possibly related to the differences in lipid composition of yeast 
membranes compared to insect cells (Pardo et al., 2017). Thus this highlights the importance 
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of measuring protein specific solubilisation efficiency and that optimal conditions will likely be 
both protein and expression system dependent. 
 
The P. pastoris growth was up scaled from shake flasks to bioreactors. Interestingly the data 
shown in Chapter 3 suggest that despite successfully harvesting higher cell biomass, the 
recombinant protein yield was much lower in bioreactors; 40% less CD81 protein was detected 
in this cultivation. Additionally, the SMA solubilisation trials also indicated lower bioreactor 
membrane solubility compared to P. pastoris membranes harvested from shake flasks. This 
was unexpected as the growth in both cultivations were performed for 72 h using the same 
culture media and under same glycerol and methanol concentrations. It is predicted that the 
lower CD81 yield and solubilisation efficiency from the bioreactor growth were hampered by 
large scale growth issues such as metabolic load, unmastered dimorphism, and oxygen 
requirements, as suggested by  (Vandermies and Fickers, 2019).  The differences between 
shake flask and bioreactor P. pastoris growth have also been observed by Bawa et al., 2014 
where leaky tetraspanin expression (hCD81 and hCD82) were observed in the pre-induction 
growth in bioreactors but not in shake flasks cultivations (Bawa et al., 2014). In future, 
conditions need to be optimised to increase                                                                                                                                                                                                                                                                                                                                                                                                  
CD81 yield from bioreactor growth, which might result in lower cell biomass yield but higher 
protein expression. 
 
8.2 SMALP-CD81 purification 
Further to successful solubilisation, SMALP-CD81 purification was performed using IMAC. For 
subsequent studies, only SMA co-2000 polymer was used as it was readily available in the 
lab and known to be the best SMA co-polymer for membrane protein solubilisation and 
purification (Morrison et al., 2014).  The initial purification attempts resulted in CD81 elution 
with a highly abundant contaminating protein, as discussed in Chapter 4. Weak CD81 binding 
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to the resin was also observed where the protein washed out during resin washing steps, 
suggested weak CD81 binding to the resin. This was not surprising given the small size of the 
His6-tagged C-terminus cytoplasmic domain of CD81 protein (12 amino acid residues long - 
UniProtKB - P60033 CD81_HUMAN). The His6-tag possibly got buried by the SMA polymer 
wrapping in SMALPs, hindering Ni+2 NTA resin binding. To trouble shoot this,  more resin per 
sample was used (at 1:2 ratio)  that resulted in stronger resin to His6 tag binding, indicated by 
significantly reduced leaky CD81 protein in washing steps and collection of most of the protein 
in elution fractions (discussed in Chapter 4). This has also been observed previously for many 
other proteins, purification of CD81 using SMA gave a cleaner purification than using 
conventional detergents (Gulati et al., 2014, Morrison et al., 2016, Liu et al., 2018). 
 
8.3 Biophysical analysis of SMALP-CD81 and DDM-CD81 
Circular dichroism (CD) analysis was performed to determine intact secondary structure of 
IMAC purified SMALP-CD81 and to compare the structural integrity with that of detergent 
purified samples. In this study (Chapter 4) CD spectroscopy showed subtle differences 
between SMA 2000 and DDM purified CD81, suggesting that SMA 2000 encapsulated CD81 
retained more of the native secondary structure. It should be noted that this was a side-by-
side comparison under comparable conditions, in buffer that did not contain NaCl or glycerol, 
which have been found to stabilize the DDM purified protein. This may explain why the DDM 
sample was less folded than the previously published crystal structure which was also 
obtained using DDM (Zimmerman et al., 2016). However it highlights that SMALPs can offer 
improved stability without the need for special handling or buffer conditions.  Interestingly, 
SMA did not offer any improvement over DDM for CD81 thermostability as measured by CD 
spectroscopy or when using a gel based aggregation assay, which contrasts with many 
previous reports (Dorr et al., 2014, Morrison et al., 2016, Liu et al., 2018). Reasons for this are 
not totally clear, perhaps the secondary structure of CD81 is inherently quite stable, and it has 
been suggested previously that the presence of detergent can help to decrease aggregation 
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for some proteins (Morrison et al., 2016). Differences between DDM and SMA purified CD81 
were observed when using a binding assay for a conformation sensitive antibody. This 
antibody is known to bind to a non-linear epitope within the large extracellular loop, which is 
important for function of CD81 (Grove et al., 2017).  Thus SMA encapsulation stabilised the 
3-dimensional folded structure of CD81, even if very little change in secondary structure 
occurred. 
 
 8.4 Size exclusion chromatography 
SEC analysis of SMA purified CD81 showed a large peak in or close to the void volume in 
addition to a second peak that eluted later. Presumably the void peak contains some form of 
larger assembly or aggregated species. CD81 itself is known to form dimers and larger 
assemblies (Bonander et al., 2013a, Kovalenko et al., 2004) so it is possible that this peak 
contains larger assemblies of CD81.  Notably, the CD81 crystal structure revealed a 
monomeric form of a tetraspanin, which contrasts with the crystal structure of the extracellular 
LEL domain of human CD81 (88 of 236 residues). This latter structure confirms the presence 
of the conserved CCG motif, two disulfide bridges and a potential dimerization interface 
(Kitadokoro et al., 2001). 
 
It has also been shown previously that SMALP discs themselves can dimerise (Postis et al., 
2015). It was interesting that the intensity of the A280 signal for the void peal was significantly 
higher than that of the second peak, and yet SDS-PAGE analysis showed almost equal 
concentrations of CD81 in both peaks. Therefore perhaps the species present in the void peak 
was also scattering light. Importantly only the CD81 in the second peak bound to the HCV E2 
glycoprotein. This suggests that either the CD81 in Peak 1 is unstructured so that the E2 
binding site is not formed, or that access to the binding site is sterically blocked in some way. 
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Further analysis of SEC elutions indicated that the protein in both peaks was folded and 
abundant in α-helical structure (discussed in Chapter 4, Section 6), where both peaks CD 
spectra appeared identical. Also, SDS-PAGE analysis showed similar protein gel band pattern 
in both peak samples, where monomeric CD81 was detected at ~25 kDa and a higher order 
band at ~45 kDa. Furthermore, isolated nanodiscs were observed in both peaks through 
negative stain cryo-EM analysis, where Peak 1 samples contained slightly larger nanodiscs 
(discussed in Chapter 5). These analyses support the assumption that the Peak 1 fraction 
contains correctly-folded and not aggregated protein. As the CD81 ECL2 (where the binding 
epitope exists) has a compact structure that is only 3 nm at its widest point, the loss of function 
could be explained due to SMALP stacking on top of each other, effectively blocking the E2 
binding epitope.  
 
8.5 Total protein identification through mass spectrometry analysis  
Mass spectrometric protein identification analysis was performed where CD81 protein was 
successfully detected in IMAC and SEC fractions. Soluble proteins, such as alcohol oxidase 
1 (AOX1p) and a ribosomal protein 40S were also identified in test samples.  This was 
unexpected as both proteins are intracellular proteins and not known to associate with yeast 
plasma membrane or membrane proteins.  
 
One of the major contaminants identified in the mass spectrometry was AOX1p which is a P. 
pastoris enzyme responsible for catalysing the oxidation of methanol to formaldehyde in the 
methanol assimilation pathway, where the AOX gene is under a strong carbon catabolite 
repression (Vonck et al., 2016). The addition of methanol induces high-levels of AOX1 
transcription and subsequent synthesis of large amounts of the protein, where it is estimated 
to encompass 30% of the total intracellular proteome (Gvozdev et al. 2010). The second most 
abundant contaminant detected was the ribosomal protein 40S, which is an essential protein 
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in yeast for RNA-precursor processing into mature RNA during translation process (Vonck et 
al., 2016). Most importantly, the hCD81 gene was cloned under the control of the AOX1 
promoter where expression of the CD81 protein would only occur in the presence of methanol. 
Therefore, to achieve high CD81 overexpression, high levels of AOX1 promoter expression 
are required and thus sufficient methanol concentration should be present in the media. The 
presence of AOX1p and 40S ribosomal protein were possibly the consequence of large-scale 
exogenous protein expression in the yeast cells.  Further studies are required to decrease 
contaminant protein levels and to investigate their strong association with the exogenous and 
overexpressed CD81 even after two purification stages. The presence and copurification of 
AOX1p with another recombinant and overexpressed protein (linoleate diol synthase) in P. 
pastoris was also observed by Koch et al. 2016 where the expression of AOX1p was an 
unexpected result and lead to its crystal structure determination (Koch et al., 2016).  
 
8.6 P. pastoris protoplast analysis 
To harvest mature CD81 protein and to minimise accompanying misfolded and/or aggregated 
protein coextraction, a novel procedure was investigated where the CD81 protein produced in P pastoris 
was directly solubilised from whole cells instead of preparing crude membranes. The yeast cells were 
treated with Zymolyase enzyme to digest the cell wall (protoplast generation) prior to direct whole cell 
solubilisation with the SMA 2000 polymer. This method has the potential to favour extraction of 
correctly-folded membrane protein that have been targeted to the plasma membranes and limit 
solubilisation of proteins stored in intracellular membrane compartments (Hartmann et al. 2017).  
 
The protoplast work (discussed in Chapter 4, Section 9) resulted in the purification of high 
amounts of alcohol dehydrogenase contaminant and only small amounts of the CD81 protein 
in the SEC elutions.  A dominant protein band was observed by SDS-PAGE at around 45 kDa 
in the SEC fractions that corresponds to alcohol dehydrogenase monomer and has the mass 
of 41 kDa. Only faint CD81 protein bands at ~25 kDa were observed by SDS-PAGE and 
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western blots. The presence and abundance of alcohol dehydrogenase, and the low CD81 
yields were confirmed by the mass spectrometry protein identification. Similar results were 
also seen with the detergent protoplast solubilisation performed in the lab. These results were 
unexpected and further studies are required to understand the reasons behind the abundance 
of a contaminant protein instead of CD81 from the whole cell solubilisation of P. pastoris 
protoplast. As previous work in Chapter 3 demonstrated that SMA solubilisation is 
instantaneous, it is predicted that the SMA polymer was able to quickly disrupt P pastoris 
protoplast by puncturing holes into the membranes, which led to cytoplasmic content leakage 
and the accumulation of alcohol dehydrogenase around CD81. This interaction between 
alcohol dehydrogenase and CD81 remained intact even after IMAC and SEC purifications.  A 
possible solution to attempt in future is to reduce polymer solubilisation time and/or incubation 
temperature (incubation at 4 °C instead of room temperature), which may result in slower 
membrane solubilisation leading to less cytoplasmic protein leakage.   
 
8.7 Structural analysis of SMALP-CD81 
SMALP-CD81 nanodiscs were successfully visualised by electron microscopy analysis of SEC 
purified samples. To resolve the structure at high resolution by single particle cryo-EM, the 
current lower molecular weight  limit of a complex or protein  is currently  ~64 kDa, after the 
structure determination of human haemoglobin (64 kDa) at 3.2 Å (Herzik et al., 2019) . As 
CD81 protein is a significantly smaller protein compared to the ones studied using cryo-EM 
techniques, the high-resolution structural determination of SMALP-CD81 was attempted using 
X-ray crystallography. 
 
Although large peak size was observed for the SEC Peak 1, as discussed in Chapter 5, the 
protein content was much lower in this peak compared to Peak 2 (smaller peak). Around 1.1 
mg/ml protein was calculated for Peak 1, while 3.7 mg/ml protein was attained for the SEC 
250 
 
Peak 2 samples, where both samples were concentrated to ~500 µl. The difference in protein 
yield was also indicated by the SDS-PAGE analysis where faint CD81 protein band was 
observed in Peak 1, whereas an intense protein gel band was observed in Peak 2 samples 
(Figure 5.12). It is predicted that the larger peak size does not correlate to higher protein 
amount in SEC analysis, where large peak size of the Peak 1 was possibly due to the presence 
of bigger particles in this fraction (Bertrand et al., 2014).    
 
 As highly concentrated protein samples are required for crystallisation work (McPherson and 
Cudney, 2014), a Peak 2 sample concentration of ~18 mg/ml was achieved after concentrating 
to 40 µl as the final volume. 6 µl of this sample was mixed with 9 µl of monoolein where lipidic 
cubic phase between SMALP-CD81 and lipid was successfully achieved as indicated by the 
formation of homogenous and colourless suspension.  Previously, DDM solubilised and SEC 
purified CD81 samples (from P. pastoris overexpressed CD81) were subjected to LCP 
crystallisation trials where the DDM-CD81 did not form LCP with monoolein as the suspension 
remained cloudy/aggregated even after repeated mixing of the protein and lipids together. 
This was, however, in contrast with successful crystals formation following DDM protein 
solubilisation by Zimmerman et al., 2016 resulting in CD81 structure determination. Although 
no protein crystals were detected in the SMALP-CD81 LCP trials, successful LCP formation 
was observed suggesting superiority of the SMALP-CD81 samples. In future, some further 
optimisation and more crystallisation condition screenings are required to successfully 
crystallise CD81 using SMALP technology.      
 
Insect cells (Sf9) overexpressing hCD81 were also employed to harvest CD81 protein for 
subsequent structural studies  The novel SMA solubilisation assay resulted in successful 
extraction and IMAC purification of the SMALP-CD81 (discussed in Chapter 5, Section 5). A 
final yield of 40 µl of ~57 mg/ml was obtained after SEC Peak 2 isolation and concentration, 
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which was much higher compared to ~19 mg/ml protein yield from the P. pastoris CD81 
preparation. This was the first and only attempt at Sf9 overexpressed CD81 solubilisation 
using SMA 2000 polymer. The solubilisation and purification conditions could be optimised in 
the future to improve SEC sample separation and protein stability in order to achieve a high 
quality sample for LCP crystallisation work.   
 
8.8 Mammalian cell imaging to study endogenous CD81 
CD81 studies were also conducted in a more physiologically-relevant membrane environment 
using Huh-7 (human liver carcinoma cell line) and HEK 293 cells (human embryonic kidney 
cell line).  The presence of endogenous CD81 was identified in both cell lines, which was 
consistent with previous mammalian cell studies on CD81 protein for HCV invasion (Timpe et 
al., 2008) Notably, 50% more CD81 protein expression was detected in in HEK cells than Huh-
7 (discussed in Chapter 6), which was unexpected as HEK cells were mostly used for studying 
recombinant tetraspanins and not known to express high amounts of endogenous CD81 
protein.  HepG2 cells (hepatocarcinoma cell line) was used as a negative control as these 
cells does not express CD81 endogenously.  
 
The membrane expression and organisation of CD81 protein in mammalian cells was 
investigated firstly using confocal microscopy. Protein was visualised by labelling with 2s131 
mAb and Alexa Fluor 488 (green) conjugated secondary antibody.  The confocal micrographs 
show an even distribution and high expression of CD81 on the plasma membranes of both 





Further to confocal microscopy studies, two gold labelled anti-CD81 antibodies (2s131 
labelled with 15 nm gold, and 1s337 labelled with 6 nm gold particle) were used as a tool to 
study the molecular distribution of CD81 on the plasma membrane. Cells were fixed, 
dehydrated, embedded and sectioned (~100 nm slices) before transmission electron 
microscopy imaging, which showed excellent ultracellular structure preservation after these 
steps. Immunogold labelling of the cell surface CD81 with both mAbs identified two 
populations in Huh-7 membranes: the 16 nm gold labelled mAb identified mostly 
monodispersed CD81 or doublets, while the smaller 6 nm conjugated mAb detected CD81 
clusters on the cell membrane.  In HEK 293 cells, monodispersed CD81 or doublets were 
observed along with the detection of smaller CD81 clusters. No preferential mAbs binding to 
monomeric or higher order structure was observed. This finding could suggest dynamic 
structural organisation of CD81, transitioning from monomeric to higher order forms 
(oligomers) and may be consistent with a concept of a dynamic equilibrium of CD81 in the 
plasma membrane. The data might also be consistent with two popular notions in the literature, 
that is the presence of tetraspanin rich membrane microdomains (tetraspanin multimers) on 
the cell membrane that function as the organisers of multi molecular complexes (Hemler, 
2005). Whereas, other literature points towards the presence of monodispersed CD81 on the 
membrane (Zimmerman et al. 2016).  The EM data is also consistent with previously published 
scanning electron microscopy studies by Grove et al., 2018  where at least two populations of 
CD81 were identified; monodisperse and higher-order assemblies (Grove et al., 2018). Further 
studies are required to understand the relevance of these dynamic structures with respect to 
CD81 function. 
 
8.9 CD81 solubilisation from mammalian cells 
Successful solubilisation of mammalian cell expressed membrane protein using SMA co-
polymers was published by (Hall et al., 2018; Jamshad et al., 2015a). Where they 
demonstrated that SMA co-polymers, such as SMA 2000 and SMI (an acid compatible 
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polymer) were capable of extracting proteins directly from the cell membrane. Furthermore, 
the solubilised human G-protein coupled receptor (from HEK 293T cell membranes) were 
functionally active (Jamshad et al., 2018; Hall et al., 2018). Following suit and in order to study 
CD81 in more native mammalian cell environment, SMA co-polymer solubilisation of CD81 
was performed.  
 
The endogenously-expressed CD81 from HEK 293 S and HEK 293 T membranes were 
solubilised using 2.5% SMA 2000 and SZ25010 polymers at 1 h room temperature incubation. 
Successful endogenous CD81 solubilisation using SMA co-polymers was achieved, where the 
solubilisation efficiency appeared comparable with DDM extraction, as very faint insoluble 
CD81 protein bands were detected on SDS-PAGE gels in both samples indicating the 
presence of most CD81 in the soluble fraction. This is consistent and comparable to the 
previously discussed P. pastoris CD81 solubilisation studies.  The receptor-ligand binding 
ELISA using HCV E2 glycoprotein resulted in SMALP-CD81 binding to E2, suggesting 
functionally-relevant protein in SMALPs. The successful SMA solubilisation of endogenous 
CD81 opens an opportunity to prepare homogenous and potentially large-scale protein 
samples in the future.  
 
To aid future CD81 research and overcome the challenges of purifying endogenous and 
untagged protein, FLAG tagged CD81 were overexpressed in HEK 293 and Huh-7 cells.  Four 
CD81 constructs were used containing either wild type, 4 PM mutated CD81, CD81 p-null or 
an empty vector containing FLAG tag but no CD81 gene. The transfection conditions were 
optimised to successfully transfect recombinant CD81 DNA into mammalian cells using both 
PEI and lipofectamine as transfection reagents. Moreover, the optimised conditions could be 
successfully upscaled to 10 cm petri plates or T75 flasks to obtain large-scale protein preps 
for subsequent downstream biochemical analysis. 
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8.10 Overall conclusion 
This thesis has demonstrated advancement in membrane protein research particularly in the 
tetraspanin field and in SMALP technology. Recombinant, full length CD81 was investigated 
using P. pastoris, where large scale protein expression and homogenous CD81 sample 
preparation were achieved. CD81 was successfully extracted and purified in SMALPs for the 
first time with high efficiency. Biophysical analysis suggested superiority of SMALP-CD81 at 
retaining intact secondary structure and functional relevance in marked contrast with detergent 
solubilised protein. The presence of monodispersed SMALP nanodiscs was also confirmed 
through electron microscopy.   
 
To determine the structure of full length CD81 protein embedded in plasma membrane 
lipoprotein environment, and to compare it with the previously solved structure, large scale 
CD81 sample preparation was performed.  A 70% pure and concentrated solution was 
achieved at ~18 mg/ml from P. pastoris, and a very high concentration of ~57 mg/ml was 
achieved from Sf9 cells. LCP crystallisation attempt resulted in LCP formation, which had 
previously proved problematic. This thesis has therefore paved the way for future research on 
high resolution structural analysis of tetraspanins using SMALP technology. 
Presented here are the novel electron microscopy studies to determine endogenous CD81 
distribution on HEK 293 and Huh-7 membranes. A dynamic structural organisation was 
detected where CD81 was organised as either isolated monomers or higher order protein 
clusters. Further research into CD81 distribution needs to be performed in order fully 
understand protein organisation on the plasma membrane and functional relevance of the 
dynamic structure. 
 
Also presented in this thesis, novel solubilisation of endogenous CD81 from mammalian cells. 
This was achieved using SMA co-polymers, where SMA extracted protein retained its 
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functional relevance.  The overexpression of FLAG-tagged CD81 was also performed 
successfully to aid future purification attempts using FLAG-purification method. This will 
enable biophysical and structural studies to be conducted using liver cells expressed CD81 
surrounded in its natural membrane environment. Moreover, extracted CD81 in SMALPs will 
enable the identification of novel CD81 interactions with partner proteins and ligands that will 



















ANDERSEN, O. S. & KOEPPE, R. E., II 2007. Bilayer thickness and membrane protein 
function: An energetic perspective. Annual Review of Biophysics and Biomolecular 
Structure, 36, 107-130. 
ANDRE, M., LE CAER, J. P., GRECO, C., PLANCHON, S., EL NEMER, W., BOUCHEIX, C., 
RUBINSTEIN, E., CHAMOT-ROOKE, J. & LE NAOUR, F. 2006. Proteomic analysis 
of the tetraspanin web using LC-ESI-MS/MS and MALDI-FTICR-MS. Proteomics, 6, 
1437-1449. 
ASHE, M. P. & BILL, R. M. 2011. Mapping the yeast host cell response to recombinant 
membrane protein production: Relieving the biological bottlenecks. Biotechnology 
Journal, 6, 707-714. 
BAILEY, R. L., HERBERT, J. M., KHAN, K., HEATH, V. L., BICKNELL, R. & TOMLINSON, 
M. G. 2011. The emerging role of tetraspanin microdomains on endothelial cells.
Biochemical Society Transactions, 39, 1667-1673.
BALDI, L., MULLER, N., PICASSO, S., JACQUET, R., GIRARD, P., THANH, H. P., 
DEROW, E. & WURM, F. M. 2005. Transient gene expression in suspension HEK-
293 cells: Application to large-scale protein production. Biotechnology Progress, 21, 
148-153.
BARRERA, N. P., ZHOU, M. & ROBINSON, C. V. 2013. The role of lipids in defining 
membrane protein interactions: insights from mass spectrometry. Trends in Cell 
Biology, 23, 1-8. 
BASORE, K., KIM, A. S., NELSON, C. A., ZHANG, R., SMITH, B. K., URANGA, C., VANG, 
L., CHENG, M., GROSS, M. L., SMITH, J., DIAMOND, M. S. & FREMONT, D. H. 
2019. Cryo-EM Structure of Chikungunya Virus in Complex with the Mxra8 Receptor. 
Cell, 177, 1725-+. 
BAWA, Z., BLAND, C. E., BONANDER, N., BORA, N., CARTWRIGHT, S. P., CLARE, M., 
CONNER, M. T., DARBY, R. A. J., DILWORTH, M. V., HOLMES, W. J., JAMSHAD, 
M., ROUTLEDGE, S. J., GROSS, S. R. & BILL, R. M. 2011. Understanding the yeast 
host cell response to recombinant membrane protein production. Biochemical 
Society Transactions, 39, 719-723. 
BAWA, Z., ROUTLEDGE, S. J., JAMSHAD, M., CLARE, M., SARKAR, D., DICKERSON, I., 
GANZLIN, M., POYNER, D. R. & BILL, R. M. 2014. Functional recombinant protein is 
present in the pre-induction phases of Pichia pastoris cultures when grown in 
bioreactors, but not shake-flasks. Microbial Cell Factories, 13, 13. 
BAYBURT, T. H., GRINKOVA, Y. V. & SLIGAR, S. G. 2002. Self-assembly of discoidal 
phospholipid bilayer nanoparticles with membrane scaffold proteins. Nano Letters, 2, 
853-856.
BAYBURT, T. H. & SLIGAR, S. G. 2010. Membrane protein assembly into Nanodiscs. Febs 
Letters, 584, 1721-1727. 
BERDITCHEVSKI, F. 2001. Complexes of tetraspanins with integrins: more than meets the 
eye. Journal of Cell Science, 114, 4143-4151. 
BERDITCHEVSKI, F. & ODINTSOVA, E. 1999. Characterization of integrin-tetraspanin 
adhesion complexes: Role of tetraspanins in integrin signaling. Journal of Cell 
Biology, 146, 477-492. 
BERSCH, B., DORR, J. M., HESSEL, A., KILLIAN, J. A. & SCHANDA, P. 2017. Proton-
Detected Solid-State NMR Spectroscopy of a Zinc Diffusion Facilitator Protein in 
Native Nanodiscs. Angewandte Chemie-International Edition, 56, 2508-2512. 
BERTAUX, C. & DRAGIC, T. 2006. Different domains of CD81 mediate distinct stages of 
hepatitis C virus pseudoparticle entry. Journal of Virology, 80, 4940-4948. 
BILL, R. M. 2014. Playing catch-up with Escherichia coli: using yeast to increase success 
rates in recombinant protein production experiments. Frontiers in Microbiology, 5. 
257 
 
BILL, R. M., HENDERSON, P. J. F., IWATA, S., KUNJI, E. R. S., MICHEL, H., NEUTZE, R., 
NEWSTEAD, S., POOLMAN, B., TATE, C. G. & VOGEL, H. 2011. Overcoming 
barriers to membrane protein structure determination. Nature Biotechnology, 29, 335-
340. 
BONANDER, N. & BILL, R. M. 2009. Relieving the first bottleneck in the drug discovery 
pipeline: using array technologies to rationalize membrane protein production. Expert 
Review of Proteomics, 6, 501-505. 
BONANDER, N., JAMSHAD, M., OBERTHUER, D., CLARE, M., BARWELL, J., HU, K., 
FARQUHAR, M. J., STAMATAKI, Z., HARRIS, H. J., DIERKS, K., DAFFORN, T. R., 
BETZEL, C., MCKEATING, J. A. & BILL, R. M. 2013a. Production, Purification and 
Characterization of Recombinant, Full-Length Human Claudin-1. Plos One, 8. 
BONANDER, N., JAMSHAD, M., OBERTHUR, D., CLARE, M., BARWELL, J., HU, K., 
FARQUHAR, M. J., STAMATAKI, Z., HARRIS, H. J., DIERKS, K., DAFFORN, T. R., 
BETZEL, C., MCKEATING, J. A. & BILL, R. M. 2013b. Production, Purification and 
Characterization of Recombinant, Full-Length Human Claudin-1. Plos One, 8. 
BOUSSIF, O., LEZOUALCH, F., ZANTA, M. A., MERGNY, M. D., SCHERMAN, D., 
DEMENEIX, B. & BEHR, J. P. 1995. A VERSATILE VECTOR FOR GENE AND 
OLIGONUCLEOTIDE TRANSFER INTO CELLS IN CULTURE AND IN-VIVO - 
POLYETHYLENIMINE. Proceedings of the National Academy of Sciences of the 
United States of America, 92, 7297-7301. 
BRADBURY, L. E., KANSAS, G. S., LEVY, S., EVANS, R. L. & TEDDER, T. F. 1992. THE 
CD19/CD21 SIGNAL TRANSDUCING COMPLEX OF HUMAN LYMPHOCYTES-B 
INCLUDES THE TARGET OF ANTIPROLIFERATIVE ANTIBODY-1 AND LEU-13 
MOLECULES. Journal of Immunology, 149, 2841-2850. 
BRETSCHER, M. S. 1973. MEMBRANE STRUCTURE - SOME GENERAL PRINCIPLES. 
Science, 181, 622-629. 
BRIMACOMBE, C. L., WILSON, G. K., HUEBSCHER, S. G., MCKEATING, J. A. & 
FARQUHAR, M. J. 2014. A Role for CD81 and Hepatitis C Virus in Hepatoma 
Mobility. Viruses-Basel, 6, 1454-1472. 
BROECKER, J., EGER, B. T. & ERNST, O. P. 2017. Crystallogenesis of Membrane Proteins 
Mediated by Polymer-Bounded Lipid Nanodiscs. Structure (London, England : 1993), 
25, 384-392. 
BRUENING, J., LASSWITZ, L., BANSE, P., KAHL, S., MARINACH, C., VONDRAN, F. W., 
KADERALI, L., SILVIE, O., PIETSCHMANN, T., MEISSNER, F. & GEROLD, G. 
2018. Hepatitis C virus enters liver cells using the CD81 receptor complex proteins 
calpain-5 and CBLB. Plos Pathogens, 14, 35. 
BURTON, C. & BARTEE, E. 2019. Syncytia Formation in Oncolytic Virotherapy. Molecular 
Therapy-Oncolytics, 15, 131-139. 
BYME, B. 2015. Pichia pastoris as an expression host for membrane protein structural 
biology. Current Opinion in Structural Biology, 32, 9-17. 
CARLONI, V., MAZZOCCA, A. & RAVICHANDRAN, K. S. 2004. Tetraspanin CD81 is linked 
to ERK/MAPKinase signaling by Shc in liver tumor cells. Oncogene, 23, 1566-1574. 
CHARRIN, S., MANIE, S., BILLARD, M., ASHMAN, L., GERLIER, D., BOUCHEIX, C. & 
RUBINSTEIN, E. 2003. Multiple levels of interactions within the tetraspanin web. 
Biochemical and Biophysical Research Communications, 304, 107-112. 
CHARRIN, S., MANIE, S., OUALID, M., BILLARD, M., BOUCHEIX, C. & RUBINSTEIN, E. 
2002. Differential stability of tetraspanin/tetraspanin interactions: role of 
palmitoylation. Febs Letters, 516, 139-144. 
CHEN, H., SHAFFER, P. L., HUANG, X. & ROSE, P. E. 2013. Rapid screening of 
membrane protein expression in transiently transfected insect cells. Protein 
Expression and Purification, 88, 134-142. 
CHEPANOSKE, C. L., RICHARDSON, B. E., VON RECHENBERG, M. & PELTIER, J. M. 
2005. Average peptide score: a useful parameter for identification of proteins derived 
from database searches of liquid chromatography/tandem mass spectrometry data. 
Rapid Communications in Mass Spectrometry, 19, 9-14. 
258 
 
CHERNOMORDIK, L., KOZLOV, M. M. & ZIMMERBERG, J. 1995. LIPIDS IN BIOLOGICAL 
MEMBRANE-FUSION. Journal of Membrane Biology, 146, 1-14. 
DAFFORN, T. R., JAMSHAD, M., LIN, Y. P., KNOWLES, T. J., WHEATLEY, M., POYNER, 
D. R., BILL, R. M., PARSLOW, R., OVERDUIN, M. & THOMAS, O. R. 2012. 
Detergent-free purification of membrane proteins. Abstracts of Papers of the 
American Chemical Society, 243. 
DAVIS, C., HARRIS, H. J., HU, K., DRUMMER, H. E., MCKEATING, J. A., MULLINS, J. G. 
L. & BALFE, P. 2012. In silico directed mutagenesis identifies the CD81/claudin-1 
hepatitis C virus receptor interface. Cellular Microbiology, 14, 1892-1903. 
DE KROON, A. I. P. M. 2007. Metabolism of phosphatidylcholine and its implications for lipid 
acyl chain composition in Saccharomyces cerevisiae. Biochimica Et Biophysica Acta-
Molecular and Cell Biology of Lipids, 1771, 343-352. 
DELGRANGE, D., PILLEZ, A., CASTELAIN, S., COCQUEREL, L., ROUILLE, Y., 
DUBUISSON, J., WAKITA, T., DUVERLIE, G. & WYCHOWSKI, C. 2007. Robust 
production of infectious viral particles in Huh-7 cells by introducing mutations in 
hepatitis C virus structural proteins. Journal of General Virology, 88, 2495-2503. 
DENISOV, I. G., GRINKOVA, Y. V., LAZARIDES, A. A. & SLIGAR, S. G. 2004. Directed self-
assembly of monodisperse phospholipid bilayer nanodiscs with controlled size. 
Journal of the American Chemical Society, 126, 3477-3487. 
DERGANC, J., ANTONNY, B. & COPIC, A. 2013. Membrane bending: the power of protein 
imbalance. Trends in Biochemical Sciences, 38, 576-584. 
DI MAIO, V. C., CENTO, V., LENCI, I., ARAGRI, M., ROSSI, P., BARBALISCIA, S., MELIS, 
M., VERUCCHI, G., MAGNI, C. F., TETI, E., BERTOLI, A., ANTONUCCI, F., 
BELLOCCHI, M. C., MICHELI, V., MASETTI, C., LANDONIO, S., FRANCIOSO, S., 
SANTOPAOLO, F., PELLICELLI, A. M., CALVARUSO, V., GIANSERRA, L., 
SICILIANO, M., ROMAGNOLI, D., COZZOLONGO, R., GRIECO, A., VECCHIET, J., 
MORISCO, F., MERLI, M., BRANCACCIO, G., DI BIAGIO, A., LOGGI, E., 
MASTROIANNI, C. M., PALITTI, V. P., TARQUINI, P., PUOTI, M., TALIANI, G., 
SARMATI, L., PICCIOTTO, A., VULLO, V., CAPORASO, N., PAOLONI, M., 
PASQUAZZI, C., RIZZARDINI, G., PARRUTI, G., CRAXI, A., BABUDIERI, S., 
ANDREONI, M., ANGELICO, M., PERNO, C. F., CECCHERINI-SILBERSTEIN, F. & 
STU, H. C. V. I. R. N. 2017. Multiclass HCV resistance to direct-acting antiviral failure 
in real-life patients advocates for tailored second-line therapies. Liver International, 
37, 514-528. 
DORR, J. M., KOORENGEVEL, M. C., SCHAFER, M., PROKOFYEV, A. V., 
SCHEIDELAAR, S., VAN DER CRUIJSEN, E. A., DAFFORN, T. R., BALDUS, M. & 
KILLIAN, J. A. 2015. Detergent-free isolation, characterization and functional 
reconstitution of a K plus channel. European Biophysics Journal with Biophysics 
Letters, 44, S234-S234. 
DORR, J. M., KOORENGEVEL, M. C., SCHAFER, M., PROKOFYEV, A. V., 
SCHEIDELAAR, S., VAN DER CRUIJSEN, E. A. W., DAFFORN, T. R., BALDUS, M. 
& KILLIAN, J. A. 2014. Detergent-free isolation, characterization, and functional 
reconstitution of a tetrameric K+ channel: The power of native nanodiscs. 
Proceedings of the National Academy of Sciences of the United States of America, 
111, 18607-18612. 
DORR, J. M., PARDO, J. J. D., VAN COEVORDEN-HAMEETE, M. H., SCHEIDELAAR, S., 
KOORENGEVEL, M. C., HOOGENRAAD, C. C. & KILLIAN, J. A. 2016a. A 
Detergent-Free Approach to Membrane Protein Research: Polymer-Bounded 
"Native" Nanodiscs. Biophysical Journal, 110, 580A-580A. 
DORR, J. M., SCHEIDELAAR, S., KOORENGEVEL, M. C., DOMINGUEZ, J. J., SCHAFER, 
M., VAN WALREE, C. A. & KILLIAN, J. A. 2016b. The styrene-maleic acid 
copolymer: a versatile tool in membrane research. European Biophysics Journal with 
Biophysics Letters, 45, 3-21. 
259 
 
EGBERTS, E., MARRINK, S. J. & BERENDSEN, H. J. C. 1994. MOLECULAR-DYNAMICS 
SIMULATION OF A PHOSPHOLIPID MEMBRANE. European Biophysics Journal 
with Biophysics Letters, 22, 423-436. 
EMMERSTORFER, A., WRIESSNEGGER, T., HIRZ, M. & PICHLER, H. 2014. 
Overexpression of membrane proteins from higher eukaryotes in yeasts. Applied 
Microbiology and Biotechnology, 98, 7671-7698. 
ENGELMAN, D. M. 2005. Membranes are more mosaic than fluid. Nature, 438, 578-580. 
FARQUHAR, M. J., HARRIS, H. J. & MCKEATING, J. A. 2011. Hepatitis C virus entry and 
the tetraspanin CD81. Biochemical Society Transactions, 39, 532-536. 
FERNANDEZ, F. J., LOPEZ-ESTEPA, M., QUEROL-GARCIA, J. & CRISTINA VEGA, M. 
2016. Production of Protein Complexes in Non-methylotrophic and Methylotrophic 
Yeasts Nonmethylotrophic and Methylotrophic Yeasts. Advanced Technologies for 
Protein Complex Production and Characterization, 896, 137-153. 
FLINT, M., MAIDENS, C., LOOMIS-PRICE, L. D., SHOTTON, C., DUBUISSON, J., MONK, 
P., HIGGINBOTTOM, A., LEVY, S. & MCKEATING, J. A. 1999. Characterization of 
hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. 
Journal of Virology, 73, 6235-6244. 
FORSTNER, M., LEDER, L. & MAYR, L. M. 2007. Optimization of protein expression 
systems for modern drug discovery. Expert Review of Proteomics, 4, 67-78. 
FOURNIER, M., PEYROU, M., BOURGOIN, L., MAEDER, C., TCHOU, I. & FOTI, M. 2010. 
CD4 dimerization requires two cysteines in the cytoplasmic domain of the molecule 
and occurs in microdomains distinct from lipid rafts. Molecular Immunology, 47, 
2594-2603. 
GOEPFERT, C., SCHEURER, W., ROHN, S., RATHJEN, B., HOFFMEISTER, H. & 
PORTNER, R. 2012. Functional Characterisation of Human Hepatoma Cell Line 
HepG2 in 3D Culture.  21st Annual Meeting of the European-Society-for-Animal-Cell-
Technology (ESACT), Jun 07-10 2009 Dublin, IRELAND. 241-246. 
GORDON-ALONSO, M., YANEZ-MO, M., BARREIRO, O., ALVAREZ, S., MUNOZ-
FERNANDEZ, M. A., VALENZUELA-FERNANDEZ, A. & SANCHEZ-MADRID, F. 
2006. Tetraspanins CD9 and CD81 modulate HIV-1-induced membrane fusion. 
Journal of Immunology, 177, 5129-5137. 
GREENFIELD, N. J. 2006. Using circular dichroism spectra to estimate protein secondary 
structure. Nature Protocols, 1, 2876-2890. 
GULAMHUSSEIN, A. A., MEAH, D., SOJA, D. D., FENNER, S., SAIDANI, Z., AKRAM, A., 
LALLIE, S., MATHEWS, A., PAINTER, C., LIDDAR, M. K., MOHAMMED, Z., CHIU, 
L. K., SUMAR, S. S., HEALY, H., HUSSAIN, N., PATEL, J. H., HALL, S. C. L., 
DAFFORN, T. R. & ROTHNIE, A. J. 2019. Examining the stability of membrane 
proteins within SMALPs. European Polymer Journal, 112, 120-125. 
GULATI, S., JAMSHAD, M., KNOWLES, T. J., MORRISON, K. A., DOWNING, R., CANT, 
N., COLLINS, R., KOENDERINK, J. B., FORD, R. C., OVERDUIN, M., KERR, I. D., 
DAFFORN, T. R. & ROTHNIE, A. J. 2014. Detergent-free purification of ABC (ATP-
binding-cassette) transporters. Biochemical Journal, 461, 269-278. 
HAEUW, J. F., GOETSCH, L., BAILLY, C. & CORVAIA, N. 2011. Tetraspanin CD151 as a 
target for antibody-based cancer immunotherapy. Biochemical Society Transactions, 
39, 553-558. 
HAINING, E. J., YANG, J. & TOMLINSON, M. G. 2011. Tetraspanin microdomains: fine-
tuning platelet function. Biochemical Society Transactions, 39, 518-523. 
HALL, S. C. L., TOGNOLONI, C., CHARLTON, J., BRAGGINTON, E. C., ROTHNIE, A. J., 
SRIDHAR, P., WHEATLEY, M., KNOWLES, T. J., ARNOLD, T., EDLER, K. J. & 
DAFFORN, T. R. 2018. An acid-compatible co-polymer for the solubilization of 
membranes and proteins into lipid bilayer-containing nanoparticles. Nanoscale, 10, 
10609-10619. 
HARDY, D., BILL, R. M., ROTHNIE, A. J. & JAWHARI, A. 2019. Stabilization of Human 
Multidrug Resistance Protein 4 (MRP4/ABCC4) Using Novel Solubilization Agents. 
Slas Discovery, 24, 1009-1017. 
260 
 
HARDY, D., MANDON, E. D., ROTHNIE, A. J. & JAWHARI, A. 2018. The yin and yang of 
solubilization and stabilization for wild-type and full-length membrane protein. 
Methods, 147, 118-125. 
HARRIS, H. J., FARQUHAR, M. J., MEE, C. J., DAVIS, C., REYNOLDS, G. M., JENNINGS, 
A., HU, K., YUAN, F., DENG, H., HUBSCHER, S. G., HAN, J. H., BALFE, P. & 
MCKEATING, J. A. 2008. CD81 and claudin 1 coreceptor association: Role in 
hepatitis C virus entry. Journal of Virology, 82, 5007-5020. 
HE, B., ZHANG, Y. H. H., RICHARDSON, M. M., ZHANG, J. S., RUBINSTEIN, E. & 
ZHANG, X. A. 2011. Differential functions of phospholipid binding and palmitoylation 
of tumour suppressor EWI2/PGRL. Biochemical Journal, 437, 399-411. 
HEMLER, M. E. 2001. Specific tetraspanin functions. Journal of Cell Biology, 155, 1103-
1107. 
HEMLER, M. E. 2003. Tetraspanin proteins mediate cellular penetration, invasion, and 
fusion events and define a novel type of membrane microdomain. Annual Review of 
Cell and Developmental Biology, 19, 397-422. 
HEMLER, M. E. 2005. Tetraspanin functions and associated microdomains. Nature Reviews 
Molecular Cell Biology, 6, 801-811. 
HEMLER, M. E. 2008. Targeting of tetraspanin proteins - potential benefits and strategies. 
Nature Reviews Drug Discovery, 7, 747-758. 
HERZIK, M. A., WU, M. Y. & LANDER, G. C. 2019. High-resolution structure determination 
of sub-100 kDa complexes using conventional cryo-EM. Nature Communications, 10. 
HIGGINBOTTOM, A., QUINN, E. R., KUO, C. C., FLINT, M., WILSON, L. H., BIANCHI, E., 
NICOSIA, A., MONK, P. N., MCKEATING, J. A. & LEVY, S. 2000. Identification of 
amino acid residues in CD81 critical for interaction with hepatitis C virus envelope 
glycoprotein E2. Journal of Virology, 74, 3642-3649. 
HOMSI, Y. & LANG, T. 2017. The specificity of homomeric clustering of CD81 is mediated 
by its delta-loop. FEBS open bio, 7, 274-283. 
HOMSI, Y., SCHLOETEL, J.-G., SCHEFFER, K. D., SCHMIDT, T. H., DESTAINVILLE, N., 
FLORIN, L. & LANG, T. 2014. The Extracellular delta-Domain is Essential for the 
Formation of CD81 Tetraspanin Webs. Biophysical Journal, 107, 100-113. 
HSU, I. C., TOKIWA, T., BENNETT, W., METCALF, R. A., WELSH, J. A., SUN, T. & 
HARRIS, C. C. 1993. P53 GENE MUTATION AND INTEGRATED HEPATITIS-B 
VIRAL-DNA SEQUENCES IN HUMAN LIVER-CANCER CELL-LINES. 
Carcinogenesis, 14, 987-992. 
HSU, M., ZHANG, J., FLINT, M., LOGVINOFF, C., CHENG-MAYER, C., RICE, C. M. & 
MCKEATING, J. A. 2003. Hepatitis C virus glycoproteins mediate pH-dependent cell 
entry of pseudotyped retroviral particles. Proceedings of the National Academy of 
Sciences of the United States of America, 100, 7271-7276. 
HUH, S. H., DO, H. J., LIM, H. Y., KIM, D. K., CHOI, S. J., SONG, H., KIM, N. H., PARK, J. 
K., CHANG, W. K., CHUNG, H. M. & KIM, J. H. 2007. Optimization of 25 kDa linear 
polyethylenimine for efficient gene delivery. Biologicals, 35, 165-171. 
IMAI, T., KAKIZAKI, M., NISHIMURA, M. & YOSHIE, O. 1995. MOLECULAR ANALYSES 
OF THE ASSOCIATION OF CD4 WITH 2 MEMBERS OF THE TRANSMEMBRANE-
4 SUPERFAMILY, CD81 AND CD82. Journal of Immunology, 155, 1229-1239. 
ISRAELOW, B., NARBUS, C. M., SOURISSEAU, M. & EVANS, M. J. 2014. HepG2 Cells 
Mount an Effective Antiviral Interferon-Lambda Based Innate Immune Response to 
Hepatitis C Virus Infection. Hepatology, 60, 1170-1179. 
IWAO, C. & SHIDOJI, Y. 2015. Upregulation of energy metabolism-related, p53-target 
TIGAR and SCO2 in HuH-7 cells with p53 mutation by geranylgeranoic acid 
treatment. Biomedical Research-Tokyo, 36, 371-381. 
IWASAKI, M., MASUDA, T., TOMITA, M. & ISHIHAMA, Y. 2009. Chemical Cleavage-
Assisted Tryptic Digestion for Membrane Proteome Analysis. Journal of Proteome 
Research, 8, 3169-3175. 
JAMSHAD, M., CHARLTON, J., LIN, Y. P., ROUTLEDGE, S. J., BAWA, Z., KNOWLES, T. 
J., OVERDUIN, M., DEKKER, N., DAFFORN, T. R., BILL, R. M., POYNER, D. R. & 
261 
 
WHEATLEY, M. 2015a. G-protein coupled receptor solubilization and purification for 
biophysical analysis and functional studies, in the total absence of detergent. 
Bioscience Reports, 35. 
JAMSHAD, M., DARBY, R. A. J., GRGIC, L. & BILL, R. M. 2006. Production of membrane 
proteins in yeast. Biochemistry and Cell Biology-Biochimie Et Biologie Cellulaire, 84, 
1069-1069. 
JAMSHAD, M., GRIMARD, V., IDINI, I., KNOWLES, T. J., DOWLE, M. R., SCHOFIELD, N., 
SRIDHAR, P., LIN, Y., FINKA, R., WHEATLEY, M., THOMAS, O. R. T., PALMER, R. 
E., OVERDUIN, M., GOVAERTS, C., RUYSSCHAERT, J.-M., EDLER, K. J. & 
DAFFORN, T. R. 2015b. Structural analysis of a nanoparticle containing a lipid 
bilayer used for detergent-free extraction of membrane proteins. Nano Research, 8, 
774-789. 
JAMSHAD, M., RAJESH, S., STAMATAKI, Z., MCKEATING, J. A., DAFFORN, T., 
OVERDUIN, M. & BILL, R. M. 2008. Structural characterization of recombinant 
human CD81 produced in Pichia pastoris. Protein Expression and Purification, 57, 
206-216. 
JENTSCH, T. J., STEIN, V., WEINREICH, F. & ZDEBIK, A. A. 2002. Molecular structure and 
physiological function of chloride channels. Physiological Reviews, 82, 503-568. 
KELLY, S. M., JESS, T. J. & PRICE, N. C. 2005. How to study proteins by circular dichroism. 
Biochimica Et Biophysica Acta-Proteins and Proteomics, 1751, 119-139. 
KINNUNEN, P. K. J. 1991. ON THE PRINCIPLES OF FUNCTIONAL ORDERING IN 
BIOLOGICAL-MEMBRANES. Chemistry and Physics of Lipids, 57, 375-399. 
KITADOKORO, K., BORDO, D., GALLI, G., PETRACCA, R., FALUGI, F., ABRIGNANI, S., 
GRANDI, G. & BOLOGNESI, M. 2001. CD81 extracellular domain 3D structure: 
insight into the tetraspanin superfamily structural motifs. Embo Journal, 20, 12-18. 
KNOWLES, T. J., FINKA, R., SMITH, C., LIN, Y. P., DAFFORN, T. & OVERDUIN, M. 2009. 
Membrane Proteins Solubilized Intact in Lipid Containing Nanoparticles Bounded by 
Styrene Maleic Acid Copolymer. Journal of the American Chemical Society, 131, 
7484-+. 
KOCH, C., NEUMANN, P., VALERIUS, O., FEUSSNER, I. & FICNER, R. 2016. Crystal 
Structure of Alcohol Oxidase from Pichia pastoris. Plos One, 11. 
KOUTSOUDAKIS, G., HERRMANN, E., KALLIS, S., BARTENSCHLAGER, R. & 
PIETSCHMANN, T. 2007. The level of CD81 cell surface expression is a key 
determinant for productive entry of hepatitis C virus into host cells. Journal of 
Virology, 81, 588-598. 
KOVALENKO, O. V., YANG, X. W., KOLESNIKOVA, T. V. & HEMLER, M. E. 2004. 
Evidence for specific tetraspanin homodimers: inhibition of palmitoylation makes 
cysteine residues available for cross-linking. Biochemical Journal, 377, 407-417. 
LAGANOWSKY, A., READING, E., ALLISON, T. M., ULMSCHNEIDER, M. B., DEGIACOMI, 
M. T., BALDWIN, A. J. & ROBINSON, C. V. 2014. Membrane proteins bind lipids 
selectively to modulate their structure and function. Nature, 510, 172-+. 
LAI, C. W., CHAN, Z. R., YANG, D. G., LO, W. H., LAI, Y. K., CHANG, M. D. T. & HU, Y. C. 
2006. Accelerated induction of apoptosis in insect cells by baculovirus-expressed 
SARS-CoV membrane protein. Febs Letters, 580, 3829-3834. 
LE MAIRE, M., CHAMPEIL, P. & MOLLER, J. V. 2000. Interaction of membrane proteins 
and lipids with solubilizing detergents. Biochimica Et Biophysica Acta-
Biomembranes, 1508, 86-111. 
LEE, A. G. 2003. Lipid-protein interactions in biological membranes: a structural perspective. 
Biochimica Et Biophysica Acta-Biomembranes, 1612, 1-40. 
LEE, S. C., KNOWLES, T. J., POSTIS, V. L. G., JAMSHAD, M., PARSLOW, R. A., LIN, Y.-
P., GOLDMAN, A., SRIDHAR, P., OVERDUIN, M., MUENCH, S. P. & DAFFORN, T. 
R. 2016. A method for detergent-free isolation of membrane proteins in their local 
lipid environment. Nature Protocols, 11, 1149-1162. 
LEVY, S. & SHOHAM, T. 2005. The tetraspanin web modulates immune-signalling 
complexes. Nature Reviews Immunology, 5, 136-148. 
262 
 
LEVY, S., TODD, S. C. & MAECKER, H. T. 1998. CD81 (TAPA-1): A molecule involved in 
signal transduction and cell adhesion in the immune system. Annual Review of 
Immunology, 16, 89-109. 
LIU, Y., MOURA, E., DORR, J. M., SCHEIDELAAR, S., HEGER, M., EGMOND, M. R., 
KILLIAN, J. A., MOHAMMADI, T. & BREUKINK, E. 2018. Bacillus subtilis MraY in 
detergent-free system of nanodiscs wrapped by styrene-maleic acid copolymers. 
Plos One, 13. 
LOGEZ, C., DAMIAN, M., LEGROS, C., DUPRE, C., GUERY, M., MARY, S., WAGNER, R., 
M'KADMI, C., NOSJEAN, O., FOULD, B., MARIE, J., FEHRENTZ, J. A., MARTINEZ, 
J., FERRY, G., BOUTIN, J. A. & BANERES, J. L. 2016. Detergent-free Isolation of 
Functional G Protein-Coupled Receptors into Nanometric Lipid Particles. 
Biochemistry, 55, 38-48. 
LUPBERGER, J., ZEISEL, M. B., XIAO, F., THUMANN, C., FOFANA, I., ZONA, L., DAVIS, 
C., MEE, C. J., TUREK, M., GORKE, S., ROYER, C., FISCHER, B., ZAHID, M. N., 
LAVILLETTE, D., FRESQUET, J., COSSET, F. L., ROTHENBERG, S. M., 
PIETSCHMANN, T., PATEL, A. H., PESSAUX, P., DOFFOEL, M., 
RAFFELSBERGER, W., POCH, O., MCKEATING, J. A., BRINO, L. & BAUMERT, T. 
F. 2011. EGFR and EphA2 are host factors for hepatitis C virus entry and possible 
targets for antiviral therapy. Nature Medicine, 17, 589-U109. 
MAKRIDES, S. C. 1996. Strategies for achieving high-level expression of genes in 
Escherichia coli. Microbiological Reviews, 60, 512-+. 
MARUKIAN, S., JONES, C. T., ANDRUS, L., EVANS, M. J., RITOLA, K. D., CHARLES, E. 
D., RICE, C. M. & DUSTIN, L. B. 2008. Cell Culture-Produced Hepatitis C Virus Does 
Not Infect Peripheral Blood Mononuclear Cells. Hepatology, 48, 1843-1850. 
MATSUMOTO, K., KUSAKA, J., NISHIBORI, A. & HARA, H. 2006. Lipid domains in bacterial 
membranes. Molecular Microbiology, 61, 1110-1117. 
MATTILA, P. K., FEEST, C., DEPOIL, D., TREANOR, B., MONTANER, B., OTIPOBY, K. L., 
CARTER, R., JUSTEMENT, L. B., BRUCKBAUER, A. & BATISTA, F. D. 2013. The 
Actin and Tetraspanin Networks Organize Receptor Nanoclusters to Regulate B Cell 
Receptor-Mediated Signaling. Immunity, 38, 461-474. 
MAURISSE, R., DE SEMIR, D., EMAMEKHOO, H., BEDAYAT, B., ABDOLMOHAMMADI, 
A., PARSI, H. & GRUENERT, D. C. 2010. Comparative transfection of DNA into 
primary and transformed mammalian cells from different lineages. Bmc 
Biotechnology, 10. 
MAYOR, S. & RAO, M. 2004. Rafts: Scale-dependent, active lipid organization at the cell 
surface. Traffic, 5, 231-240. 
MAZZOCCA, A., BIRGANI, M. T., SABBA, C. & CARLONI, V. 2014. Tetraspanin-enriched 
microdomains and hepatocellular carcinoma progression. Cancer Letters, 351, 23-
29. 
MCKEATING, J. A., ZHANG, L. Q., LOGVINOFF, C., FLINT, M., ZHANG, J., YU, J., 
BUTERA, D., HO, D. D., DUSTIN, L. B., RICE, C. M. & BALFE, P. 2004. Diverse 
hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner. 
Journal of Virology, 78, 8496-8505. 
MCKENZIE, E. A. & ABBOTT, W. M. 2018. Expression of recombinant proteins in insect and 
mammalian cells. Methods, 147, 40-49. 
MCPHERSON, A. & CUDNEY, B. 2014. Optimization of crystallization conditions for 
biological macromolecules. Acta Crystallographica Section F-Structural Biology 
Communications, 70, 1445-1467. 
MEE, C. J., HARRIS, H. J., FARQUHAR, M. J., WILSON, G., REYNOLDS, G., DAVIS, C., 
VAN IJZENDOORN, S. C. D., BALFE, P. & MCKEATING, J. A. 2009. Polarization 
Restricts Hepatitis C Virus Entry into HepG2 Hepatoma Cells. Journal of Virology, 83, 
6211-6221. 
MILES, A. J. & WALLACE, B. A. 2016. Circular dichroism spectroscopy of membrane 
proteins. Chemical Society Reviews, 45, 4859-4872. 
263 
 
MIROUX, B. & WALKER, J. E. 1996. Over-production of proteins in Escherichia coli: Mutant 
hosts that allow synthesis of some membrane proteins and globular proteins at high 
levels. Journal of Molecular Biology, 260, 289-298. 
MONTPELLIER, C., TEWS, B. A., POITRIMOLE, J., ROCHA-PERUGINI, V., D'ARIENZO, 
V., POTEL, J., ZHANG, X. A., RUBINSTEIN, E., DUBUISSON, J. & COCQUEREL, 
L. 2011. Interacting Regions of CD81 and Two of Its Partners, EWI-2 and EWI-2wint, 
and Their Effect on Hepatitis C Virus Infection. Journal of Biological Chemistry, 286, 
13954-13965. 
MORRISON, K. A., AKRAM, A., MATHEWS, A., KHAN, Z. A., PATEL, J. H., ZHOU, C., 
HARDY, D. J., MOORE-KELLY, C., PATEL, R., ODIBA, V., KNOWLES, T. J., 
JAVED, M.-U.-H., CHMEL, N. P., DAFFORN, T. R. & ROTHNIE, A. J. 2016. 
Membrane protein extraction and purification using styrene-maleic acid (SMA) 
copolymer: effect of variations in polymer structure. Biochemical Journal, 473, 4349-
4360. 
MOSER, J. W., PRIELHOFER, R., GERNER, S. M., GRAF, A. B., WILSON, I. B. H., 
MATTANOVICH, D. & DRAGOSITS, M. 2017. Implications of evolutionary 
engineering for growth and recombinant protein production in methanol-based growth 
media in the yeast Pichia pastoris. Microbial Cell Factories, 16, 16. 
NAKABAYASHI, H., TAKETA, K., MIYANO, K., YAMANE, T. & SATO, J. 1982. GROWTH 
OF HUMAN HEPATOMA-CELL LINES WITH DIFFERENTIATED FUNCTIONS IN 
CHEMICALLY DEFINED MEDIUM. Cancer Research, 42, 3858-3863. 
NIKAIDO, H. & VAARA, M. 1985. MOLECULAR-BASIS OF BACTERIAL OUTER-
MEMBRANE PERMEABILITY. Microbiological Reviews, 49, 1-32. 
NYBLOM, M., OBERG, F., LINDKVIST-PETERSSON, K., HALLGREN, K., FINDLAY, H., 
WIKSTROM, J., KARLSSON, A., HANSSON, O., BOOTH, P. J., BILL, R. M., 
NEUTZE, R. & HEDFALK, K. 2007. Exceptional overproduction of a functional 
human membrane protein. Protein Expression and Purification, 56, 110-120. 
OBERG, F. & HEDFALK, K. 2013. Recombinant production of the human aquaporins in the 
yeast Pichia pastoris (Invited Review). Molecular Membrane Biology, 30, 15-31. 
OLDHAM, M. L., KHARE, D., QUIOCHO, F. A., DAVIDSON, A. L. & CHEN, J. 2007. Crystal 
structure of a catalytic intermediate of the maltose transporter. Nature, 450, 515-U7. 
OLUWOLE, A. O., KLINGLER, J., DANIELCZAK, B., BABALOLA, J. O., VARGAS, C., 
PABST, G. & KELLER, S. 2017. Formation of Lipid-Bilayer Nanodiscs by 
Diisobutylene/Maleic Acid (DIBMA) Copolymer. Langmuir, 33, 14378-14388. 
OOI, A., WONG, A., ESAU, L., LEMTIRI-CHLIEH, F. & GEHRING, C. 2016. A Guide to 
Transient Expression of Membrane Proteins in HEK-293 Cells for Functional 
Characterization. Frontiers in Physiology, 7. 
OPELLA, S. J. 1997. NMR and membrane proteins. Nature Structural Biology, 4, 845-848. 
OREN, R., TAKAHASHI, S., DOSS, C., LEVY, R. & LEVY, S. 1990. TAPA-1, THE TARGET 
OF AN ANTIPROLIFERATIVE ANTIBODY, DEFINES A NEW FAMILY OF 
TRANSMEMBRANE PROTEINS. Molecular and Cellular Biology, 10, 4007-4015. 
OSUMI, M. 1998. The ultrastructure of yeast: Cell wall structure and formation. Micron, 29, 
207-233. 
PARMAR, M., RAWSON, S., SCARFF, C. A., GOLDMAN, A., DAFFORN, T. R., MUENCH, 
S. P. & POSTIS, V. L. G. 2018. Using a SMALP platform to determine a sub-nm 
single particle cryo-EM membrane protein structure. Biochimica Et Biophysica Acta-
Biomembranes, 1860, 378-383. 
PAULSEN, C. E., ARMACHE, J. P., GAO, Y., CHENG, Y. F. & JULIUS, D. 2015. Structure 
of the TRPA1 ion channel suggests regulatory mechanisms. Nature, 520, 511-+. 
PEITZSCH, R. M. & MCLAUGHLIN, S. 1993. BINDING OF ACYLATED PEPTIDES AND 
FATTY-ACIDS TO PHOSPHOLIPID-VESICLES - PERTINENCE TO 
MYRISTOYLATED PROTEINS. Biochemistry, 32, 10436-10443. 
PILERI, P., UEMATSU, Y., CAMPAGNOLI, S., GALLI, G., FALUGI, F., PETRACCA, R., 
WEINER, A. J., HOUGHTON, M., ROSA, D., GRANDI, G. & ABRIGNANI, S. 1998. 
Binding of hepatitis C virus to CD81. Science, 282, 938-941. 
264 
 
POPOT, J. L., ALTHOFF, T., BAGNARD, D., BANERES, J. L., BAZZACCO, P., BILLON-
DENIS, E., CATOIRE, L. J., CHAMPEIL, P., CHARVOLIN, D., COCCO, M. J., 
CREMEL, G., DAHMANE, T., DE LA MAZA, L. M., EBEL, C., GABEL, F., GIUSTI, F., 
GOHON, Y., GOORMAGHTIGH, E., GUITTET, E., KLEINSCHMIDT, J. H., 
KUHLBRANDT, W., LE BON, C., MARTINEZ, K. L., PICARD, M., PUCCI, B., 
SACHS, J. N., TRIBET, C., VAN HEIJENOORT, C., WIEN, F., ZITO, F. & 
ZOONENS, M. 2011. Amphipols From A to Z. In: REES, D. C., DILL, K. A. & 
WILLIAMSON, J. R. (eds.) Annual Review of Biophysics, Vol 40. 
POSTIS, V., RAWSON, S., MITCHELL, J. K., LEE, S. C., PARSLOW, R. A., DAFFORN, T. 
R., BALDWIN, S. A. & MUENCH, S. P. 2015. The use of SMALPs as a novel 
membrane protein scaffold for structure study by negative stain electron microscopy. 
Biochimica Et Biophysica Acta-Biomembranes, 1848, 496-501. 
POZZA, A., PREZ-VICTORIA, J. M. & DI PIETRO, A. 2009. Overexpression of 
homogeneous and active ABCG2 in insect cells. Protein Expression and Purification, 
63, 75-83. 
PRESTON, G. M., CARROLL, T. P., GUGGINO, W. B. & AGRE, P. 1992. APPEARANCE 
OF WATER CHANNELS IN XENOPUS OOCYTES EXPRESSING RED-CELL 
CHIP28 PROTEIN. Science, 256, 385-387. 
PRIVE, G. G. 2007. Detergents for the stabilization and crystallization of membrane proteins. 
Methods, 41, 388-397. 
PULFER, M. & MURPHY, R. C. 2003. Electrospray mass spectrometry of phospholipids. 
Mass Spectrometry Reviews, 22, 332-364. 
QUAST, T., EPPLER, F., SEMMLING, V., SCHILD, C., HOMSI, Y., LEVY, S., LANG, T., 
KURTS, C. & KOLANUS, W. 2011. CD81 is essential for the formation of membrane 
protrusions and regulates Rac1-activation in adhesion-dependent immune cell 
migration. Blood, 118, 1818-1827. 
RODRIGUES, A. F., GUERREIRO, M. R., SANTIAGO, V. M., DALBA, C., KLATZMANN, D., 
ALVES, P. M., CARRONDO, M. J. T. & COROADINHA, A. S. 2011. Down-
Regulation of CD81 Tetraspanin in Human Cells Producing Retroviral-Based 
Particles: Tailoring Vector Composition. Biotechnology and Bioengineering, 108, 
2623-2633. 
ROTHNIE, A. J. 2016. Detergent-Free Membrane Protein Purification. Methods in molecular 
biology (Clifton, N.J.), 1432, 261-7. 
ROUTLEDGE, S. J., MIKALIUNAITE, L., PATEL, A., CLARE, M., CARTWRIGHT, S. P., 
BAWA, Z., WILKS, M. D. B., LOW, F., HARDY, D., ROTHNIE, A. J. & BILL, R. M. 
2016. The synthesis of recombinant membrane proteins in yeast for structural 
studies. Methods, 95, 26-37. 
SALIBA, A. E., VONKOVA, I. & GAVIN, A. C. 2015. The systematic analysis of protein-lipid 
interactions comes of age. Nature Reviews Molecular Cell Biology, 16, 753-761. 
SASAKI, M., YAMAUCHI, K., NAKANISHI, T., KAMOGAWA, Y. & HAYASHI, N. 2003. In 
vitro binding of hepatitis C virus to CD81-positive and -negative human cell lines. 
Journal of Gastroenterology and Hepatology, 18, 74-79. 
SCHEIDELAAR, S., KOORENGEVEL, M. C., VAN WALREE, C. A., DOMINGUEZ, J. J., 
DORR, J. M. & KILLIAN, J. A. 2016. Effect of Polymer Composition and pH on 
Membrane Solubilization by Styrene-Maleic Acid Copolymers. Biophysical Journal, 
111, 1974-1986. 
SCHMIDT, T. H., HOMSI, Y. & LANG, T. 2016. Oligomerization of the Tetraspanin CD81 via 
the Flexibility of Its delta-Loop. Biophysical Journal, 110, 2463-2474. 
SEELIG, A. & SEELIG, J. 1974. DYNAMIC STRUCTURE OF FATTY ACYL CHAINS IN A 
PHOSPHOLIPID BILAYER MEASURED BY DEUTERIUM MAGNETIC-
RESONANCE. Biochemistry, 13, 4839-4845. 
SEIGNEURET, M. 2006. Complete predicted three-dimensional structure of the facilitator 
transmembrane protein and hepatitis C virus receptor CD81: Conserved and variable 
structural domains in the tetraspanin superfamily. Biophysical Journal, 90, 212-227. 
265 
 
SHI, Y. G. & MASSAGUE, J. 2003. Mechanisms of TGF-beta signaling from cell membrane 
to the nucleus. Cell, 113, 685-700. 
SILVIE, O., CHARRIN, S., BILLARD, M., FRANETICH, J. F., CLARK, K. L., VAN GEMERT, 
G. J., SAUERWEIN, R. W., DAUTRY, F., BOUCHEIX, C., MAZIER, D. & 
RUBINSTEIN, E. 2006. Cholesterol contributes to the organization of tetraspanin-
enriched microdomains and to CD81-dependent infection by malaria sporozoites. 
Journal of Cell Science, 119, 1992-2002. 
SILVIE, O., RUBINSTEIN, E., FRANETICH, J. F., PRENANT, M., BELNOUE, E., RENIA, L., 
HANNOUN, L., ELING, W., LEVY, S., BOUCHEIX, C. & MAZIER, D. 2003. 
Hepatocyte CD81 is required for Plasmodium falciparum and Plasmodium yoelii 
sporozoite infectivity. Nature Medicine, 9, 93-96. 
SIMONS, K. & VAZ, W. L. C. 2004. Model systems, lipid rafts, and cell membranes. Annual 
Review of Biophysics and Biomolecular Structure, 33, 269-295. 
SINGER, S. J. & NICOLSON, G. L. 1972. The Fluid Mosaic Model of the Structure of Cell 
Membranes. Science, 175, 720-+. 
SKAAR, K., KORZA, H. J., TARRY, M., SEKYROVA, P. & HOGBOM, M. 2015. Expression 
and Subcellular Distribution of GFP-Tagged Human Tetraspanin Proteins in 
Saccharomyces cerevisiae. Plos One, 10. 
SOLDAINI, E., WACK, A., D'ORO, U., NUTI, S., ULIVIERI, C., BALDARI, C. T. & 
ABRIGNANI, S. 2003. T cell costimulation by the hepatitis C virus envelope protein 
E2 binding to CD81 is mediated by Lck. European Journal of Immunology, 33, 455-
464. 
SONAWANE, N. D., SZOKA, F. C. & VERKMAN, A. S. 2003. Chloride accumulation and 
swelling in endosomes enhances DNA transfer by polyamine-DNA polyplexes. 
Journal of Biological Chemistry, 278, 44826-44831. 
SREERAMA, N. & WOODY, R. W. 2000. Estimation of protein secondary structure from 
circular dichroism spectra: Comparison of CONTIN, SELCON, and CDSSTR 
methods with an expanded reference set. Analytical Biochemistry, 287, 252-260. 
STIPP, C. S., KOLESNIKOVA, T. V. & HEMLER, M. E. 2001. EWI-2 is a major CD9 and 
CD81 partner and member of a novel Ig protein subfamily. Journal of Biological 
Chemistry, 276, 40545-40554. 
STIPP, C. S., KOLESNIKOVA, T. V. & HEMLER, M. E. 2003. Functional domains in 
tetraspanin proteins. Trends in Biochemical Sciences, 28, 106-112. 
STROUD, Z., HALL, S. C. L. & DAFFORN, T. R. 2018. Purification of membrane proteins 
free from conventional detergents: SMA, new polymers, new opportunities and new 
insights. Methods, 147, 106-117. 
SWAINSBURY, D. J. K., SCHEIDELAAR, S., VAN GRONDELLE, R., KILLIAN, J. A. & 
JONES, M. R. 2014. Bacterial Reaction Centers Purified with Styrene Maleic Acid 
Copolymer Retain Native Membrane Functional Properties and Display Enhanced 
Stability. Angewandte Chemie-International Edition, 53, 11803-11807. 
TIMPE, J. M., STAMATAKI, Z., JENNINGS, A., HU, K., FARQUHAR, M. J., HARRIS, H. J., 
SCHWARZ, A., DESOMBERE, I., ROELS, G. L., BAFE, P. & MCKEATING, J. A. 
2008. Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of 
neutralizing antibodies. Hepatology, 47, 17-24. 
TOKIWA, T., NAKABAYASHI, H., MIYAZAKI, M. & SATO, J. 1979. ISOLATION AND 
CHARACTERIZATION OF DIPLOID CLONES FROM ADULT AND NEWBORN 
RAT-LIVER CELL-LINES. In Vitro-Journal of the Tissue Culture Association, 15, 393-
400. 
TRIBET, C., AUDEBERT, R. & POPOT, J. L. 1996. Amphipols: Polymers that keep 
membrane proteins soluble in aqueous solutions. Proceedings of the National 
Academy of Sciences of the United States of America, 93, 15047-15050. 
TSENG, C. T. K. & KLIMPEL, G. R. 2002. Binding of the hepatitis C virus envelope protein 




VAN MEER, G., VOELKER, D. R. & FEIGENSON, G. W. 2008. Membrane lipids: where they 
are and how they behave. Nature Reviews Molecular Cell Biology, 9, 112-124. 
VAN ZELM, M. C., SMET, J., ADAMS, B., MASCART, F., SCHANDENE, L., JANSSEN, F., 
FERSTER, A., KUO, C. C., LEVY, S., VAN DONGEN, J. J. M. & VAN DER BURG, 
M. 2010. CD81 gene defect in humans disrupts CD19 complex formation and leads 
to antibody deficiency. Journal of Clinical Investigation, 120, 1265-1274. 
VANDERMIES, M. & FICKERS, P. 2019. Bioreactor-Scale Strategies for the Production of 
Recombinant Protein in the Yeast Yarrowia lipolytica. Microorganisms, 7. 
VEREB, G., SZOLLOSI, J., MATKO, J., NAGY, P., FARKAS, T., VIGH, L., MATYUS, L., 
WALDMANN, T. A. & DAMJANOVICH, S. 2003. Dynamic, yet structured: The cell 
membrane three decades after the Singer-Nicolson model. Proceedings of the 
National Academy of Sciences of the United States of America, 100, 8053-8058. 
VONCK, J., PARCEJ, D. N. & MILLS, D. J. 2016. Structure of Alcohol Oxidase from Pichia 
pastoris by Cryo-Electron Microscopy. Plos One, 11, 20. 
WAN, F. T., WANG, Q. M., TAN, J., TAN, M., CHEN, J., SHI, S. H., LAN, P. F., WU, J. & 
LEI, M. 2019. Cryo-electron microscopy structure of an archaeal ribonuclease P 
holoenzyme. Nature Communications, 10. 
WASHBURN, M. P., WOLTERS, D. & YATES, J. R. 2001. Large-scale analysis of the yeast 
proteome by multidimensional protein identification technology. Nature 
Biotechnology, 19, 242-247. 
WHITMORE, L. & WALLACE, B. A. 2004. DICHROWEB, an online server for protein 
secondary structure analyses from circular dichroism spectroscopic data. Nucleic 
Acids Research, 32, W668-W673. 
WHITMORE, L. & WALLACE, B. A. 2008. Protein secondary structure analyses from circular 
dichroism spectroscopy: Methods and reference databases. Biopolymers, 89, 392-
400. 
YANEZ-MO, M., BARREIRO, O., GORDON-ALONSO, M., SALA-VALDES, M. & SANCHEZ-
MADRID, F. 2009. Tetraspanin-enriched microdomains: a functional unit in cell 
plasma membranes. Trends in Cell Biology, 19, 434-446. 
ZHANG, B., SHAN, H., LI, D., LI, Z. R., ZHU, K. S., JIANG, Z. B. & HUANG, M. S. 2012. 
Different methods of detaching adherent cells significantly affect the detection of 
TRAIL receptors. Tumori, 98, 800-803. 
ZHU, X., XIE, C., LI, Y. M., HUANG, Z. L., ZHAO, Q. Y., HU, Z. X., WANG, P. P., GU, Y. R., 
GAO, Z. L. & PENG, L. 2016. TMEM2 inhibits hepatitis B virus infection in HepG2 
and HepG2.2.15 cells by activating the JAK-STAT signaling pathway. Cell Death & 
Disease, 7. 
ZIMMERMAN, B., KELLY, B., MCMILLAN, B. J., SEEGAR, T. C. M., DROR, R. O., KRUSE, 
A. C. & BLACKLOW, S. C. 2016. Crystal Structure of a Full-Length Human 
Tetraspanin Reveals a Cholesterol-Binding Pocket. Cell, 167, 1041-+. 
ZONA, L., TAWAR, R. G., ZEISEL, M. B., XIAO, F., SCHUSTER, C., LUPBERGER, J. & 
BAUMERT, T. F. 2014. CD81-Receptor Associations - Impact for Hepatitis C Virus 
Entry and Antiviral Therapies. Viruses-Basel, 6, 875-892. 
ZUBER, A., PURDEY, M., SCHARTNER, E., FORBES, C., VAN DER HOEK, B., GILES, D., 
ABELL, A., MONRO, T. & EBENDORFF-HEIDEPRIEM, H. 2016. Detection of gold 
nanoparticles with different sizes using absorption and fluorescence based method. 
Sensors and Actuators B-Chemical, 227, 117-127. 
ZUIDSCHERWOUDE, M., GOTTFERT, F., DUNLOCK, V. M. E., FIGDOR, C. G., VAN DEN 
BOGAART, G. & VAN SPRIEL, A. B. 2015. The tetraspanin web revisited by super-
resolution microscopy. Scientific Reports, 5. 
 
 
